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  ABSTRACT 
 
ABSTRACT 
Mitochondrial dysfunction is thought to contribute to neurodegenerative processes. As an 
example, dysfunction of complex I of the electron transport chain has been observed in 
Parkinson’s disease patients and 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP), a 
complex I inhibitor, produces a Parkinsonian state in mammals. The aims of the present 
study were to determine the effects of MPTP on the mitochondrial proteome in a cellular 
model using mouse N2a neuroblastoma cells and to identify novel biomarkers of MPTP-
induced toxicity. 
 
The enrichment of mitochondria and the presence of cross-contamination from other 
subcellular components were monitored using a range of molecular markers. Mitochondrial 
proteins were then fractionated using an optimised 2-dimensional gel electrophoresis (2DE) 
protocol and the reproducibility of the method was investigated. A preliminary study 
comparing the mitochondrial proteome profile from two different states of mouse N2a 
neuroblastoma cells, mitotic and differentiated, was undertaken to establish whether 
differentiation of cells had major effects on the mitochondrial proteome. Since nine 
proteins showed changes in levels, which included stress-70 protein and aconitase, it was 
decided that differentiation did affect the mitochondrial proteome: hence, differentiated 
cells were used for further studies. 
 
The effects of different concentrations (0 to 5 mM) and time-points (0 to 48 hours) of 
MPTP on plasma membrane integrity, cellular metabolic activity, cellular ATP 
concentration, mitochondrial potential, cytochrome c release and a variety of caspase 
activities were investigated. From this study, sub-cytotoxic and cytotoxic concentrations 
were defined and 1 mM MPTP for 24 hours was chosen as an example of a sub-cytotoxic 
concentration for further analysis. Using the previously optimised protocol for 2DE, 
mitochondrial preparations from differentiated N2a neuroblastoma cells treated with 1 mM 
MPTP for 24 hours were fractionated and compared to controls. Up to 32 proteins showed 
changes in protein levels, of which 10 were identified by peptide mass fingerprinting. 
Increases in the levels of 60 kDa heat shock protein (Hsp60), heat shock cognate 71 kDa 
protein (Hsc70), glutamate oxaloacetate 2 (GOT2) and voltage-dependent anion channel 1 
(VDAC1) were validated as potential markers of MPTP-induced toxicity using western blot 
analysis. In parallel, a study of the mitochondrial phosphoproteome was undertaken. 
Despite the limitations of detection methods, a change in the phosphorylation status of a 
few mitochondrial proteins was observed following MPTP treatment, notably potential 
increased phosphorylation of Hsc70 and Hsp60. 
 
Further analysis was undertaken in order to gain a better understanding of the increase in 
VDAC1 levels following sub-cytotoxic treatments with MPTP. Although VDAC1 protein 
levels were increasing in a dose- and time-dependent manner, no mRNA upregulation was 
observed. Similarly, the use of other inhibitors of the electron transfer chain led to 
increased VDAC1 protein levels but no change in mRNA. Finally, modulations in VDAC1 
phosphorylation were observed following MPTP-induced toxicity, further implicating the 
channel in mitochondrial dysfunction. 
 
To conclude, studies with this cellular model implicate the involvement of several 
mitochondrial pathways in the MPTP-induced Parkinsonian syndrome. In particular, 
alterations to VDAC1 may represent a novel target of neurodegeneration. 
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1.1 PARKINSON’S DISEASE AND OTHER NEURODEGENERATIVE 
CONDITIONS 
 
1.1.1 Background to Parkinson’s disease 
 
Parkinson’s disease (PD) was first described by James Parkinson in 1817. It is the second 
most common neurodegenerative disorder after Alzheimer’s disease (Palacino et al., 2004). 
It affects 0.2 % of the population worldwide (Smith, 2002), and  around 1 % of individuals 
over 50 years-old (Huang et al., 2004); the incidence is increasing as the world’s elderly 
population grows. The mean age of onset is 55 years-old with the risk of developing the 
disease increasing five-fold by 70 years-old (Hald and Lotharius, 2005). However, in rare 
cases, an early onset of the disease is observed in patients below 40 years-old (Golbe, 
1990).  
Parkinson’s disease is a disorder with neurological impairment in controlling movement. 
The clinical features appear progressively; starting commonly by tremors in the hand, that 
can progress to bradikynesia, akynesia and postural instability (reviewed in Lane et al., 
2008). 
The aetiology of the disease has not been completely resolved but the origin of the disorder 
is the selective degeneration of dopaminergic neurons, mainly in the substantia nigra pars 
compacta, but also in other parts of the brain such as the locus coeruleus, nucleus basalis, 
hypothalamus, cerebral cortex, cranial nerve motor nuclei, and central and peripheral 
components of the autonomic nervous system (Olanow and Tatton, 1999). The substantia 
nigra was first described by Trétiakoff in 1919. Its name reflects a particular dark 
pigmentation due to the presence of neuromelanin in the cells. The function of nigral cells 
is mainly attributed to the regulation of motility and movement. Nigral cells secrete 
dopamine and their axons provide a dense innervatation to the corpus striatum; nearly 80 % 
of all dopamine in the brain is found in the striatum (and dopamine modulates striatal γ-
aminobutyric acid-producing (GABAergic) neurons).  
In PD patients, symptoms appear following the degeneration of over 50 % of the nigral 
dopaminergic neurons and corresponding to a reduction to 20 % of the levels of dopamine 
in the striatum (Deumens et al., 2002). Consequently, the balance between dopamine and 
other neurotransmitters, such as acetylcholine, is disturbed, resulting in dysfunction in 
muscle motility.  
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Over 90 % of PD cases are thought to be sporadic, the rest being linked to genetic causes 
(Huang et al., 2004). Sporadic cases may be caused by several factors, including 
environmental factors. Examples of environmental factors are pesticides such as rotenone 
(Zhou et al., 2004) or paraquat (Brown et al., 2006). Several mutated genes have been 
linked to PD; the most common mutated protein and first to be discovered was α-synuclein 
(Golbe et al., 1990; for other examples see section 1.1.2). 
Although treatments are available to alleviate the symptoms, there is currently no treatment 
to prevent neurodegeneration. The main treatment involves the use of 3,4-dihyrdroxy-L-
phennylalanine (L-DOPA), a precursor of dopamine (Lane et al., 2008). Monoamine 
oxidase (MAO) inhibitors can also be administered to block the breakdown of dopamine in 
neurons (Leung and Mok, 2005). Other treatments directed to stimulating the dopaminergic 
nervous system or inhibiting dopamine catabolism, as well as the use of antioxidants, are 
being trialled (Lane et al., 2008). 
Another treatment, called deep-brain stimulation, consists of implanting electrodes in the 
subthalamus. This stimulates the deep-brain nuclei, which can result instantly in the 
regression of the tremors (Lane et al., 2008). 
 
1.1.2 Pathological features of Parkinson’s disease 
 
The exact aetiology has not been resolved yet but several pathological hallmarks of PD 
have been observed in patients. Observations in sporadic and genetic forms of the disease 
suggest that mitochondrial dysfunction is one of the main factors in the neurodegeneration. 
In particular, complex I activity of the electron transfer chain (ETC) is decreased by up to 
30 % in brains, muscles and platelets from patients (Schapira et al., 1990). The use of 
complex I inhibitors in models of study reproduces similar biochemical features to those 
observed in PD patients (Cardoso et al., 2005). Coenzyme Q 10, an antioxidant improving 
the ETC function, is also impaired in patients (Cardoso et al., 2005). These two factors can 
lead to increased intracellular oxidative stress, reduced ATP production and proton gradient 
impairment. Mutations in DJ-1, PTEN-induced putative kinase 1 (PINK1), α-synuclein and 
the protease Htra2 / Omi have all been linked to genetic forms of the disease and also are 
all either localised in the mitochondria or linked to mitochondrial function (Fitzgerald and 
Plun-Favreau, 2008). Additionally, mitochondrial DNA (mtDNA) deletions have been 
observed at higher levels in aging substantia nigra, in particular in PD brains (Bender et al., 
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2005 and Kraytsberg et al., 2005). Whether this could be a cause of mitochondrial 
dysfunction in PD or a consequence of high levels of oxidative stress in mitochondria has 
not been resolved.  
Another feature of PD is excitotoxicity of dopaminergic neurons, due to hyperstimulation 
of glutamate receptors, which can activate Ca2+ channels leading to increased intracellular 
Ca2+ concentrations. Disruption of calcium homeostasis could have effects on 
mitochondrial function and increase nitric oxide synthase (NOS) levels, contributing to 
increased oxidative stress (Brazilai and Melamed, 2003). Interestingly, complex I inhibition 
by specific inhibitors (e.g. rotenone and MPP+) was also found to cause excitotoxicity 
(Barzilai and Melamed, 2003). 
A pathological hallmark of PD was observed in 1912 by Lewy, who observed 
intracytoplasmic inclusions (Lewy bodies) in post-mortem neurons from PD patients 
(described in Holdorff, 2002). Since then, these inclusions have been the subject of many 
studies and their formation is thought to be linked to proteolytic impairment, particularly in 
the ubiquitin-proteasome system (UPS). Indeed, mutations in the parkin gene leading to 
loss of ubiquitin ligase activity (Greenmyre and Hastings, 2004), the ubiquitin carboxyl-
terminal esterase L1 (UCHL-1) gene, which encodes a neuronal specific deubiquitinating 
enzyme (Leroy et al., 2003) and in the α-synuclein gene, coding for a potential substrate of 
the UPS and also a major component of Lewy bodies (Zhang et al., 2008), are all linked to 
genetic cases of PD patients. Decreased proteasome activity has been reported in the 
substantia nigra pars compacta of PD brains (McNaught and Jenner, 2001), suggesting the 
role of disrupted proteolytic pathways in the pathology.  
Inflammation has also been linked to the disease. Indeed, activation of astrocytes and 
microglia was observed in the substantia nigra of PD patients (McGeer et al., 1998). 
Astrocytes can be activated by inflammatory factors and C reactive protein, which was 
shown to be upregulated in PD patients and can in turn activate NOS and cyclooxygenase 2 
(McGeer et al., 1998). To support these observations, high levels of cytokines and 
antibodies against proteins oxidised by dopamine were found in cerebrospinal fluid and 
striatum (Hald and Lotharius, 2005). This activation may be due to neuronal cell death but 
it is not really known if the consequences would be protective or would exacerbate 
neurodegeneration (Hald and Lotharius, 2005). 
The pathological features observed in PD patients seem to be all linked to a further 
biochemical hallmark: oxidative stress. The substantia nigra is a part of the brain that is 
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more particularly vulnerable to oxidative stress due to dopamine auto-oxidation and MAO-
induced production of hydrogen peroxide (H2O2) (Blum et al., 2001). Indeed, PD patients 
have high levels of iron, NOS and lipid peroxidation coupled with a loss of antioxidant 
defences (Ghandi and Wood, 2005). Additionally, as noted earlier, in some genetic cases a 
mutation in DJ-1, which encodes a scavenger of H2O2 and potential chaperone, has been 
observed. Causes of increased oxidative stress could be linked to the observed 
inflammation reaction but it could also be linked to mitochondrial dysfunction, for 
example, via mitochondrial calcium homeostasis impairment and complex I inhibiton 
(Blum et al., 2001). Consequences of oxidative stress could include disruption of calcium 
homeostasis, UPS impairment, aggregation of oxidised proteins and activation or inhibition 
of various signaling pathways (figure 1.1). 
 
1.1.3 Pathological features of other neurodegenerative diseases 
 
1.1.3.1 Alzheimer’s disease 
 
Alzheimer’s disease (AD) is the most common neurodegenerative disease (Butterfield et 
al., 2006), affecting around 1.4 % of the population in the USA, and the leading cause of 
dementia worldwide (Conejero-Goldberg et al., 2008). It is characterised by progressive 
impairment in language, skilled movement, recognition and decision making (Conejero-
goldberg et al., 2008). It is due to the degeneration of cholinergic neurons from the 
forebrain, hippocampal pyramidal and cortical neurons (Cassarino and Bennet, 2008).  
The pathological hallmarks of the disease include the formation of intraneuronal fibrillary 
tangles, mainly composed of phosphorylated tau protein (cytoskeletal protein), and the 
formation of extracellular plaques, mainly composed of oxidised amyloid (Cassarino and 
Bennett, 1999). Increased intracellular levels of calcium are observed, contributing to an 
increase of reactive oxygen species (ROS) and the impairment of mitochondrial and 
endoplasmic reticulum calcium homeostasis. 
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Tightly linked to oxidative stress, mitochondrial dysfunction is also observed in AD 
patients, with complex IV of the ETC impaired (Atamna and Frey, 2007). Whether 
mitochondrial impairment is the cause or the consequence of increased oxidative stress has 
not been resolved. However, increased oxidative damage is associated with increased 
mtDNA mutations in AD brains (Cassarino and Bennet, 1999). Other markers of oxidative 
damage have been observed in AD brains such as increased levels of iron and lipid 
peroxidation. Finally inflammatory reactions have also been observed in AD patients and 
may exacerbate oxidative stress in cholinergic neurons (McGeer and McGeer, 1998). 
 
1.1.3.2 Huntington’s disease 
 
Huntington’s disease (HD) affects 7 in 100,000 people worldwide (Mitra and Finkbeiner, 
2008). It is characterised by involuntary movement, dystonia, rigidity, lack of coordination 
of movements, saccadic eye movements and inability to voluntarily maintain muscle tone 
(Mitra and Finkbeiner, 2008). It is due to the degeneration of neurons from the basal 
ganglia and brain cortex caused by a mutation in the huntingtin gene leading to a 
polyglutamylation of the resultant protein (Mitra and Finkbeiner, 2008). The mutant protein 
is cleaved into fragments that deposit into large inclusion bodies found in the neuronal 
cytoplasm, nucleus and processes (Mitra and Finkbeiner, 2008). The UPS has been 
observed to be the major proteolytic pathway involved in huntingtin degradation and 
inclusion formation is reversed by increasing the proteasome activity indicating a key role 
of the latter in HD (Mitra and Finkbeiner, 2008). In addition to proteolytic dysfunction, 
mitochondrial dysfunction has also been implicated in HD. Indeed, complex II of the ETC 
is impaired in post-mortem brains from HD patients together with disruption of calcium 
signaling pathways and depolarisation of the mitochondrial membrane potential, decreased 
ATP production and reduced cellular metabolism (Perez-de la Cruz and Santamaria, 2007). 
Consistent with mitochondrial dysfunction and protein accumulation, high levels of 
oxidative stress were observed, exacerbated by microglial activation, a marker of 
inflammation (Perez-de la Cruz and Santamaria, 2007). 
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1.1.3.3 Amyotrophic lateral sclerosis 
 
Amyotrophic lateral sclerosis is another motor disease due to the progressive degeneration 
of anterior horn cells of the spinal cord and of cortical motor neurons (Baron et al., 2007). 
One of the identified causes is a mutation in the Cu2+ / Zn2+ superoxide dismutase 1 gene 
(Baron et al., 2007). The consequent hallmarks of this mutation observed in the antioxidant 
scavenging system include increased oxygen radical damage in patients’ brains, glutamate 
excitotoxicity, formation of proteinaceous inclusions containing mutated superoxide 
dismutase, neurofilaments and ubiquitin, as well as mitochondrial damage (Baron et al., 
2007), including mtDNA mutations, ETC impairment (complex I activity was decreased in 
brains and muscles from patients) and decreased ATP production (Dupuis et al., 2004). 
 
1.1.4 Common pathological features in neurodegenerative diseases 
 
Although these four neurodegenerative conditions affect different parts of the brain and 
lead to different symptoms in patients, they show certain similarities in their pathological 
features. Indeed, oxidative stress is a major hallmark in all four diseases and is linked to all 
the other biochemical features found in neurodegeneration (Butterfield et al., 2006). In all 
cases, post-translationally modified proteins accumulate to form proteinaceous inclusions, 
associated with dysfunction of proteolysis (Rubinsztein, 2006; Cassarino and Bennett, 
1999). Mitochondrial dysfunction has also been strongly related to the four 
neurodegenerative diseases, as indicated by the impairment of ETC complexes and the loss 
of mitochondrial potential (Cassarino and Bennett, 1999; Perez-de la Cruz and Santamaria, 
2007). Whether the impairment of oxidative phosphorylation is the cause or consequence of 
increased levels of ROS has not yet been resolved. However, decreased mitochondrial 
antioxidant defences and increased levels of ROS, contributing to mtDNA oxidative 
damage is common to all four neurodegenerative diseases (Howell et al., 2005; Dupuis et 
al., 2004; Kasraie et al., 2008). 
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1.2 MITOCHONDRIA 
 
1.2.1 General features 
 
Mitochondria are referred as the “power-house” organelles of the cells, with reference to 
their important role in energy production but they also have roles in cell survival and death. 
In 1963, Nass was the first to discover that mitochondria contained their own DNA 
(Reviewed in Chinnery and Schon, 2003). It is thought that these eukaryotic organelles are 
of bacterial descent derived from a symbiotic relationship with a primitive eukaryotic 
organism, explaining the presence of mtDNA, but have a high dependence on nuclear gene 
products (Gabaldon and Huymen, 2004). 
The DNA of mitochondria is a circular double stranded DNA that contains around 16.6 
kbp, which represents 0.1 to 2 % of total cellular DNA (Druzhyna et al., 2003). Two of its 
genes encode ribosomal RNAs, 22 encode transfer RNAs, and 13 encode protein subunits 
of the ETC complexes (Chinnery and Schon, 2003). Each mitochondrion can contain from 
1,000 to 100,000 copies of mtDNA that continuously replicate independently of the cell 
cycle state and that are all maternally transmitted (Chinnery and Schon, 2003). Contrary to 
nuclear DNA, mtDNA does not associate with histone proteins and has a much simpler 
repair mechanism. Consequently, it is less well protected against oxidative stress and other 
types of damage compared to nuclear DNA (Pieczenik and Neustadt, 2007).  
Although mitochondria contain their own DNA, they are composed of an estimated 800 to 
1,500 proteins (Liebler, 2002; Taylor et al., 2003a), virtually all imported from the 
cytoplasm (apart from the 13 complex subunits encoded by the mtDNA). An extremely 
well regulated import mechanism is then required for the entry of these proteins into 
mitochondria (For a review see Bolender et al., 2008).  
 
The mitochondrion is a membrane-rich organelle composed of 4 compartments: the matrix, 
the inner mitochondrial membrane (IMM), the outer mitochondrial membrane (OMM) and 
the intermembrane space (IMS); all participating in the integrity and functions of the 
organelle, such as its role in survival and death (Bolender et al., 2008) (Figure 1.2). 
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Figure 1.2: Electron micrograph of a typical mitochondrion  
Electron microscopy from Fawcett (1994) 
 
1.2.2 Mitochondrial cycle of life 
 
Mitochondria are grouped in networks that continuously undergo fusion and fission states 
(Twig et al., 2008). Both mechanisms are important in the maintenance of mitochondrial 
integrity, electrical and biochemical connectivity, regulation of mitochondrial turnover, 
segregation, stabilisation and protection of mtDNA (Van Laar and Berman, 2009). 
Mitochondria are degraded by an autophagic pathway that is thought to be activated via a 
decrease of mitochondrial potential (Twig et al., 2008). However, degradation of unfolded 
and misfolded IMM and matrix proteins involves proteases associated with the IMM (Twig 
et al., 2008). E3-ubiquitin ligase has been associated with a few outer mitochondrial 
membrane proteins, suggesting a potential role of the proteasome in the degradation of at 
least some OMM proteins (reviewed in Twig et al., 2008). 
 
1.2.3 Principal cellular roles of mitochondria 
 
Overall, mitochondria are responsible for up to 90% of the total cellular energy production 
(Mootha et al., 2003). They are the centre of many catabolic pathways including fatty acid 
oxidation and the Krebs cycle, which drives both carbohydrate and fatty acid metabolism 
(Mootha et al., 2003). These pathways lead to the formation of some ATP energy but also 
the reduction of cofactors. The ETC situated in the IMM is responsible for the oxidation of 
reduced cofactors allowing the formation of ATP via proton transfer through the IMM.  
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The ETC is composed of five enzymatic complexes (Figure 1.3). Complex I is composed of 
40 subunits that form the enzyme called NADH dehydrogenase (or NADH:ubiquinone 
oxidoreductase). It is responsible for the oxidation of NADH cofactor and transfer of 
electrons to coenzyme Q, carrying the electrons to complex III. Complex II is composed of 
4 subunits and is called succinate dehydrogenase (or succinate:ubiquinone oxidoreductase) 
and forms part of the Krebs cycle. It is responsible for the transfer of electrons from FADH 
to coenzyme Q that also carries electrons to complex III. Complex III is composed of 11 
subunits and is also called the bcl complex (or ubiquinone cytochrome c oxidoreductase). It 
transfers electrons from coenzyme Q to cytochrome c carrier. Electrons are then carried to 
complex IV, which is composed of 13 subunits and is called cytochrome c oxidase (or 
reduced cytochrome c:oxygen oxidoreductase). It transfers electrons to reduce oxygen into 
water. Complexes I, III and IV pump protons from the matrix to the inter-membrane space 
of the mitochondria for each electron transferred. This flow of protons creates a proton 
gradient that drives the protons back to the mitochondria through complex V (or ATP 
synthase), which synthesizes ATP (Schapira, 2006; Pieczenik and Neustadt, 2007, Kidd, 
2005 and figure 1.3). 
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Figure 1.3: Schematic diagram of the electron transfer chain 
coQ: coenzyme Q; cytc: cytochrome c 
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Mitochondria also contain key enzymes of other metabolic pathways such as the urea cycle, 
heme biosynthesis, ketone body generation, and hormone synthesis (Mootha et al., 2003). 
Apart from their metabolic roles, mitochondria have a variety of other functions. They 
participate in calcium homeostasis, regulating calcium signaling. They are the centre of 
many other signaling pathways including guanine, GTP-related proteins, Ras-related 
proteins, kinases and phosphatases, protease inhibitors and signaling receptors (Taylor et 
al., 2003b). 
Mitochondria are the main producer of ROS in conjunction with highly regulated 
antioxidant defences to protect against these oxidative molecules (Mootha et al., 2003). 
Finally, one of the crucial functions of mitochondria includes their role in cell death via 
housing key regulators of programmed cell death in the IMS and their OMM interaction 
with B-cell lymphoma 2 (Bcl2) family proteins (originally found in B-cell lymphoma), 
including pro- and anti-apoptotic molecules that lead to or prevent the release of pro-
apoptotic regulators into the cytoplasm (Suen et al., 2008). 
 
1.2.4 Mitochondria and neuronal cells 
 
Neuronal cells have been observed to have different characteristics compared to other cell 
types. They are terminally differentiated in the adult brain, being unable to divide and 
regenerate in case of brain injury. Moreover, they are unable to survive anaerobically, 
meaning that if there is no oxygen provided to neurons, cells can die within a few minutes. 
Finally, they have a particular asymmetrical morphology due to the outgrowth of axonal 
processes and dendrites from their cell body (Dowling, 2001). Protein synthesis mostly 
occurs in the cell body and axons need a particular mechanism for the transport of 
molecules such as proteins, lipids and carbohydrates to and from the synapse. Axonal 
transport occurs along networks of cytoskeletal proteins (Dowling, 2001). Maintenance of 
neuronal integrity needs to be highly regulated. Because of their energy requirements and to 
ensure cell survival, neurons contain a high number of mitochondria per cell compared to 
other cell types. Moreover, mitochondria are transported along axons to bring ATP energy 
to the synapses and throughout the cell. Mitochondrial fusion and fission dynamics have 
been found to be crucial for axon development and survival (Berman et al., 2008). Another 
reason why mitochondria are especially important in neurons is their capacity for 
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scavenging oxidative insult. Maintenance of oxidant production and antioxidant system is 
important in the normal functioning and survival of neurons. 
 
1.2.5 Mitochondrial dysfunction due to oxidative stress 
 
Mitochondria are efficient organelles in the production of up to 90 % of ATP by using O2 
as a substrate (Mootha et al., 2003). However, O2 is highly reactive and has a high affinity 
for electrons, with approximately 2 % being converted to superoxide anion (O2-●) (Boegarts 
et al., 2008). O2-● is a ROS and the precursor of most other ROS molecules. Indeed, it can 
be converted to H2O2 by the antioxidant enzyme superoxide dismutase (Boegarts et al., 
2008). H2O2 can, in turn, be converted to water by diverse antioxidant enzymes (figure 1.4). 
However, when ROS molecules accumulate in the mitochondria (e.g. over time during 
aging), the antioxidant defence system does not scavenge all the oxidative molecules, 
which are converted to other free radical molecules that cause oxidative damage to 
biological molecules such as lipid, protein and DNA oxidation (figure 1.4). The 
consequences can be numerous; examples are damage to the ETC leading to a decrease in 
ATP production, malfunction of proteins, decreased enzyme activities (e.g. proteolytic 
enzymes leading to protein accumulation). There is also an increased risk of mutations and 
deletions in the mtDNA, exacerbating the above mentioned effects. The accumulation of all 
these events can eventually lead to cell death (Kidd, 2005; Fukui and Morales, 2008). 
 
 
Figure 1.4: ROS production from oxygen 
Modified schematic inspired by Boegarts et al. (2008). 
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1.3 CELL DEATH 
 
Many different cell death pathways have been described in different cell types, distinct by 
morphological, enzymological, functional and immunological features (reviewed in 
Kroemer et al., 2009). However, three main types of cell death, termed necrosis, apoptosis 
and autophagy, have been more commonly observed in neuronal cells (Yuan et al., 2003) 
 
1.3.1 Apoptotic cell death 
 
Apoptotic cell death was first described by Kerr et al. in 1972, who observed that cells 
could undergo different cell death pathways of which apoptosis was programmed by the 
cell itself, as opposed to necrosis (reviewed in Boujrad et al., 2007). The morphological 
features of apoptosis include rounding of cells, loosening from surroundings, shrinkage, 
chromatin condensation and DNA fragmentation. The peculiarity of this type of cell death 
is that the plasma membrane remains intact, allowing the formation of apoptotic bodies 
(vesicles containing parts of cellular content) that are engulfed by macrophages without the 
release of toxic cellular content in the environment and without activation of inflammatory 
processes (Boujrad et al., 2007; Han et al., 2008b). 
Apoptosis is an active process, also called “suicide of the cell” occurring naturally in 
development and homeostasis of neurons and requiring ATP energy and the regulation of a 
number of molecules involved in the process (Han et al., 2008b). Such molecules belong to 
different protein families and have different characteristics, as discussed below. 
 
1.3.1.1 Cysteine-dependent aspartate-directed proteases (caspases) 
 
Caspases are cysteinyl proteases able to cleave other proteins, including other caspases, on 
aspartate residues (Parone et al., 2002). There are around 12 different proteins in this 
family. They are all found as inactive pro-enzymes, which upon stimulus, can be activated 
by cleavage via extra- or intra-cellular stimuli or via other caspases. Active caspases can 
activate other molecules, including caspases of the same or different groups (Orrenius, 
2004). 
There are two groups of caspases: the initiators (caspase-2, -8, -9 and -10) and the effectors 
(caspase-3, -6 and -7). The initiator caspases are generally activated by the formation of a 
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complex requiring initiator caspase binding for its activation. Activated caspases can then 
activate effector caspases, which in turn can activate other caspases and also cleave specific 
substrates that will lead to cell death. 
 
1.3.1.2 Bcl2 family proteins 
 
Another group of proteins known to regulate apoptosis is the Bcl2 family, which includes at 
least 17 members that can be either pro-apoptotic or anti-apoptotic (Han et al., 2008b). 
They contain 4 sequence motifs called Bcl2 homology (BH) domains and they all share one 
of them (BH3), while the other domains are shared between groups of proteins. Anti-
apoptotic Bcl2 molecules share the four domains (BH1 to 4; e.g. Bcl2 and Bcl-xL), whereas 
pro-apoptotic molecules share three domains (BH1 to 3; e.g. Bax and Bak). Another group 
of Bcl2 molecules only contains the BH3 domain, called BH3-only molecules (e.g. Bid, 
Bim, Bad, NOXA, PUMA); these promote cell death by interaction with and activation of 
pro-apoptotic Bcl2 molecules and by inhibition of anti-apoptotic Bcl2 molecules (Han et al., 
2008b).  
Their localisation in healthy cells differs depending on the protein. For example, Bcl2 
localises to membranes, particularly of the endoplasmic reticulum but also nuclear and 
mitochondrial membranes (Krawjeski et al., 1993); however, Bax and Bcl-xL are found in 
the cytoplasm of healthy cells and translocate to mitochondria following apoptotic stimulus 
(Hsu et al., 1997). 
The pro-apoptotic process of Bcl2 molecules is thought to involve permeabilisation of the 
outer mitochondrial membrane (OMM), leading to the release of proteins from the 
intermembrane space (IMS) to the cytosol; this can then lead to toxicity and apoptotic cell 
death. The molecular events by which Bcl2 molecules permeabilise the OMM have not yet 
been resolved. Several hypotheses have been proposed including the formation of a channel 
composed of Bax, tBid and Bak themselves or composed of a mitochondrial channel, 
voltage–dependent-anion channel (VDAC); the diameter of the latter is thought to increase 
upon interaction with Bax and Bak or following physical rupture of the OMM induced by 
osmotic swelling (process reviewed in Garrido et al., 2006). 
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1.3.1.3 Molecular pathways of apoptosis 
 
Depending on the stimulus, two different pathways of apoptosis have been distinguished. 
The extrinsic pathway, also called receptor-mediated death pathway, is activated in 
response to an extracellular stimulus by ligand binding (e.g. TRAIL, TRADD, FasL or 
TNFα) and activation of cell surface death receptors (e.g. Fas, DR4/DR5, TNFα-receptor 
1). Following this interaction, an adaptor protein (Fas associated death domain, FADD) 
binds to the receptor on the cytosolic side which leads to the cleavage of an initiator pro-
caspase, which is mainly procaspase-8 but can also be procaspase-10 depending in the 
death receptor activated. Activated caspase-8 and -10 can directly cleave caspase-3 and -7, 
the effector caspases, which will lead to cell death (figure 1.5), or caspase-8 can cleave Bid 
to truncated Bid (tBid) which will associate with Bax on the OMM and activate the 
mitochondria-dependent apoptotic pathway (figure 1.5) (reviewed in Rossi and Gaidano, 
2003; Han et al., 2008b).  
The intrinsic pathway is activated by an intracellular trigger, for example activation of 
initiator procaspase-2 (e.g. due to intracellular stimuli such as irradiation, withdrawal of 
serum, survival stimulus; Rossi and Gaidano, 2003). This leads to the activation of the 
mitochondria-dependent apoptotic pathway (figure 1.6). Whether via intrinsic or extrinsic 
pathway, the OMM loses its permeability leading to the release of molecules found in the 
IMS, such as cytochrome c, apoptosis-inducing factor and pro-caspases. Following its 
release, cytochrome c binds to Apaf1, ATP and procaspase-9 to form a complex called the 
apoptosome leading to the activation of caspase-9, an initiator caspase that will 
subsequently activate effector caspase-3, -6 and -7 (figure 1.6; Rossi and Gaidano, 2003). 
Caspase-3 is the main effector caspase, although caspase-7 is thought to have a similar role 
(Thornbery et al., 1997). Caspase 3 activation leads to the cleavage of many protein 
substrates including caspase-3 itself and caspase-6 and -7, which will lead to the apoptotic 
morphology and eventually cell death (Rossi and Gaidano, 2003). 
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Figure 1.5: Schematics representing the molecular events involved in the extrinsic 
pathway in mitochondria-independent and mitochondria dependent pathways. 
Figure inspired by Rossi and Gaidano, 2003 
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Figure 1.6: Schematics representing molecular events involved in the intrinsic 
pathway.  
Figure inspired by Rossi and Gaidano, 2003 
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Caspase-7 was originally observed by Duan and colleagues (1996). It was found in a range 
of tissues and can be activated in vitro by activation of cell death receptors such as 
Fas/APO-1 (also called CD95) or TNFR-1. Caspase-7 has a substrate sequence for caspase-
3, -6, -8 and -9 and for granzyme B (Thornberry et al., 1997). As already mentioned, it has 
also been shown to have a similar substrate specificity to caspase-3 (Thornberry et al., 
1997) although it might have a different subcellular localisation (Chandler et al., 1997). 
Indeed, both caspases are observed in the cytosol; however, only caspase-7 is found in 
microsomes and its activated form is found in mitochondria (Chandler et al., 1997). 
 
1.3.1.4 Regulation of apoptotic molecules by signaling kinases 
 
The apoptotic pathway, involving many pro- and anti-apoptotic molecules has been 
observed to be regulated by phosphorylation. Although many kinases have been linked to 
the apoptotic process, all pathways have not yet been resolved and only the most studied 
will be discussed here. 
Protein kinase B, also called Akt, a serine-threonine kinase, has long been known to be 
linked to apoptosis (Datta et al., 1997). Indeed, Akt was observed to phosphorylate Bad on 
its serine 136 residue. When phosphorylated in this way, Bad could not associate with and 
prevent the anti-apoptotic effects of Bcl2 and Bcl-xL (Datta et al., 1997). Since then, Akt 
has been shown to phosphorylate other molecules, for example the serine protease 
Htra2/Omi (preventing it from cleaving apoptotic inhibitor proteins; Yang et al., 2007), 
caspase-9 (inactivating it in humans; Cardone et al., 1998), and other proteins reviewed in 
Parcellier et al. (2008). Such findings show that Akt activation is associated with an anti-
apoptotic phenotype. Moreover, Akt has been shown to inhibit the pro-apoptotic effects of 
both glycogen synthase kinase (GSK)-3β and c-Jun amino N-terminal kinase (JNK), a 
stress-activated protein kinase (SAPK) (Kajta, 2004). For example, JNK activation 
increases the phosphorylation and protein levels of transcription factor cJun, which led to 
the elevated transcription of pro-apoptotic molecules Bax and FasL. In parallel, JNK 
inhibits Bcl2 and Bcl-xL by phosphorylating them. Moreover, GSK-3β inhibits by 
phosphorylation the anti-apoptotic molecule Mcl-1 (Kajta, 2004) 
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1.3.2 Necrotic cell death 
 
Necrosis has long been thought to be a passive, accidental process but it has recently been 
shown that it can also be a programmed and physiological pathway (Boujrad et al., 2007; 
Niquet et al., 2006). Pathological causes of necrosis include DNA damage, tumor necrosis 
factor induction and cell-cell interactions (Han et al., 2008b), although it has also been 
observed in developmental neuronal death (Golstein and Kroemer, 2006).  
As opposed to apoptosis, necrosis is associated with a different cell morphology 
characterized by the swelling of organelles and the cell due to disruption of calcium 
homeostasis and to the disruption of the plasma membrane resulting from a combination of 
calcium overload, increased ROS production, damaging biological membranes, and 
depletion of ATP, leading to loss of integrity of the membranes (Golstein and Kroemer, 
2006). The exact molecular pathways involved have not been completely resolved; 
however, there is evidence of activation of a few proteases including calpains, cathepsins 
and granzyme, further explaining the disruption of organelle membranes (Golstein and 
Kroemer, 2006). Disruption of the plasma membrane during necrosis leads to the release of 
cytoplasmic content to the extracellular environment, including release of cytokines, TNF-
α, heat shock proteins and others, which can stimulate an inflammatory response when 
released and can lead to propagation of necrosis to surrounding cells (Han et al., 2008b). 
 
1.3.3 Autophagic cell death 
 
Autophagy was first observed by Schweichel and Merker in 1973 (reviewed by Yuan et al., 
2003). It is characterised by the formation of double membrane vacuoles containing the 
cytoplasmic content or fragments of cellular organelles that will be digested by lysosomal 
hydrolases upon fusion of these vacuoles with lysosomes (reviewed by Kroemer et al., 
2007). There are three different types of autophagic processes: the chaperone-mediated 
autophagy involves delivering specific single proteins to the lysosomes for protein 
degradation; microautophagy is associated with engulfing cytosol portions or organelles to 
recycle damaged organelles; while macroautophagy involves forming sequestering vesicles 
in the cytoplasm containing intracellular organelles and portions of the cytoplasm, the latter 
process leads to cell death (Yuan et al., 2003).  
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Autophagic cell death has been observed in neuronal development and also in cases of 
extracellular (e.g. nutrient deprivation or hypoxia) and intracellular (accumulation of 
damaged organelles and cytoplasmic components) stress conditions (Yuan et al., 2003). 
 
1.3.4 Cell death and mitochondria 
 
As previously mentioned, the involvement of mitochondria in cell death occurs at different 
levels through their involvement in ATP production and distribution, Ca2+ homeostasis, 
ROS production and also by the release of molecules toxic for the cytoplasm due to a loss 
of permeability of mitochondrial membranes (e.g. cytochrome c, apoptosis-inducing 
factor,…)  
Following increased Ca2+ and ROS production or other intra- or extra-cellular stimuli, 
mitochondria are subjected to what is called the mitochondrial permeability transition, 
which is caused by a sudden increase in membrane permeability due to the opening of a 
pore through the OMM only or through the IMM at contact sites (Halestrap et al., 2002). 
Such pores have been described to be composed of the protein cyclophilin D from the 
matrix, the adenine nucleotide translocator (ANT) from the IMM and VDAC from the 
OMM, although this complex composition has been challenged in the literature (Garrido et 
al., 2006).  
Permeabilisation of the mitochondrial membrane leads to the release of IMS proteins but 
also small molecules from the mitochondrial matrix, including cations such as Ca2+. 
Additionally, the permeabilisation of the IMM has led to the uncoupling of the ETC leading 
to a drop in ATP production and even a reverse reaction of ATP synthase leading to ATP 
hydrolysis, further depleting ATP stores (Halestrap et al., 2002). This phenomenon has 
been observed in both the apoptotic and necrotic pathways (Orrenius et al., 2004). 
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1.4 MPTP AS A MODEL FOR PARKINSON’S DISEASE 
 
1.4.1 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) emergence as a toxin 
 
The first time MPTP was linked to PD occurred in the late 1970s when a graduate student, 
trying to reproduce a narcotic analogue of meperidine (analgesic drug), injected himself 
with the substance he made and started to develop PD-like symptoms. Analysis of the 
injected drug showed that it contained MPTP (Davis et al., 1979). Another similar incident 
occurred a few years later when a group of addicted young people were taking some 
synthetic heroin supposed to contain the same narcotic analogue of meperidine. The 
analysis of the drug compounds showed that it also contained MPTP (Langston et al., 
1983). MPTP-induced symptoms included tremors, rigidity, slowness of movement, 
postural instability, freezing episodes similar to PD symptoms (Langston et al., 1983). The 
symptoms were attenuated when treated with PD treatments such as L-DOPA and 
carbidopa (Langston et al., 1983). 
 
1.4.2 MPTP as a model of Parkinson’s disease 
 
MPTP became of particular interest when it was observed to reproduce symptomatic, 
pathological and biochemical features of PD in animal models. Interestingly, MPTP-
induced symptoms in monkeys were virtually identical to human symptoms, more 
particularly in African green monkeys which reproduced resting tremors, the most similar 
to human PD (Tetrud and Langston, 1992). MPTP-induced damage to the nigrostriatal 
dopaminergic pathway with a larger damage in the substantia nigra than in the ventral 
tegmental area in both humans and monkeys (Seniuk et al., 1990). MPTP-induced effects 
have been observed to be acute and although biochemical features are similar to PD in 
patients, MPTP did not show formation of Lewy bodies in both humans and monkeys 
(Bové et al., 2001). Although higher concentrations were needed, MPTP also mimicked PD 
in mice. However, rats were much less sensitive to MPTP-induced toxicity (reviewed in 
Przedborski et al., 2001). The differences observed in the different animals and between 
species of the same animal to MPTP-induced toxicity have not completely been explained.  
 
 - 22 - 
CHAPTER I  GENERAL INTRODUCTION 
 
The choice of administration showed different outcomes with a preference to systemic 
administration (Przedboski et al., 2001). Moreover, as shown with mice models, the age, 
body weight, gender and strain are factors in MPTP-induced toxicity (Przedboski et al., 
2001); more particularly, the age of animals has been an important factor as aged mice and 
monkeys have been found to be more sensitive to MPTP (Gupta et al., 1986; Forno et al., 
1988).  
 
1.4.3 MPTP metabolism 
 
MPTP is a neutral and highly lipophilic compound able to cross the blood brain barrier (see 
structure in figure 1.7; Beal, 2001). It can be taken up by the cells in a non-specific manner 
where it will be metabolized to an intermediate compound MPDP+ (1-methyl-4-phenyl-2,3-
dihydropyridinium ion), a reaction catalysed by the catecholaminergic enzyme MAO-B 
mainly and MAO-A to a lesser extent and involving two electron oxidation (Chiba et al., 
1985; Salach et al., 1984). MPDP+ being unstable it subsequently auto-oxidises into MPP+ 
(1-methyl-4-phenylpyrimidium), also involving two electron oxidation. MAO-B levels 
were shown to be lower in catecholaminergic cells compared to glial and serotoninergic 
cells (Levitt et al., 1982), it was then shown that MPTP oxidation to MPP+ was primarily 
occurring in glial cells (Brooks et al., 1989). Following MPP+ formation, the charged 
compound is released to the extracellular space where it will be specifically taken up by 
dopaminergic neurons via dopamine transporters (DAT) for which it has high affinity 
(Bezard et al., 1999). Upon entry into dopaminergic neurons, MPP+ can have three 
different outcomes: (a) MPP+ is taken up by neuromelanin, a by-product of dopamine auto-
oxidation (D’Amato et al., 1987) delaying its release to the cytoplasm whereupon delaying 
its cytotoxicity; (b) MPP+ is confined to synaptic vesicles via uptake by vesicular 
monoamine transporters (Takahashi et al., 1997); (c) free MPP+ present in the cytoplasm 
relocates to mitochondria where it will have its cytototoxic effects. 
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Figure 1.7: MPTP metabolism  
Figure from Kopin, 1987. 
 
1.4.4 Inhibition of complex I of the electron transfer chain 
 
MPP+ was observed to accumulate in the mitochondria via an ATP-dependent uptake 
system, which was followed by the inhibition of oxidation of NAD+ and of its linked 
substrates (e.g. pyruvate and glutamate oxidation; Nicklas et al., 1985; Ramsay et al., 
1986). This was followed by ATP depletion (DiMonte et al., 1986) accompanied by loss of 
mitonchondrial potential, increase in ROS production and impairment of calcium 
homeostasis (reviewed in Blum et al., 2001). Following these observations, Ramsay and 
colleages (1987) found that MPP+ was inhibiting the ETC by inhibiting the transfer of 
electrons from the iron-sulfur cluster of highest potential to the endogenous coenzyme Q10, 
from complex I to complex III, explaining the above mentioned effects. 
 
1.4.5 MPTP and generation of reactive oxygen species 
 
The observation that MPTP caused increased production of ROS was noted by Johannessen 
et al. (1986). Since then, several modes of actions of MPTP to produce ROS have been 
undercovered. (a) The intermediate MPDP+ was observed to induce O2-● during its multi-
step auto-oxidation to MPP+ (Zang and Misra, 1992). (b) MPP+ potentially can lead to the 
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formation of MPP● radical as an extra radical production (Adams et al., 1993). (c) 
Inhibition of complex I increases O2-● production (Boegarts et al., 2008).  
Along with increased ROS production, a decrease in the antioxidant system was also 
observed following MPTP-induced toxicity, particularly a decrease in glutathione levels 
(Sriram et al., 1997; Caneda-Ferron et al., 2008). Overall deleterious consequences of 
increased oxidative stress to cellular processes have previously been described (section 
1.3.5). 
Following MPTP-induced toxicity, glial cells (microglia and astrocytes) have been shown 
to be activated (O’Callaghan et al., 1990) leading to an inflammation response linked to 
further increased oxidative stress, as previously described in the pathology of Parkinson’s 
disease description (section 1.1.2; figure 1.1). 
 
1.4.6 Excitotoxicity and calcium homeostasis disruption 
 
Excitotoxicity has been linked to MPTP-induced effects as N-methyl-D-aspartate (NMDA) 
antagonists prevented MPTP-induced toxicity (Turski et al., 1991). Moreover, a recent 
study showed that MPTP treatment of mice led to an increase in extracellular glutamate 
concentration in the subtantia nigra and an increase in glutamate transporter affinity for the 
neurotransmitter (Meredith et al., 2009), consistent with the idea that MPTP leads to 
excitotoxicity. This phenomenon was thought to happen due to ATP depletion and 
oxidative stress, consequent to complex I inhibition, leading to a decrease in plasma 
membrane potential and blockade of NMDA receptors becoming overexcited by glutamate. 
The direct consequence of this would lead to an excessive release of glutamate parallel to 
an excessive influx of Ca2+ into the cell (Sawada and Shimohama, 1999). Ca2+ overload can 
lead to activation of many Ca2+–dependent enzymes of which NOS (participating in nitric 
oxide radical, NO●, production; Sawada and Shimohama, 1999), signaling kinases, 
proteases and endonucleases that can lead to activation of cell death pathways (Blum et al., 
2001).  
Consistently, peroxinitrite (ONOO-) production has been also linked to MPTP-induced 
toxicity (Obata and Yamanaka, 2001; Obata, 2006). Indeed, NO●, a reactive nitrogen 
species  important as an intracellular messenger can react with O2-● to form ONOO- radical 
a powerful oxidant also linked with protein oxidation, lipid peroxidation and mtDNA 
damage, exacerbating the oxidative damage (Boegarts et al., 2008). 
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1.4.7 Proteolysis dysfunction  
 
Despite a lack of Lewy body formation using acute MPTP treatment in human and animal 
models, chronic treatments have led to the formation of intraneuronal proteinaceous 
inclusions resembling Lewy bodies in old monkeys (Forno et al., 1988) and of  nigral 
inclusions containing ubiquitin and α-synuclein in MPTP-treated mice (Fornai et al., 2005), 
further supporting MPTP as a model for PD. Parallel to the accumulation of proteins into 
inclusion bodies, a decrease in proteasome activity has also been observed following MPTP 
treatment in mice (Fornai et al., 2004), in marmoset (decrease in activity of 20S-α subunit 
but not -β subunit; Zeng et al., 2006) and in human SH-SY5Y neuronal cells (Caneda-
Ferron et al., 2008).  
 
1.5 AIMS OF THE PROJECT 
 
As described above, mitochondrial dysfunction is thought to be an important factor in 
neurodegenerative pathways. The overall objective of the present study was to investigate 
changes in the mitochondrial proteome of cultured neuronal cells, of relevance to 
neurodegeneration, in particular PD, with the potential to uncover markers of mitochondrial 
dysfunction. 
In order to further investigate the role of mitochondrial impairment in neurodegeneration, a 
protocol for the study of the mitochondrial proteome was optimised, including optimisation 
of mitochondrial isolation from cellular extracts and resolution of the mitochondrial 
proteome profile using 2DE followed by the use of peptide mass fingerprinting to attempt 
to identify proteins from the profile.  
As neuronal cells are found in the post-mitotic state in the developed brain, mitochondrial 
profiles from differentiated neuroblastomas were compared to profiles from the mitotic 
state in order to evaluate the importance of differentiation in the mitochondrial proteome. 
Due to MPTP’s characteristics in mimicking PD and in mitochondrial impairment in 
humans and animal models, it was decided that it would be used as a model in the present 
study. To unravel markers of mitochondrial dysfunction prior cell death, cytotoxic and sub-
cytotoxic concentrations of MPTP in mouse N2a neuroblastoma cells were defined using 
cell viability and mitochondrial activity assays. Early markers of cell death pathways, for 
example apoptosis, were then investigated following sub-cytotoxic concentrations of MPTP 
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in order to further characterise the cellular state under the treatments chosen for further 
study. 
Using the optimised protocol for mitochondrial proteome study and the characterised 
model, the effects of MPTP on the mitochondrial proteome were investigated and potential 
mitochondrial markers of MPTP-induced toxicity were identified, followed by a validation 
process for some of them.  
Finally, VDAC1, one of the proteins previously identified as changing in levels following 
MPTP-treatment was further analysed. This study included further insights on the changes 
in levels and also a comprehensive analysis of its phosphorylation states following 
treatment with the neurotoxin as compared to controls in order to further understand its role 
in mitochondrial dysfunction. 
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CHAPTER II  MATERIALS AND METHODS 
 
2.1 MATERIALS 
 
2.1.1 Specialised equipment 
Aida image Analyser v.4.03 software, Raytek Scientific Ltd, Germany 
Axima CFR MALDI-TOF, Shimadzu UK Limited, UK 
Beckman Coulter DU 530 Life Science UV / VIS Spectrophotometer, Beckman, UK 
Bio-Rad mode 680 microplate reader, Bio-Rad Laboratories Ltd, UK 
CBS Isothermal liquid nitrogen storage system 2300 series, Sanyo Biomedical division, UK 
Consort Mini Power supply, Geneflow Ltd, UK 
Electro Blot mini, Geneflow Ltd, UK 
FLUOStar OPTIMA, BMG Labtech, UK 
Fujifilm FLA-5100 gel scanner, Fujifilm Life Sciences Products, UK 
Fujifilm Intelligent dark box, Fujifilm Life Sciences Products, UK 
Gilson pipettes (P10ml, P1000, P200, P100, P20, P10, P2), Anachem Ltd, UK 
Leica CLSM confocal laser microscope, Leica, Germany. 
MC1 Analytic AC2105 balance, Sarorius, UK 
MIKRO 22R microfuge, Hettich, Germany 
Mini-PROTEAN III system, Bio-Rad Laboratories Ltd, UK 
Nikon Digital Net camera DN100, Nikon, Japan 
Nikon Eclipse TS 100 inverted microscope, Nikon, Japan 
Ohaus Scout Pro balance, Fisher Scientific, UK 
OLYMPUS CK2 ULWCD light microscope, Olympus, Japan 
Philips pH meter – PW9409, Pye-Unicam, UK 
Power Pac 3000, Bio-Rad Laboratories Ltd, UK 
Power Pac Mini Power supply, Bio-Rad Laboratories Ltd, UK 
Protean IEF Cell, Bio-Rad Laboratories Ltd, UK 
Protean xi Vertical Electrophoresis Cells, Bio-Rad Laboratories Ltd, UK  
REVCO Ultima II -80oC freezer, Biocold Laboratories, UK 
Rotor-gene 3000 Thermal cycler, Corbett Research, Germany 
Sanyo CO2 incubator MCO-17AIC, Sanyo Gallenkamp PLC, UK 
Sanyo Harrier 18/80 refridgerated centrifuge, Sanyo Gallenkamp PLC, UK 
SM1 magnetic stirrer, Stuart Scientific, UK 
Stuart Block Heater SBH130D, Geneflow Ltd, UK 
Stuart Orbital Shaker SSL1, Geneflow Ltd, UK 
Stuart SA7 vortex mix, Geneflow Ltd, UK 
Tecan SPECTRA Fluor plate reader, Tecan UK Ltd, UK 
Ultraflex III TOF / TOF, Bruker Daltonics Limited, UK 
Walker class II microbiological safety cabinet, Walker safety cabinets Ltd, UK 
Water bath 20-90oC, Grant, UK 
Water purification system, Millipore, USA 
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2.1.2 Plastic ware 
All sterile plastic ware for tissue culture and of general laboratory use was supplied by 
Sarstedt, Leicester, UK 
Cryotube vials (Nunc brand products), Merck Ltd. Leicester, UK 
Disposable Haemocytometer C-Chip, Labtech International Ltd, UK 
15μ Slide 8-well for live cell analysis IbiTreat, Thistle Scientific, UK 
 
2.1.3 Glass ware 
Dounce All Glass 2 ml capacity Tissue Grinder, Apollo Scientific, UK 
 
2.1.4 Laboratory reagents 
All laboratory reagents were of the highest grade and purchased from Sigma-Aldrich 
Chemical Company, Poole, UK, unless otherwise specified. 
 
2.1.4.1 Cell culture reagents 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (M0896), N6,2′-O-
Dibutyryladenosine 3′,5′-cyclic monophosphate sodium salt (D0627), USA origin, sterile-
filtered, cell culture tested, hybridoma tested Foetal bovine serum (FBS) (F2442), Hybri-
Max™, sterile-filtered, hybridoma tested Dimethylsulfoxide (DMSO) (D2650), Trypan 
blue solution (0.4 %) (T8154), Sigma-Aldrich Chemical Company, UK 
Dulbecco’s Modified Eagles Medium (DMEM) (BE12-614F), L-Glutamine 200 mM 
(BE17-605E), Penicillin /streptomycin (DE17-603E), Lonza, UK 
Dulbecco’s Phosphate Buffer Saline (PBS) (H15-001), PAA laboratories, UK 
 
2.1.4.2 Laboratory reagents 
Acetyl-Asp-Glu-Val-Asp-7-amido methyl Coumarin (260-031-M005), Acetyl-Asp-Glu-
Val-Asp-CHO Alexis Biochemicals AXXORA Ltd, UK 
Glycerol 99% (v/v) (158920025), ACROS organics, UK 
RNaseZap (AM9780), Applied Biosystems, UK 
Bromophenol blue, BDH Laboratory Chemicals Group, UK 
7 cm pI 3-10 (163-2002), 7 cm pI 5-8 (163-2004), 7 cm pI 7-10 (163-2005), 17 cm pI 3-10 
IPG strips (163-2007), BioLyte 3/10 ampholyte (163-2094), Readystrip 100X pI 7-10 
Buffer (163-2093), Bio-Rad protein assay dye reagent concentrate (500-0006), Mineral Oil 
(163-2129), Precision Plus Protein Dual Color Standards (161-0374), Precision Plus 
Protein Unstained Standards (161-0363), ReadyPrep Overlay Agarose (163-2111), Bio-Rad 
Laboratories Ltd, UK 
3MM chromatography paper (CJF240090), Acetonitrile (A/0620/25), Dimethylsulfoxide 
(DMSO) (D/4120/PB08), Ethanol 95% (v/v) (E/0500/17), Ethylacetate 99% GLC 
(E/0850/17), Hydrochloric acid (H/1000/PB17), Methanol (M/3900/17), Sucrose 
(S/8560/60), Trifluoroacetic acid (T/3258/04), Fisher Scientific, Leicestershire, UK 
Accugel 29:1 (30% bis-acrylamide) (A20064), Geneflow, UK 
Destreak reagent (17-6003-18), PlusOne Silver Stain kit (17.1150.01), GE Healthcare Life 
Sciences, UK 
Nitrocellulose 0.22 μM pore size (WP2HY00010), Genetic Research Instrumentation, 
Essex, UK. 
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Accuprime Taq DNA Polymerase System (12339-016), PeppermintStick phosphoprotein 
molecular weight standards (P27167), ProQ-Diamond Phosphoprotein Gel Stain (P-33300), 
Superscript II Reverse Transcriptase (18064-022), Sypro Ruby Protein Gel Stain (S-
12000), Invitrogen, UK 
Peptide calibration Mix 4 (Proteomix) (C104), Re-crystallized α-cyano-4-hydroxycinnamic 
acid (αCHCA) matrix (M101), LaserBio Labs, France 
Vialight HS kit, (LT07-111), LumiTech Ltd, Nottingham UK 
[3-[(3-Cholamidopropyl)-dimethylammonio]-1-propanesulfonate] (CHAPS) (B2006), 
Dithiothreitol (DTT) (MB1015), Melford Laboratories Ltd, UK  
PCRSizer 100bp DNA Ladder (11400), Norgen Biotek, USA 
Microplate BCA protein assay Kit-reducing agent compatible (23252), Pierce ECL Western 
Blotting Substrates (32106), Perbio Science UK Ltd, UK 
dNTP mix, Sequencing Grade Trypsin (V5113), Promega UK, UK 
RNeasy Mini Kit (74104), Qiashredder (79654), Qiagen House, UK 
SensiMix SYBR (QT605), Quantace Ltd, UK 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (M2128), 
Oligonucleotides, Phosphatase inhibitor cocktail 2 (P5726), Protease inhibitor cocktail 
(P8340), Sigma-Aldrich Chemical Company, Poole, UK 
3088S Syngene Gene Genius Bioimaging System, Syngene Europe, UK 
 
2.1.5 Antibodies 
2.1.5.1 Primary antibodies 
Anti-Hsp60 antibody (ab46798), anti-LAMP2 antibody (ab37024), Abcam plc, UK 
Anti-caspase-2 antibody (ALX-804-355), Alexis Biochemicals, UK 
Anti-cleaved caspase-3 (9661), anti-GAPDH antibody (2118), anti-Lamin A/C antibody 
(2032), anti-phosphothreonine (42H4) (9386), anti-phosphotyrosine (P-Tyr-102) (9416), 
anti-VDAC antibody (4866), New England Biolabs, UK 
Anti-AATM antibody (C-21) (sc-46704), anti-cytochrome c antibody (7H8) (sc-13560), 
Anti-Heat Shock Protein 70 Clone BRM-22 (H5147), anti-phosphoserine antibody clone 
PSR-45 (P5747), Sigma-Aldrich Chemical Company, Poole, UK 
 
2.1.5.2 Secondary antibodies  
Goat anti-mouse immunoglobulin horseradish peroxidase conjugated (P0447), Goat anti-
rabbit immunoglobulin horseradish peroxidase conjugated (P0447), DAKO Ltd, UK 
Peroxidase-conjugated AffiniPure Bovine Anti-Goat IgG (H+L) (805-035-180), Stratech 
Scientific, UK 
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2.2 METHODS 
 
2.2.1 Cell culture of mouse N2a neuroblastoma cells 
 
Mouse N2a neuroblastoma cells were obtained from Flow Laboratories (Irving, UK). 
 
2.2.1.1 Maintenance of N2a neuroblastoma cells 
 
N2a cells were maintained as monolayer in growth medium containing Dulbeco’s modified 
Eagle’s medium (DMEM), 10 % (v/v) fetal bovine serum (FBS), 2 mM 2-L-glutamine, 100 
units/ml penicillin and 100 units/ml streptomycin. Cells were incubated at 37oC in a 
humidified atmosphere of 95 % air/5 % CO2.  
 
2.2.1.2 Subculture of N2a neuroblastoma 
 
Cells were assessed via light microscopy to check viability and confluency. At 60-85 % 
confluence, cells were mechanically detached using a Pasteur pipette, aspirating medium 
and squirting it out on the wall of the flask to detach the cells. Medium containing the cells 
was transferred to a Sterilin tube. Cells were then passaged by centrifuging the medium 5 
minutes at 300 g, re-suspending the pellet in 1 ml growth medium and transferring three to 
four drops to sterile flasks containing fresh medium. T25 flasks contained 8 ml; T75 flasks, 
20 ml of and T175 flasks, 40 ml growth medium. Flasks containing passaged cells were 
incubated at 37oC in a humidified atmosphere of 95 % air/5 % CO2 until 60-85 % 
confluency. 
 
2.2.1.3 Cell seeding 
 
To seed the cells, a 1 in 20 dilution of cell suspension was prepared during sub-culture 
following harvesting by re-suspending the pellet in 1 ml growth medium. A count of visible 
cells was performed using a Haemocytometer (0.1 mm depth). Five fields of 1 mm2 each 
were counted at a * 100 magnification. The average of cells per field was calculated as well 
as the cell density per ml: 
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 Cell density = average of cells per field *104 *dilution factor 
Cell density per ml was used to calculate the volume necessary to seed the cell at a required 
density. Mouse N2a cells were plated out in growth medium at a cell density of 5,000 
cells/well in a 96-wells plate (100 µl were added to each well) or 500,000 cells/T25 flask or 
4*106 cells/T75 flask or 9*106 cells/T175. The cells were allowed to recover for 24 hour at 
37oC in a humidified atmosphere of 95 % air/5 % CO2. 
 
2.2.1.4 Cryo-preservation of cells 
 
For long-term storage preservation, cells were frozen in liquid nitrogen storage. Cells were 
seeded in a T25 flask. Following 24 hours incubation, cells were harvested and resuspended 
in 1ml ice-cold freezing medium containing 2.5 % FBS, 25 units/ml Penicillin / 
Streptomycin, 1 mM glutamine and 10 % DMSO in DMEM and transferred into freezing 
vials on ice. These vials were rapidly transferred to -80oC freezer overnight before being 
transferred to the liquid nitrogen storage. 
 
2.2.1.5 Resuscitation of cryo-preserved cells 
 
A vial was removed from liquid nitrogen storage and quickly thawed in 37oC water bath. 
The content of the vial was transferred to a Sterilin tube containing 10 ml fresh growth 
medium previously warmed to 37oC. The tube was centrifuged at 300 g for 5 minutes and 
the supernatant was discarded. The pellet was re-suspended again in 10 ml growth medium 
and centrifuged the same way. Once the supernatant was discarded, the pellet was re-
suspended in 1 ml growth medium and transferred to a T25 flask containing growth 
medium. Cells were allowed to recover at 37oC in a humidified atmosphere of 95 % air/5 % 
CO2. 
 
2.2.1.6 Differentiation of N2a cells 
 
N2a cells were plated out in growth medium at a required cell density. The cells were 
allowed to recover for 24 hours at 37oC in a humidified atmosphere of 95 % air/5 % CO2. 
For the differentiation of cells, the growth medium was carefully removed. The cell 
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monolayer was carefully rinsed twice with DMEM to remove all traces of serum. The 
required volume of serum free medium (SFM) was then added, comprising 0.3 mM 
dibutiryl adenosine 3',5'-cyclic monophosphate (dbcAMP), 2 mM 2-L-glutamine, 100 
units/ml penicillin and 100 units/ml streptomycin in DMEM. Cells were incubated at 37oC 
in a humidified atmosphere of 95 % air/5 % CO2. 
 
2.2.1.7 MPTP treatment 
 
Following induction of differentiation, cells were incubated for 16 hours. The medium was 
then replaced by SFM containing 0.3 mM dbcAMP and the required concentration of 
MPTP (0 to 5 mM). Cells were incubated at 37oC in a humidified atmosphere of 95 % air/5 
% CO2 for the period of time required. 
 
2.2.1.8 Staurosporine (STS) treatments 
 
Following induction of differentiation in T25 flask, cells were incubated for 16 hours. The 
medium was then replaced by 1 ml SFM containing 0.3 mM dbcAMP and 500 nM STS. 
Cells were incubated at 37oC in a humidified atmosphere of 95 % air/5 % CO2 for the 
period of time required. 
 
2.2.1.9 Caspase-3/7 inhibitor treatment 
 
For choosing the most adequate concentration of caspase-3/7 inhibitor (DEVD-CHO), 
mitotic cells were treated with different concentration of the inhibitor (0 to 50 μM) for 1 
hour in parallel to controls. Following the incubation, different treatments were added to 
the cells in presence or absence of inhibitor. 
For the effects of the inhibitor in conjunction with MPTP or STS treatments, 5 μM caspase-
3/7 inhibitor was added to the medium following 16 hours differentiation in SFM 
supplemented with 0.3 mM dbcAMP. After 1 hour incubation, cell treatments were 
performed in the presence and absence of 5 μM inhibitor. 
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2.2.2 Cell viability 
 
2.2.2.1 Morphology of the cells 
 
Live cells were observed using phase contrast microscopy at a * 400 magnification. Digital 
images of cells were then taken. 
 
2.2.2.2 Trypan blue exclusion assay 
 
Trypan blue is a dye that can enter non viable cells that have lost their membrane integrity. 
Following cell differentiation and MPTP treatment in T25 flasks, cells were harvested and 
resuspended in 1 ml growth medium. 20 μl of cell suspension were added to 100 μl trypan 
blue and 80 μl DMEM (cells were then diluted 1 in 10) in a 1.5 ml Eppendorf tube. The 
tube was vortex mixed thoroughly and left to stand for 2 minutes. A count of unstained 
cells (viable cells) was performed using a Haemocytometer as well as a count of total cells 
(refer to section 2.2.1.3). The percentage of viable cells was calculated as follows:  
% viable cell = number unstained cells / total number of cells * 100. 
 
2.2.2.3 MTT assay 
 
3-(4,5-dimethylthiaxol-2yl)-2,5-diphenyltetrazolium bromide (MTT) is a yellow substrate 
that is reduced by reductase enzymes. Once reduced to a purple formazan product, the 
product accumulates in the cells if the integrity of the cell membrane is intact (Mosmann, 
1983). 
Typically, differentiating cells were exposed to different concentrations of MPTP (0 to 5 
mM) in 96-well plates. After 24 to 48 hours exposure (time points), 10 µl filtered MTT 
solution (5 mg/ml) were added to each well for 1 hour. The medium was then carefully 
removed from the wells and 100 µl dimethyl sulphoxide (DMSO) were added to each well. 
Plates were gently shaken on a plate shaker for 2 minutes. The absorbance in each well was 
read at 570 nm within 30 minutes. Results were expressed as a mean percentage cell 
viability compared to controls (untreated cells) ± SEM. Data were statistically analysed by 
a paired t-test using a two-tailed distribution. 
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2.2.2.4 JC-1 fluorescent stain 
 
Mouse N2a neuroblastoma cells were seeded at a density of 8,000 cells / 300 μl growth 
medium on 15 micro-8-well Slides similarly as described in section 2.2.1.3 and 
differentiated and treated as described in sections 2.2.1.6-7. Following 24 hours treatment, 
the medium was removed. Three hundred microliters 10 μM JC-1 staining (Molecular 
probes) diluted in DMEM were added to each well. The slide was incubated 3-5 minutes at 
37oC in a humidified atmosphere of 95 % air/5 % CO2. The medium was then discarded, 
the cells were washed several times in DMEM and then incubated 30 minutes at 37oC in a 
humidified atmosphere of 95 % air/5 % CO2 for recovery. The slide was observed on the 
laser confocal microscope. Using the Leica confocal software, the green signal and the red 
signal of ten cells present in a field of view were measured for each treatment. The data 
were expressed as a mean of green / red signal intensity per cell compared to the ratio in 
controls and statistically analysed by a paired t-test using a two-tailed distribution ± SEM 
(n = 10). 
 
2.2.2.5 Cellular ATP assay 
 
Cellular ATP presence was monitored using the Vialight HS kit’s manufacturer’s 
guidelines. The principle of the method relies on the ability of luciferase to catalyse the 
formation of light from ATP and luciferin. This light production is proportional to ATP 
concentration.  
Known concentrations of ATP were used to build a standard curve as shown in table 2.2 
using stock solutions previously made up as shown in table 2.1. Each standard was plated 
in triplicates. Cells were plated out in a 96-well plate at a 10,000 cells / well density, 
differentiated and treated as previously described (section 2.2.1). Each treatment was plated 
in triplicates. After the required time, the plate was removed from the incubator and left at 
room temperature for 5 minutes. Fifty microliters medium were removed from each well. A 
total of 25 μl of Cell Lysing Reagent were added to each sample well and also to wells 
containing 50 μl ATP standards previously prepared and the plate was left for 10 minutes. 
Fifty microliters of each cell lysate and ATP standards were transferred to wells in a white 
96-well microplate. Then, 50 μl of ATP monitoring reagent PLUS were added to each well 
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to generate the luminescence signal. The plate was incubated for 2 minutes. Luminescence 
of each well was read using a luminescence plate reader. 
 
ATP concentration ATP volume (stock used) (μl) DMEM (μl) 
200 μM 22 (10 mM) 980 
2 μM 10 (200 μM) 990 
0.1 μM 50 (2 μM) 950 
Table 2.1: ATP stock concentrations used to produce an ATP calibration graph. 
 
ATP concentration ATP volume (stock used) (μl) DMEM (μl) 
0 nM 0 (0 mM) 1000 
5 nM 50 (0.1 μM) 950 
25 nM 250 (0.1 μM) 750 
100 nM 50 (2 μM) 950 
500 nM 250 (2 μM) 750 
1,000 nM 5 (200 μM) 995 
2,500 nM 12.5 (200 μM) 987.5 
Table 2.2: ATP Concentration for each standard used to produce a calibration graph. 
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Figure 2.1: Typical standard calibration graph for ATP using the ViaLight HS 
bioluminescent method. 
 
A typical standard calibration curve of mean luminescence for ATP standards (blanked to 
zero ATP) versus ATP concentration (nM) is shown in figure 2.1. Using the linear 
correlation, ATP concentration in each sample was estimated. 
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Results were also expressed as a mean percentage ATP presence compared to controls ± 
SEM. Data were statistically analysed by a paired t-test using a two-tailed distribution. 
 
2.2.3 Protein estimation of samples 
 
Unless otherwise indicated, the protein content of each sample was estimated using the Bio-
Rad protein assay based on the Bradford method (Bradford, 1976). This method is based on 
the particularity of Coomassie brilliant blue G-250 to shift in colour when binding to 
proteins. The assay was used in accordance with the manufacturer’s specifications. Bovine 
serum albumin (BSA) standards ranging from 0 to 50 μg were used to produce a calibration 
graph from which a linear correlation was calculated. Each BSA standards and samples 
were diluted as shown in table 2.3 in duplicates. 
BSA concentration / 
sample (μg) 
Volume of BSA 
stock (1 mg / ml) 
(μl) 
Volume of extraction 
buffer / sample (μl) 
Volume of 
water (μl) 
0 0 10 790  
5 5 10  785 
10 10 10 780 
15 15 10 775 
20 20 10 770 
25 25 10 765 
30 30 10 760 
40 40 10 750 
50 50 10 740 
Sample 0 10 790 
Table 2.3: Preparation of BSA standards and samples prior Bio-Rad protein 
estimation  
 
Each Eppendorf tube was vortex mixed. 200 μl of Bio-Rad protein assay reagent were 
added to each tube. Each replicate was vortex mixed again. 100 μl of each replicate were 
transferred onto a transparent 96-well plate. The plate was read within an hour at 570 nm. 
Protein content of each sample was calculated from the mean of duplicates using the linear 
correlation obtained from the BSA calibration curve. 
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2.2.4 Differential centrifugation 
 
2.2.4.1 Cell harvesting 
 
All the steps were undertaken on ice. Following seeding, differentiating and treatment, cells 
were detached from flasks and harvested at 300 g for 5 minutes. The supernatant was 
discarded and the pellet was resuspended into 1 ml sterile PBS buffer. This step was 
repeated three times, following which the pellet was resuspended in 500 μl extraction 
buffer (EB) containing 10 mM HEPES, pH 7.5, 70 mM sucrose, 200 mM mannitol, 1 mM 
EGTA, 1 % protease inhibitors and 1 % phosphatase inhibitors. 
 
2.2.4.2 Homogenisation of the sample 
 
The homogeniser used was a Dounce All Glass 2 ml capacity Tissue Grinder accompanied 
with a Loose Pestle and a Tight Pestle (Apollo Scientific, UK). Following harvesting, the 
cell extract was transferred into the glass-glass homogeniser and homogenised ten times 
with the loose pestle and then ten times with the tight pestle. The cell lysate was then 
transferred to a 1.5 ml plastic tube. 
 
2.2.4.3 Differential centrifugation protocol 
 
Differential centrifugation was then carried out following a modified protocol from Lai and 
Clark (1979). Two initial low speed spins were used. The first centrifugation was at 1,000 g 
for 10 minutes and the second, using the resulting pellet resuspended in 200 μl EB, for 5 
minutes at 1,000 g. The resultant pellet was called “nuclear fraction”, which mainly 
contained nuclei. Supernatants from these spins were combined and centrifuged at 10,000 g 
for 15 minutes and the subsequent pellet was further centrifuged at 10,000 g for 10 minutes 
after resuspension in extraction buffer. The resultant pellet was called “mitochondrial 
pellet”, which contained mostly enriched mitochondria. Supernatants were combined and 
called “cytoplasmic fraction”, which contained mainly the cytoplasm and organelles except 
nuclei and mitochondria (figure 2.2). The fractions were protein estimated using the Bio-
rad assay (section 2.2.3) and then stored at -80oC but for further analysis of purity 
assessment, fresh pellets were resuspended in extraction buffer. 
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Figure 2.2: Schematic view of the subcellular fractionation protocol 
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2.2.5 SDS-PAGE 
 
Proteins from samples were separated in accordance to their molecular weight using 
sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
 
2.2.5.1 Preparation of resolving gel 
 
The Bio-Rad mini-Protean III apparatus was used for mini-gels and the Bio-Rad Protean II 
XL Cell was used for large gels. Combs and spacer plates were generally 1.5 mm thick. 
For mini-gels, 10 ml resolving gel mix were prepared; while 60 ml were prepared for large 
gels. The percentage of polyacrylamide used was chosen in function of the molecular 
weights of the proteins of interest (refer to table 2.4 for mini gels as an example). 
Tetramethylethylene diamine (TEMED) and ammonium persulfate (APS) were added prior 
pouring the gel as they are catalyst and polymerising agents, respectively. 8 ml resolving 
gel were poured for mini gels and 50 ml for large gels. Distilled water was layered on top 
of the gel. The gel mix was allowed to polymerise at room temperature for approximatively 
30-45 minutes. 
 
Reagent 7.5 % resolving gel 
10 %  
resolving gel 
12 %  
resolving gel 
15 % 
resolving gel 
30 % acrylamide stock 2.5 ml 3.3 ml 4.0 ml 5 ml 
1.5 M Tris, pH 8.8 2.5 ml 2.5 ml 2.5 ml 2.5 ml 
10 % (w/v)SDS 0.1 ml 0.1 ml 0.1 ml 0.1 ml 
Distilled water 4.9 ml 4.1 ml 3.4 ml 2.4 ml 
TEMED (add to 
polymerise) 10 μl 10 μl 10 μl 10 μl 
APS (add to 
polymerise) 50 μl 50 μl 50 μl 50 μl 
Table 2.4: Preparation of 10 ml polyacrylamide resolving gels for mini gels. 
Those volumes were multiplied by 6 for large gels. 
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2.2.5.2 Preparation of stacking gel 
 
Once the resolving gel was polymerised, the distilled water layer was removed. 1 ml 4 % 
acrylamide stacking gel (table 2.5) was added to the top of the plate for both mini and 
large-scale gels. The required comb was applied to the gel. The gel mixture was allowed to 
polymerise at room temperature for approximatively 45-60 minutes. 
 
Reagent 10 ml 4 % resolving gel 
30 % acrylamide stock 1.33 ml 
0.65 M Tris, pH 6.8 2.5 ml 
10 % (w/v)SDS 0.1 ml 
Distilled water 6.1 ml 
TEMED (add to polymerise) 20 μl 
APS (add to polymerise) 50 μl 
Table 2.5: Preparation of polyacrylamide stacking gels. 
 
2.2.5.3 Preparation of samples and loading 
 
The required amount of sample was aliquoted and mixed with the same volume of sample 
buffer (0.125 M Tris pH6.8, 20 % (v/v) glycerol, 4 % (v/v) SDS, 0.004 % (w/v) 
bromophenol blue, 10 % (v/v) β-mercaptoethanol). When the volume of sample was too 
high (over 20 μl), the sample was acetone precipitated by adding ten times the sample 
volume of ice-cold acetone and incubating at -20°C overnight. The samples were then 
centrifuged at 10,000 g for 15 minutes and acetone was removed. The appropriate sample 
buffer volume was added and samples were boiled for 10 minutes before being pulse-
centrifuged for 10 seconds prior to analysis by SDS-PAGE.  
 
2.2.5.4 Running the gel 
 
Once the stacking gel was polymerised, the comb was carefully removed. The set-up was 
transferred to the tank. SDS-PAGE buffer (0.0265 M Tris, 0.192 M glycine, 0.1 % SDS 
(w/v), pH 8.3) was first added to the tank. Each sample was added to each lane and 5 μl 
pre-stained molecular weight markers were added to a further lane. Separation of proteins 
was allowed at a constant voltage (180V). Voltage was stopped as the dye front was at the 
bottom level of the plates. 
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2.2.6 Immunoblotting  
 
2.2.6.1 Wet western blotting 
 
Separated proteins were then transferred to nitrocellulose membranes by wet blotting 
(Towbin et al., 1979) using the manufacturer’s instructions (Geneflow Electro Blot Mini). 
Two pieces of filter paper (9 cm * 6 cm) pre-soaked in elecroblotting buffer were laid onto 
a fibre pad over the black plastic side of the cassette. The gel was transferred onto it and 
overlaid by a nitrocellulose membrane (9 cm * 6 cm) being careful to remove any air 
bubbles. And two other filter papers were added followed by a fibre pad and the whole 
“sandwich” was sealed in the cassette. Each cassette was transferred to the tank being 
careful to orientate the gel side towards the negative electrode. Electroblotting buffer (39 
mM glycine, 48 mM tris, 0.0375 % (w/v) SDS, 20 % (v/v) methanol) was added up to the 
top of the cassettes and a constant voltage of 30V was applied overnight.  
The following day, blotting efficiency was checked by staining with copper phthalocyanine 
3,4’,4’’,4’’’- tetrasulfonic acid tetrasodium salt in 12.5 mM HCl. Blots were destained in 
12.5 mM NaOH prior to immunoprobing, after recording a digital image. 
 
2.2.6.2 Immunoprobing 
 
Membranes were incubated in blocking reagent to reduce non-specific binding. Two 
different blocking solutions were used depending on the primary antibody. Typically, 5 % 
(w/v) BSA in Tris buffer saline (TBS: 50 mM tris, 200 mM NaCl, pH 7.4) for 2 hours was 
used with anti-phosphorylated antibodies and 3 % (w/v) Marvel milk for 1 hour was used 
for other antibodies. Following blocking, nitrocellulose membranes were incubated in 
primary antibody overnight at 4oC with gentle shaking. Table 2.6 shows the details of 
which blocking reagent was used and the antibody working dilutions required for each 
antibody. 
Unbound primary antibody was washed away by incubating the membrane in TBS 
containing 0.1 % (v/v) Tween 20 (TBS-tween) thoroughly shaking for 20 minutes at room 
temperature. This wash was repeated 3 times in total. The membrane was then incubated 2 
hours at room temperature in secondary antibody corresponding to species specificity of the 
primary antibody used (table 2.6) and being conjugated with horseradish peroxidase (HRP) 
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while being gently shaken. The membrane was then washed as before 3*20 minutes in 
TBS-tween and then 5 minutes in TBS for washing away the tween prior exposing the 
membrane. The membrane was incubated with HRP substrates for enhanced 
chemilunescence (ECL) using the manufacturer’s instructions (Pierce). The membrane was 
incubated for 1 minute in substrates. Excess of substrate was drained before exposing the 
membrane to chemiluminescence using the Fujifilm LAS 3100 from Raytek Scientific 
Limited. The exposure times used for each primary antibody are shown in table 2.6. 
 
Primary 
antibody 
specificity 
Epitope 
specificity 
Blocking 
reagent 
used 
Working 
dilution 
Secondary 
antibody 
working 
dilution 
Exposure 
time to 
ECL 
Cytochrome c 
(7H8) 
monoclonal 
Full length of 
human origin 
3 % (w/v) 
marvel 
milk 
1:500 
in 5 % 
(w/v) BSA 
1:1,000  
anti-mouse  
10 
minutes 
LAMP2 
Polyclonal 
17 amino 
acids from C-
terminus of 
human origin 
3 % (w/v) 
marvel 
milk 
1:500 
in 5 % 
(w/v) BSA 
1:1,000  
anti-rabbit  
15 
minutes 
Lamin A/C 
polyclonal 
Residues 
surrounding 
Asp230 of 
human origin 
3 % (w/v) 
marvel 
milk 
1:1,000 
in 5 % 
(w/v) BSA 
1:1,000  
anti-rabbit 
10 
minutes 
GAPDH 
(14C10) 
monoclonal 
Full length of 
human origin 
3 % (w/v) 
marvel 
milk 
1:1,000 
in 5 % 
(w/v) BSA 
1:1,000  
anti-rabbit 
10 
minutes 
VDAC1 
polyclonal 
Amino 
terminus of 
human origin 
3 % (w/v) 
marvel 
milk 
1:1,000 
in 5 % 
(w/v) BSA 
1:1,000  
anti-rabbit 
10 
minutes 
AATM 
(GOT2) (C21) 
polyclonal 
C-terminus of 
GOT2 of 
human origin 
3 % (w/v) 
marvel 
milk 
1:500 
in 5 % 
(w/v) BSA 
1:10,000 
Anti-goat 8 minutes 
Hsp60 
polyclonal 
Synthetic 
peptide of 
human origin 
3% (w/v) 
marvel 
milk 
1:5,000 
in 5% (w/v) 
BSA 
1:1,000  
anti-rabbit 
30 
seconds 
Hsp70 (BRM-
22) 
monoclonal 
Full length of 
bovine brain 
origin 
3 % (w/v) 
marvel 
milk 
1:10,000 
in 5 % 
(w/v) BSA 
1:1,000  
anti-mouse 1 minute 
Phospho-
serine (PSR-
45) 
monoclonal 
N/A 5 % (w/v) BSA 
1:500 
in 5 % 
(w/v) BSA 
1:1,000  
anti-mouse 1 hour 
Phospho-
threonine N/A 
5 % 
(w/v)BSA 
1:1,000 
in 5 % 
1:1,000  
anti-mouse 
10 
minutes 
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(42H4) 
monoclonal 
(w/v) BSA 
Phospho-
tyrosine (P-
Tyr-102) 
monoclonal 
N/A 5% (w/v) BSA 
1:500 
in 5 % 
(w/v) BSA 
1:1,000  
anti-mouse 1 hour 
Caspase-3 
amino-
terminal 
residues 
adjacent to 
(Asp175), 
human origin 
3% (w/v) 
marvel 
milk 
1:500 
in 5 % 
(w/v) BSA 
1:1,000  
anti-rabbit 
15-20 
minutes 
Caspase-2 Epitope of P19 subunit  
3% (w/v) 
marvel 
milk 
1:500 
in 5 % 
(w/v) BSA 
1:1,000  
anti-rat 
10-15 
minutes 
Table 2.6: Epitope and species specificity and working dilutions for each primary 
antibody used for immunoblotting. 
 
2.2.6.3 Stripping and re-probing of western blot 
 
Primary and secondary antibodies could be un-bound from the membrane by using 
stripping stringent conditions. The membrane was washed in TBS-tween for a few minutes 
to ensure that ECL substrates were removed. Nitrocellulose was bathed in 50 ml stripping 
buffer (62.5 mM Tris-HCl, pH 6.7, 2 % (w/v) SDS, 100 mM β-mercaptoethanol (added 
fresh)) at 55oC for 30 minutes. The membrane was then transferred to TBS-tween for 4*10 
minutes washes prior blocking in a suitable solution (see table 2.6). The membrane was 
then probed as explained in section 2.2.6.2. 
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2.2.6.4 Quantification of bands detected on western blot 
 
To allow comparison between samples, band intensities were measured using AIDA 
software according to the manufacturer’s instructions. Intensities of each band of interest 
were measured and corrected for background. Each band intensity was then also corrected 
for total protein using the corresponding copper stained full lane (figure 2.3). Each 
treatment was then expressed as a percentage compared to corresponding control ± SEM. 
Data were statistically analysed by a paired t-test using a two-tailed distribution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Copper stained western blots showing total protein staining of different samples. 
Cells were pre-differentiated for 16 hours in serum free medium supplemented with 0.3 mM 
dbcAMP. Following incubation, cells were treated or not with 1 mM MPTP for 24 hours. 
Subcellular fractionation was then carried out and 20 μg protein from each fraction for each 
treatment were fractionated by 1D-SDS-PAGE (12 % resolving gel) and then transferred onto a 
nitrocellulose membrane. Blots were stained with copper pthalocyanine (section 2.2.6.1) to check 
for protein loading and efficiency of transfer. A typical digital image is shown here. Each lane 
intensity was quantified, using AIDA software. Each lane was labeled as profile 1 to 8. 
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2.2.7 Purity assessment of subcellular fractions using activity assays 
 
2.2.7.1 Succinate dehydrogenase activity assay 
 
To assess the mitochondrial yield in the “mitochondrial fraction” and contamination in 
other fractions, a succinate dehydrogenase (SDH) activity assay was used. Following 
subcellular fractionation (refer to section 2.2.4), glass test tubes were prepared containing 1 
% (w/v) iodonitrotetrazolium (INT), 100 μl SDH buffer (0.25 M sodium phosphate, 5 mg / 
ml bovine serum albumin (BSA), pH 7.4), 150 μl distilled water and 50 μl fraction sample. 
Tubes were equilibrated at 37oC in a water bath prior to the addition of 100 μl sodium 
succinate (100 mM). The tubes were incubated for 1 hour 30 minutes in a water bath at 
37oC and the reaction was stopped by the addition of 500 μl trichloroacetic acid (TCA) (10 
% (w/v)). 3 ml ethylacetate were added to each tube and thoroughly vortex mixed. Tubes 
were incubated overnight for the organic phase to separate from the aqueous phase. 100 μl 
of the top aqueous phase were transferred to a 96-well-plate and the absorbance was read at 
490 nm. Absorbance versus time was plotted and the gradient of the plot was used to 
calculate the specific activity in each sample. Results were expressed as a mean specific 
activity per microgram protein (each fraction was protein estimated using the Bio-Rad 
reagent, refer to section 2.2.3); in order to check for enrichment, the specific activity values 
for various fractions were normalised against the specific activity of the total extract  (given 
a value of 1). Data were expressed as mean ± SEM and statistically analysed by a paired t-
test using a two-tailed distribution. 
 
2.2.7.2 NADPH-cytochrome c reductase (NADPH-CR) activity assay 
 
In a cuvette, 1 ml of NADPH-CR buffer (50 mM sodium phosphate, 0.1 mM EDTA, pH 
7.7), 50μl cytochrome c (25 mg/ml) in NADPH-CR buffer and 50 μl fraction sample were 
added. 100 μl NADPH (2 mg/ml) in NADPH-CR buffer were added. Absorbance was 
recorded every 15 seconds for 3 minutes at 550 nm. Absorbance versus time was plotted 
and the gradient of the plot was used to calculate the specific activity in each sample. 
Results were expressed as a mean specific activity per microgram protein (each fraction 
was protein estimated using the Bio-Rad reagent, refer to section 2.2.3); in order to check 
for enrichment, the specific activity values for various fractions were normalised against 
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the specific activity of the total extract  (given a value of 1). Data were expressed as mean ± 
SEM and statistically analysed by a paired t-test using a two-tailed distribution. 
 
2.2.7.3 Marker protein detection by western blot analysis 
 
The different fractions and total extracts following subcellular fractionation (section 2.2.4) 
were further analysed by western blotting (section 2.2.5 and 6) using anti-cytochrome c, 
anti-lamin A/C, anti-GAPDH and anti-LAMP2 antibodies as specific markers of 
mitochondrial, nuclear, cytoplasmic and lysosomal fractions, respectively, as primary 
antibodies (for protocol refer to table 2.6). Intensities of each band were measured relative 
to copper stain band intensities as described in section 2.2.6.4. In order to check for 
enrichment, the corrected intensity values for various fractions were normalised against the 
corrected intensity of the total extract (given a value of 1). Data were expressed mean ratio 
± SEM and statistically analysed by a paired t-test using a two-tailed distribution. 
 
2.2.8 2-Dimensional-SDS-PAGE (2DE) 
 
To improve protein separation on a gel, proteins can be separated by their charge using 
isoelectrofocusing (IEF) prior to being separated by their molecular weight using SDS-
PAGE (O’Farrell, 1975). 
 
2.2.8.1 First dimension: the IEF step 
 
- pI 3-10 large gels 
Mitochondrial samples containing 150-200 µg protein were pelleted as explained in section 
2.2.4.3. 300 µl (IEF) rehydration buffer (8 M urea, 4 % (w/v) CHAPS, 2 % (v/v) carrier 
ampholyte, 0.0002 % (w/v) bromophenol blue, 65 mM DTT (added freshly) in nanopure 
water) were added to the mitochondrial pellets and shaken for 2 hours at room temperature. 
Then, samples were transferred to the large IEF focusing tray (17 cm) along with a 
ReadyStrip immobilized pH gradient (IPG) strip (pH 3-10, 17 cm, Bio-Rad) and allowed to 
passively rehydrate for 1 hour before overlaying each strip with 4 ml mineral oil. Strips 
were then actively rehydrated for 13 hours 40 minutes at 50 V using a PROTEAN IEF cell 
followed by focusing (250 V for 20 min linear, 10,000 V for 2 hours 30 minutes linear, 
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10,000 V for 60,000 V/hour rapid). Strips were then transferred to a plastic equilibration 
tray and stored at -80oC or processed to equilibration immediately. 
 
- pI 3-10 and pI 5-8 mini-gels 
A similar protocol was used except that volumes and quantities were smaller. 
Mitochondrial samples containing 50-80 µg protein were pelleted or acetone precipitated. 
Up to 125µl sample IEF rehydration buffer were added to the mitochondrial pellets and 
shaken for 2 hours at room temperature. Then, samples were transferred to the small IEF 
focusing tray (7 cm) along with a ReadyStrip IPG strip (pH 3-10 or pH 5-8, 7 cm, Bio-Rad) 
and allowed to passively rehydrate for 1 hour before overlaying each strip with 2 ml 
mineral oil. Strips were then actively rehydrated for 13 hours 40 minutes at 50 V using a 
PROTEAN IEF cell followed by focusing (250 V for 15 min linear, 4,000 V for 2 hours 
linear, 4,000 V for 10,000 V/hour rapid). Strips were then transferred to a plastic 
equilibration tray and stored at -80oC or processed to equilibration immediately. 
For optimisation purposes, different detergents were trialled in the IEF rehydration buffer: 
4% CHAPS was replaced by 1.5 % triton or 4 % ASB-14. 8 M urea could also been 
replaced by 6 M urea and 2 M thiourea for the same purposes and acetone precipitation 
prior sample lysis was also tested. 
 
- pI 7-10 mini gels 
A different protocol had to be used for pI 7-10 mini-gels. 50-80 µg mitochondrial samples 
were acetone precipitated. Then, 1.5 % destreak reagent was added to pI 7-10 IEF 
rehydration buffer (6 M urea, 2 M thiourea, 4 % (w/v) CHAPS, 1X (v/v) pI 7-10 Bio-lyte, 
0.0002 % (w/v) bromophenol blue in nanopure water) and mixed thoroughly. Then, 110 µl 
buffer were transferred to a small plastic equilibration tray (7 cm) along with a ReadyStrip 
IPG strip (pH 7-10, Bio-Rad) and allowed to passively rehydrate for 1 hour before 
overlaying each strip with 2 ml mineral oil. Strips were then passively rehydrated overnight 
on the bench. Strips were transferred to the IEF focusing tray. Wicks were added on both 
sides of the strips between the electrodes and the strips. Up to 65 mM DTT were added to 
15 µl freshly thawed pI 7-10 IEF rehydration buffer and mixed for 1 hour with 50-80 µg 
acetone precipitated mitochondrial proteins. The samples were then added under the 
passively rehydrated strips on the positive side. Following a 30 minutes incubation, 2 ml 
mineral oil were overlaid and strips were focused (250 V for 15 min linear, 4,000 V for 2 
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hours linear, 4,000 V for 15,000 V/hour rapid). Strips were then transferred to a plastic 
equilibration tray and stored at -80oC or processed to equilibration immediately. 
 
2.2.8.2 Equilibration of strips 
 
Following IEF, strips were equilibrated by shaking gently for 15 minutes in equilibration 
buffer I (6 M urea, 2 % (w/v) SDS, 20 % (v/v) glycerol, 50 mM Tris pH 8.8, in nanopure 
water and 2 % (w/v) DTT) and then 15 minutes in equilibration buffer II (6 M urea, 2 % 
(w/v) SDS, 20 % (v/v) glycerol, 50 mM Tris pH 8.8 in nanopure water and 2.5 % (w/v) 
iodoacetamide). 
For optimisation purposes, a different concentration of glycerol (30 % (v/v)) was trialled in 
both equilibration buffers. 
 
2.2.8.3 Second dimension: SDS-PAGE  
 
12 % (w/v) polyacylamide resolving gels overlaid with a 1-2 cm 4 % (w/v) polyacylamide 
stacking gel were prepared (refer to section 2.2.5). Strips were then rinsed in running 
buffer, inserted onto the SDS-PAGE stacking gel and overlaid with 1.5 % melted agarose. 
SDS-PAGE was then run as explained in section 2.2.5.4. Gels were then transferred onto a 
nitrocellulose membrane and probed as explained in section 2.2.6 or transferred to a plastic 
tray for staining. 
 
2.2.8.4 Gel staining 
 
- Silver stain 
PlusOne Silver staining kit was used to dye total proteins. The protocol was following the 
manufacturer’s instructions (GE Healthcare) and is shown in table 2.7. Gels were then 
imaged using The Fujifilm FLA-5100 image scanner using digitising parameters. 
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Table 2.7: Silver staining steps 
STEP REAGENT PROTOCOL 
Fixation step 
50 % (v/v) ethanol,  
10 % (v/v) acetic acid in ultra pure 
water 
2 * 15 min 
Thorough shaking 
Washing step Ultrapure water 4 * 5 min Thorough shaking 
Sensitization step 
30 % (v/v) ethanol 
0.2 % (v/v) sodium thiosulphate 
500 µM sodium acetate in 
ultrapure water 
1 * 30 min 
Gentle shaking 
Washing step Ultrapure water 4 * 15 min Thorough shaking 
Silver stain step 0.25 % (v/v) silver nitrate solution in ultrapure water 
1 * 20 min 
Gentle shaking 
Washing step Ultrapure water 2 * 1 min Thorough shaking 
Developing step 
236 µM sodium carbonate 
0.148 % (v/v) Formaldehide in 
ultrapure water 
Until proteins appear 
Thorough shaking 
Stopping step 183 µM EDTA-Na2 
1 * 10 min 
Thorough shaking 
Wash step Ultrapure water 
2 * 5 min 
Until pick spots 
Thorough shaking 
 
- SyproRuby 
SyproRuby dye kit was also used to dye total proteins. The protocol was following the 
manufacturer’s instructions (Invitrogen) and is shown in table 2.8. Gels were then imaged 
with The Fujifilm FLA-5100 image scanner using the following parameters: 1 image / 1 
Laser, 473 nm laser, LPB filter at 600 V resolution. 
If the gels were stained with ProQ Diamond dye prior SyproRuby, the fixation step was 
replaced by a 2 * 5 minutes washing step in ultrapure water. 
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STEP REAGENT PROTOCOL 
Fixation step 
50 % (v/v) ethanol,  
10 % (v/v) acetic acid in ultra pure 
water 
2 * 15 min 
Thorough shaking 
Stain step SYPRO Ruby gel stain Overnight (16 hours) Gentle shaking 
Background 
destain step 
10 % (v/v) methanol 
7 % (v/v) acetic acid 
30 min 
Thorough shaking 
Wash step Ultrapure water 2 * 5 min Thorough shaking 
Table 2.8: SyproRuby staining steps. 
 
- ProQ Diamond 
ProQ Diamond dye kit was used to dye specifically phosphorylated proteins. The protocol 
was following the manufacturer’s instructions (Invitrogen) and is shown in table 2.9. Gels 
were then imaged with The Fujifilm FLA-5100 image scanner using the following 
parameters: 1 image / 1 Laser, 532 nm laser, Cy3 filter at 600 V resolution. 
 
STEP REAGENT PROTOCOL 
Fixation step 50 % (v/v) methanol,  10 % (v/v) acetic acid 
overnight 
30 min 
Wash step Heated Ultrapure water 4 * 15 min 
Stain step ProQ diamond stain 3 hours 
Destain step 20 % (v/v) acetonitrile 50 mM sodium acetate, pH4 4 * 1 hour 
Wash step Ultrapure water 
5 min 
5 min (image 1) 
20 minutes (image 2) 
Table 2.9: ProQ Diamond staining steps. 
 
2.2.8.5 2D-SDS-PAGE image analysis 
 
To allow comparison between 2D-gel electrophoretogram pictures, the SameSpots software 
from Progenesis was used. Images of each gel were taken using Fujifilm FLA-5100 image 
scanner. Pictures were transferred to Samespots software (Progenesis) and each gel image 
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was aligned to one chosen gel (called reference). The statistical package allowed choosing 
the best alignment features. Each isolated spot volume was normalised to the total volume 
spot calculated for the given gel. Each treatment gel was paired with its corresponding 
control gel and each aligned spot was compared for normalised volume in each gel and 
compared to other gels. The statistical analysis was included in the software. Any spot 
showing changes in level between controls and treatments with a p < 0.1 using a paired 
student t-test was selected.  
 
2.2.9 Spot picking and trypsinisation 
 
Following image capture, gels were washed in ultrapure water. Selected spots (for 2DE) 
were picked using sterile tips with cut ends and transferred to 1.5 ml sterile Eppendorf 
tubes. These spots were incubated overnight in LC-MS grade water. 
A solution of 25 mM ammonium bicarbonate was prepared fresh as well as 2:1 (v:v) 
acetonitrile (ACN): 25 mM ammonium bicarbonate. Water was removed from the tubes 
containing gel pieces, after which gel pieces were dehydrated in 50 µl ACN: ammonium 
bicarbonate (2:1) for 15 minutes whilst shaking. Then, they were rehydrated in 50 µl 25 
mM ammonium bicarbonate for 10 minutes. Gel pieces were dehydrated again the same 
way as before for 15 minutes. Eppendorf tubes were pulsed centrifuged and supernatants 
removed. The gel pieces were left until dry. Then, 25 µl 10 mM DTT in 25 mM ammonium 
bicarbonate were then added to each Eppendorf tube followed by 45 minutes incubation in 
56oC. Supernatants were then removed and replaced by 25 µl 55 mM iodoacetamide in 25 
mM ammonium bicarbonate. Samples were incubated at room temperature in the dark for 
30 minutes. Supernatants were then removed and gel pieces were then rehydrated as before, 
followed by a dehydration step, another rehydration step and a final dehydration step. Gel 
pieces were left to dry. When the spots were dry, 15 µl 12.5 ng / μl trypsin were added to 
the gel pieces and left on ice for 2 minutes. Once the samples were fully rehydrated, the 
excess trypsin was removed and replaced by 15 µl 25 mM ammonium bicarbonate. 
Eppendorf tubes were quickly spun to make sure the gel pieces were fully immersed in the 
solution. Samples were incubated at 37oC for 4 hours. Eppendorf tubes were transferred 
onto a shaker for 20 minutes. Supernatants were then transferred to 0.5 ml Eppendorf tubes 
leaving the used tip in the small tube. To improve peptide recovery, 10 µl 4:1 ACN : LC-
MS grade water (v/v) were added to the gel pieces and left for 15 minutes while shaking. 
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Tubes were pulsed centrifuged prior transferring the supernatant to the corresponding 0.5 
ml tube using the tips used in the last transfer. Then, 5 µl 0.1 % trifluoroacetic acid (TFA) 
were added to each tube. Finally, 1 µl sample was plated on the MALDI plate followed by 
1 µl 10 mg CHCA matrix / ml in 50 % (v/v) ACN / 0.1% (v/v) TFA. 
 
2.2.10 Mass spectrometry and database searching 
 
Peptide mass spectra were processed using Matrix-Assisted-Laser-Desorption ionisation-
time-of-flight (MALDI-TOF) mass spectrometer (Axima mass spectrometer, Shimadzu). 
Proteins were then identified by transferring mass lists from mass spectra to the Mascot 
database. The Swiss-Prot database was chosen as well as carbamidomethylation as a fixed 
modification and oxidation (M) as a variable modification. Positive identity was given by 
scores over 54 (comparing Swiss-Prot database) and their molecular mass and pI were 
compared to the position of the spot on the original gel. 
 
2.2.11 Phosphorylated amino acid co-localisation with VDAC detection using 2D-blot 
analysis 
 
Proteins separated by 2DE were transferred onto nitrocellulose membranes. Blots were 
stained with copper stain as described in section 2.2.6.1. The membrane was cut around the 
molecular weight level of VDAC1 according to the copper stain as compared to the spot 
previously identified as VDAC1 using silver stained gels by MALDI-TOF mass 
spectrometry (figure 2.5). Immunoprobing with anti-phosphoserine, anti-phosphothreonine 
or anti-phosphotyrosine antibodies was carried out as described in section 2.2.6.2 and table 
2.6. Following visualisation, antibodies were stripped off the membrane and the blots were 
re-probed using the anti-VDAC1 antibody as described in section 2.2.6.3. Spots at the basic 
end of the blots co-localising with VDAC detection, following phosphoamino acid residue 
detection were considered to be phosphorylated forms of VDAC1 protein. 
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Figure 2.4: Copper stained 2D-blots showing total protein staining and VDAC1 location 
50 μg protein from mitochondrial fractions were fractionated by 1D-SDS-PAGE (12 % resolving 
gel) and then transferred onto a nitrocellulose membrane. Blots were stained with copper 
pthalocyanine (section 2.2.6.1) to check for protein loading and efficiency of transfer. The picture 
represents a typical digital image, in which VDAC1 is circled. The rectangle shows the part of the 
blot cut out for further antibody labeling with anti-phosphoamino acid antibodies followed by 
stripping the blot and VDAC1 detection. 
 
2.2.12 Caspase-3 activity assay 
 
2.2.12.1 Fluorimetric activity assay 
 
Caspase-3 activity was determined using a fluorimetric assay by measuring the apparition 
of a fluorescent peptide product of caspase-3 cleavage.  
Cell pellets were prepared from one T25 flask per treatment as explained in section 2.2.1. 
Pellets were resuspended in 100 μl ice-cold lysis buffer (50 mM HEPES, pH7.4, 5 mM 
CHAPS, 5 mM DTT) and vortex mixed for 1 minute prior to centrifugation for 2 minutes at 
13,000 g. Samples were then set up as follows in a black 96-well plate: 80 μl assay buffer 
(20 mM HEPES, pH 7.4, 2 mM EDTA, 0.1% (w/v) CHAPS, 5 mM DTT) and 10 μl sample 
supernatant. Two blanks were added as follows: 80 μl assay buffer and 10 μl lysis buffer. 
To start the reaction, 10 μl peptide substrate (Ac-DVED-AMC) were added to each well to 
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start the reaction. The fluorescence was read every 5 minutes for 2 hours using 360 nm 
excitation and 460 nm emission wavelengths using a fluorimeter plate reader. 
 
2.2.12.2 Bicinchoninic (BCA) protein assay 
 
Because reducing and detergent reagents were used in the caspase-3 lysis buffer, the Bio-
Rad protein estimation reagent was not compatible. The BCA protein assay kit from 
Thermo Scientific was used following the manufacturer’s instruction. BSA standards 
ranging from 0 to 2000 μg / ml were used to produce a calibration graph from which a 
linear correlation was calculated. Duplicate BSA standards were prepared as shown in table 
2.10. 
 
Tube label Concentration of BSA (μg / ml) 
Source and volume 
BSA (μl) 
Volume of 
lysis buffer 
(μl) 
A 2,000 100 μl 2mg / ml stock 0 
B 1,500 100 μl 2mg / ml stock 33 
C 1,000 50 μl tube A 50 
D 750 50 μl tube B 50 
E 500 50 μl tube C 50 
F 250 50 μl tube E 50 
G 125 50 μl tube F 50 
H 0 0 μl 100 
Table 2.10: Serial dilutions of BSA standards using the provided 2 mg / ml BSA stock.  
 
Nine microliters of each sample and standards were added to the centre of the 96-well plate 
provided. Then, 260 μl freshly prepared BCA working reagent (50:1 provided reagents 
A:B) were added to each well. The plate was then covered with foil and mixed on a shaker 
at medium speed for 1 minute. The plate was then incubated at 37oC for 30 minutes. The 
plate was then cooled at room temperature for 5 minutes prior to measuring the absorbance 
at 570 nm using a plate reader. The protein concentration of each sample was calculated 
from the mean of duplicates using the linear correlation obtained from the BSA calibration 
curve. 
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2.2.12.3 Data analysis 
 
Results were expressed as the mean of specific caspase-3 activity (activity / μg) ± SEM. 
Data were statistically analysed by a paired t-test using a two-tailed distribution. 
 
2.2.13 RT-PCR 
 
2.2.13.1 RNA isolation from cells 
 
Isolating RNA from cells requires very clean, particularly ribonuclease-free, surfaces and 
equipment. All surfaces and equipment were therefore cleaned carefully with water, 
sprayed with 70 % (v/v) ethanol, followed by a RNaseZap spray. All steps were carried out 
at room temperature. 
One T75 flask of mouse N2a neuroblastoma cells per treatment was grown as explained in 
section 2.2.1. RNA was extracted using the Qiagen RNeasy mini kit following the 
manufacturer’s instructions. Cell pellets were then washed twice by centrifugation in PBS. 
The subsequent pellets were resuspended in 300 μl RLT buffer (from kit) with 1% (v/v) β-
mercaptoethanol. Suspensions were applied onto Qia-Shredder columns (Qiagen) followed 
by a 2 minute centrifugation at 10,000 g. Columns were then discarded and 300 μl 70 % 
(v/v) ethanol were added to the flow through and mixed by pipetting. Samples were then 
applied onto the RNeasy columns (from kit). They were centrifuged for 15 seconds at 
10,000 g and flow throughs were discarded. 700 μl RW1 buffer (from kit) were added to 
each column, which were centrifuged again at 10,000 g for 15 seconds. The flow-throughs 
were discarded. 500 μl RPE buffer (from kit) were added and columns were centrifuged for 
15 seconds at 10,000 g. These two steps (RPE buffer and spin) were repeated once more. 
Flow throughs were discarded and columns were centrifuged at 10,000 g for 2 minutes. 
Flow throughs were once more discarded. Columns were transferred onto fresh tubes, 35 μl 
RNase free water (from kit) were applied, columns were left to stand for 5 minutes and then 
centrifuged at 10,000 g for 2 minutes. Columns were discarded. The flow through 
contained the RNA. RNA was kept at -80oC or processed immediately. 
RNA concentration of RNA dilutions was measured using the Beckman spectrophotometer. 
Absorbance at 260 nm (A260) was used for RNA concentration (should be over 0.2; if not, a 
lower dilution of the RNA was needed). Absorbance at 280 nm (A280) corresponded to the 
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DNA concentration. The A260 / A280 ratios were calculated. An adequate ratio should be 
over 1.6. RNA concentration was calculated for each sample as follows:  
RNA concentration (ng / μl) = A260 * dilution factor * 44 
 
2.2.13.2 Reverse transcription 
 
Typically, 2 μg RNA were used and diluted in autoclaved distilled water for a total of 10 μl 
in 0.5 ml Eppendorf tubes. Two master mixes were prepared. Master mix 1 was containing 
1 μl dNTPs and 1 μl oligo dT18 (TTTTTTTTTTTTTTTTTT primer from Sigma) per 
number of samples used. Master mix 2 contained 4 μl 5X first strand buffer (Invitrogen), 2 
μl 0.1 M DTT (Invitrogen) and 1 μl water per number of samples used. 2 μl master mix 1 
were added to each 10 μl RNA sample. Tubes were vortex mixed, spun, left 5 minutes at 
65oC and then transferred to melting ice for 2 minutes. Tubes were then quickly spun at 
10,000 g (1 second). 7 μl master mix 2 were added to each tube. Samples were vortex 
mixed, quickly spun and left 2 minutes at 42oC. 1 μl SuperScript II enzyme (Invitrogen) 
was quickly added to each tube and mixed. Tubes were incubated at 42oC for 70 minutes 
followed by 15 minutes at 70oC. Resulting cDNA samples were then frozen at -20oC.  
 
2.2.13.3 Polymerase chain reaction (PCR) 
 
The sequences of the primers (Sigma) are shown in table 2.11. Paired forward and reverse 
primers were mixed together at a 10 mM concentration each. A master mix 3 was prepared 
as follows: 20 μl water, 2.5 μl 10X Accuprime PCR buffer and 1 μl primer mix per number 
of samples used. Two master mixes were prepared: one for VDAC1 DNA sequence 
amplification and one for GAPDH DNA sequence amplification. Then, 23.5 μl master mix 
3 were added to 1 μl template. Templates were also aliquoted in duplicates: one for 
VDAC1 sequence and one for GAPDH amplifications. Tubes were vortex mixed and spun 
quickly. To start the reaction, 0.5 μl Accuprime Taq polymerase (Invitrogen) were added. 
Tubes were mixed very gently and transferred to the PCR machine. The program was as 
follows: 2 minutes at 95oC, 30 cycles of [30 seconds at 95oC, 30 seconds at 59oC and 1 
minute at 68oC], 2 minutes at 68oC and hold at 4oC. 
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Primer name Sequence (5’- 3’) Annealing temperature 
mVDAC1-forward GGGTACAAGAGGGAGCACATCA 68oC 
mVDAC1-reverse CTCTGTCCCGTCATTCACATTAG 68oC 
mGAPDH-forward CTCATGACCACAGTCCATGC 64.4oC 
mGAPDH-reverse CACATTGGGGGTAGGAACAC 64oC 
Table 2.11: Sequences of primers used. 
 
2.2.13.4 Agarose gel electrophoresis 
 
Agarose (1.5 % w/v) was prepared in 100 ml Tris acetate EDTA (TAE) buffer (40 mM 
Tris, 0.1 % (v/v) acetic acid, 2 mM EDTA). The agarose was heated until completely 
melted. 4 μl ethidium bromide were added. Melted agarose was then cooled under tap water 
until the bottle could be held with bare hands. The agarose was poured onto the gel 
electrophoresis tray, a comb was added and gel was allowed to set. Then, 3 μl 10X loading 
buffer (0.025 % (w/v) bromophenol blue, 20 % (v/v) Ficoll, 1 % (w/v) SDS, 0.1 M EDTA, 
pH 8.0) were added to each 25 μl sample. When the gel was set, it was transferred to the 
tank, the comb was removed and the gel was immersed in TAE buffer. The required 
volume of sample was loaded onto each lane as well as the DNA ladder on the two lanes on 
both sides. The gel was run at 60 mA until samples were in the gel and 1 hour at 80 mA. 
The gel was stopped and imaged using the UV transluminator. 
To allow comparison between samples, band intensities were measured using AIDA 
software according to manufacturer’s instructions. Intensities of each band resulting from 
VDAC1 and GAPDH gene amplifications were measured and corrected for background. 
Log intensities were plotted against log volumes. For the chosen volume (8 μl), each 
intensity was calculated from the linear equation. Then, VDAC1 band intensities were 
corrected to corresponding GAPDH intensities (calculated ones). Corrected values were 
then expressed as a percentage compared to the corresponding control ± SEM. Data were 
statistically analysed by a paired t-test using a two-tailed distribution. 
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2.2.14 Real-time RT PCR 
 
2.2.14.1 Sample preparation 
 
RNA isolation from cell extracts and reverse transcription was undertaken as previously 
described in 2.2.13.1 and 2.2.13.2. 
 
2.2.14.2 DNA standards preparation 
 
A PCR reaction was set up using two control samples with the primer pairs for GAPDH 
and VDAC1 amplification as described previously in section 2.2.13.3. A 1.5 % (w/v) 
agarose gel was prepared as described in section 2.2.13.4. Amplified DNA samples were 
applied onto the gel and electrophoresed as previously described. The resulting bands were 
excised using a scalpel and cDNA bands were extracted from the gel following the 
QIAquick gel extraction kit (Qiagen) manufacturer’s intructions. The resultant samples, 
constituting the amplicons extracted from the gel, were then cloned into pCR-2.1-TOPO 
plasmid and transformed into TOP10 E.coli competent cells using TOPO TA cloning kit 
according to the manufacturer’s instructions (Invitrogen). The plasmid DNA were then 
extracted from the bacteria using the QIAprep Spin Mini-prep kit (QIAGEN) followed by 
EcoRI digestion following the manufacturer’s instructions (Qiagen digestion kit, 
QIAGEN). Clones showing a band corresponding to the molecular weight of VDAC1 or 
GAPDH inserts were selected for sequencing (MWG The Genomic Company, Eurofins 
MWG Operon, UK) for checking the insert sequences.  
Positive sequencing was followed by plasmid DNA extraction from the bacteria using the 
QIAGEN Plasmid Midi kit (QIAGEN). The DNA concentration was measured by 
measuring the absorbance of a 1:200 dilution as carried out previously in section 2.2.13.1.  
The DNA plasmids containing GAPDH and VDAC1 inserts were linearised by digesting 
10 μg DNA with Hind III restriction enzyme following the manufacturer’s instructions 
(Fermentas, Germany). An aliquot of linear vector (5 μl) was electrophoresed on agarose 
gel to check that only one band was present. The rest of the linear vector solutions were 
further purified using QIAquick PCR purification kit (QIAGEN). 
 
 
 - 60 - 
CHAPTER II  MATERIALS AND METHODS 
 
2.2.14.3 Standard dilutions 
 
The concentration in DNA of each linear vector was measured as previously described 
(section 2.2.13.1). The number of double-stranded DNA molecules per μl in the original 
solution (labelled UL) was calculated as follows: 
 
 
c: Concentration of DNA previously measured (g / μl) 
NA: Avogadro’s number = 6.022 ×1023 molecules / mol  
Mr: molecular weight of double stranded DNA = 660 g / mol × bp  
 
Serial standard solutions were prepared from the UL solution, containing 1010, 108 and 107 
as stocks of cDNA molecules, stored at -20oC.  
 
2.2.14.4 Real-time PCR 
 
cDNA sample content was quantified using Rotor-gene 3000 Thermal cycler (Corbett 
Research, Germany). Dilutions of GAPDH cDNA samples were prepared (1 in 5 dilution in 
autoclaved water). A master mix containing SensiMixPlus SYBR was prepared following 
the manufacturer’s instructions (Quantace Ltd, UK, table 2.12). 
VDAC1 and GAPDH standard solutions from 107 to 101 molecules, were freshly prepared 
from the 107 solution previously obtained (section 2.2.14.3), using RT buffer (10 mM Tris, 
15 mM KCl, 0.6 mM MgCl2, pH 8.0) as a diluent. 
 
 Solution Volume * no. sample 
(μl) 
SensiMix SYBR 5  
Primer mix (5 μM each ) 0.4 
Autoclaved water 3.6 
 
 
 
Table 2.12: Master mix containing SensiMix SYBR for real-time PCR 
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Then, 9 μl SensiMix SYBR master mix were transferred to Rotor-gene real-time PCR 
tubes, followed by addition of 1 μl standard or sample to each tube. Tubes were transferred 
to the Rotor-gene Thermo cycler and run through the following program: 95oC for 10 
minutes for initiation and enzyme activation, 35 cycles of [95oC for 15 seconds, 65oC for 
30 seconds, 72oC at 66 bp /sec].  
 
2.2.14.5 Data analysis 
 
Data were analysed using the Rotor-gene 6000 series software. Selecting all samples on the 
graph showing the fluorescent signal expansion as the cycle number increases, a threshold 
value was calculated automatically by the software. The cycle number reached at the 
threshold for each sample was called the Ct value. Each Ct value for standards was 
transferred onto a standard graph of Ct against concentrations as defined by the serial 
dilutions prepared. Sample Ct values could then be reported to the standard graph and the 
copy number for each sample calculated. Each triplicate sample was run in duplicate for 
each gene of interest, GAPDH and VDAC1. VDAC1 mRNA was expressed as molecules 
VDAC1 mRNA per 1,000 molecules GAPDH mRNA ratios ± SEM for each sample. Data 
were statistically analysed by a paired t-test using a two-tailed distribution. 
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3.1 INTRODUCTION 
iated mouse neuroblastoma cells: a model to investigate 
Parkinson’s disease 
imental models 
of model often 
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n used to study Parkinsonism features; these are post-mortem observations of 
es that occurred 
 observation of 
., 2004) and are, 
as with most post-mortem 
 the cell death 
 precious brain 
e animal should 
l development, 
ilar 
istics such as 
e disease should 
 2001). Animal 
tic reactions and 
ior to human testing (Deumens et al., 2002). 
However animal models have their limitations. For example, since the toxins or other 
methods of study lead to changes in several cell types, a detailed study of individual cell 
types is difficult (this is also the case using primary cell cultures). Moreover, the actual 
concentration of agent reaching dopaminergic neurons is not known. Finally, using animal 
models raises ethical issues (Deumens et al., 2002). 
 
3.1.1 Pre-different
 
3.1.1.1 Experimental models of study for Parkinson’s disease 
 
To study neurodegeneration in Parkinson’s disease (PD) different exper
have been used, each exhibiting strengths and limitations. The choice 
depends on the specific study carried out. Three different types of exper
have bee
neurons, use of experimental animal models and various cell line cultures (Olanow and 
Taton, 1999).  
Post-mortem neurons from patients are an important tool to observe chang
in PD patient’s brain. For example, Lewy bodies were discovered by the
post-mortem neuronal tissues of patients in 1912 (reviewed in Olanow et al
nowadays, an important hallmark of the disorder. However, 
studies, it is difficult to establish which changes are actively involved in
process. (Olanow et al., 2004). Moreover, it is difficult to obtain access to
samples and only limited laboratories work with them. 
An ideal animal model for PD should have the following characteristics. Th
have normal health during development notably in respect to its neurona
until starting gradual neurodegeneration in adulthood. The disorder should have sim
symptoms to the disease in humans and similar cellular character
mitochondrial dysfunction and formation of Lewy bodies. The period of th
be short to allow rapid screening of drugs for potential therapies (Beal,
models are useful for studying the pathological, behavioural and symptoma
are essential for curative treatment trials pr
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Primary cultures are composed of neuronal and glial cells and are adequate for loo
the overall effects of treatment on brain cells and particularly the interactio
and neuronal cells. However, it is again difficult to separate astrocytes 
(Augusti-Tocco and Sato, 1969). Separation techniques used in
centrifugation (Subbalakshmi and Murphy, 1983
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) and flow cytrometry (Rozental et al., 
nd, established 
e a good model 
on-metabolised 
dvantages include the 
introduction of spontaneous genetic recombinations following a number of passages and 
the lack of potential interactions between different cell types that could occur in vivo. 
ies. Human and 
only used 
a good cell line 
cells have been 
cells and mouse 
 neuroblastoma cells. Human SH-SY5Y neuronal cells are cholinergic cells exhibiting a 
ey are of human 
eck, 2004, PhD 
PC12 cells are rat adrenal pheochromocytoma cells that are able to synthesise, store and 
secrete dopamine similarly to dopaminergic nigral cells (Greene and Tischler, 1976). They 
can be induced to differentiate by extending neurites and acquiring the appearance of 
neurons when treated with nerve growth factor (NGF) (Greene and Tischler, 1976) but this 
is an expensive process.  
 
 
 
1995) although the purity of each resulting cell line is not neat. 
The most ethical experimental models are in vitro models. On the other ha
cell lines are essentially composed of one clonal cell type and they provid
for understanding the particular molecular pathways involved in a n
treatment in a particular type of cell (Cappelletti et al., 2001). Disa
 
3.1.1.2 In vitro cultured cells 
 
A good cell line for studying PD features should express neuronal propert
rodent neuroblastomas and central nervous system tumour cells are more comm
for that purpose (Cappelletti et al., 2001). An important characteristic of 
would be a stable genotype and phenotype (Beal, 2001). Three types of 
mainly used for studying PD: human SH-SY5Y neuronal cells, rat PC12 
N2a
neuronal phenotype (Shindo et al., 1996). Their main advantages are that th
origin and have properties similar to dopaminergic neurons (Hu et al., 2005), whilst a 
disadvantage is that their differentiation is not always easy to achieve (B
thesis). 
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ronal tumour in 
rt et al., 1969). 
acterised by cell 
 
s of dopamine, 
and Bondareff, 
cterised using 
o et al., 2000). 
 promoted the 
in cAMP levels 
senberg, 1978). 
 wide range of 
of a range of 
et al., 2009; Flaskos et al., 1998) and their use as a 
eimer’s disease 
zal et al., 2007; 
advantages of this cell line are that it is not primarily noradrenergic and it does not 
contain dopamine transporters (DAT) that would take up MPP+, the metabolised active 
can take up MPTP, which is 
+ s MAO activity (Mizuno et al., 1987; De Girolamo et al., 
2001). 
3.1.2.1 Subcellular fractionation methods 
 
To enrich the mitochondrial proteome, the choice of method for mitochondrial isolation and 
enrichment is the most important step. Subcellular fractionation involves separating the 
cells into different fractions corresponding to single organelles or groups of organelles. It is 
 
Mouse N2a neuroblastoma cells derived from a mouse spontaneous neu
Jackson’s Laboratories that has been maintained from the 1940s (Schube
The N2a clone is an adrenergic clone that shows neuronal morphology char
bodies with a large number of elongated processes (Augusti-Tocco and Satto, 1969). The
cell line contains high levels of tyrosine hydroxylase and also low level
norepinephrine, serotonin and monoamine oxidase (MAO) (Narotzsky 
1994). Mouse N2a neuroblastoma differentiation has been well chara
dbcAMP and removing serum (Prashad and Rosenberg, 1978, De Girolam
Indeed, Prashad and colleagues observed that cyclic AMP (cAMP)
organisation of microtubules and microfilaments, whilst Chang and Prasad (1976) reported 
that cAMP decreased cell division. DbcAMP induced significant increases 
in N2a cells when treated with serum free medium (Prashad and Ro
Additionally, mouse N2a neuroblastoma cells have widely been used in a
studies. These include toxicological studies to investigate the effects 
neurotoxins on neuronal cells (Harris 
model of study for a range of neurodegenerative diseases such as Alzh
(Zhou et al., 2009), Huntington’s disease (Ye et al., 2008) and PD (Amaz
De Girolamo et al., 2001). 
Dis
compound of MPTP (Song et al., 1997). Nevertheless, the cells 
converted to MPP  by endogenou
 
3.1.2 Isolation of mitochondria using subcellular fractionation 
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divided into two steps: cell homogenisation and cell fractionation (de Araújo and Huber, 
2007). The choice of method for these two steps depends on the nature
Cultured cells need a softer homogenisation than animal tissues such as, f
liver, to avoid disruption of organelle membranes. The cytoskeleton an
cytoskeletal proteins with organelles was observed to vary with each differ
the homogenisation protocol has to be optimised for each cell line (de Araújo and Huber,
2007). Different types of soft homogenisation techniques have been descr
including mechanical techniques, such as the use of manual dounce h
sonication, physical methods (e.g. freeze/thaw method) and chemical tech
hypotonic shock (Lizotte et al., 2005). For each method, it is important t
were efficiently broken and if the organelles are intact. This can be don
methods and microscopy or using electron microscopy (Huber et al.
laboratories have used different fractionation methods depending on the fra
wanted. Differential centrifugation (Lai and Clark, 1979; Fernandez-Vizar
use of detergents (Lizotte et al., 2005), chemical gradients (Pertoft, 1999; A
2006) and, sometimes, antibody based techniques have been employed 
2004). The most commonly used fractionation method for cultured cells is differential 
centrifugation (Cox and Emili, 2006), developed by L
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, 2003). Many 
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ra et al., 2002), 
ubry and Klein, 
(Murray et al., 
ai and Clark (1979) and modified by 
urify the crude 
se, salts, poly-
s have all been 
tion and it is an 
ecific cell type 
nown to be an 
inner side of the 
ms 
its role in the ETC; it is also found in the intermembrane space as a soluble protein (Garrido 
et al., 2006). Due to these properties SDH and cytochrome c were chosen as suitable 
mitochondrial markers. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an aerobic 
and anaerobic glycolytic enzyme is a cytosolic protein, although GAPDH has also been 
observed to translocate to the nucleus during apoptosis (Hara et al., 2006). The nuclear 
groups to suit the sample used. Gradient steps have been added to p
mitochondrial extracts resulting from differential centrifugation. Sucro
sucrose (for example Ficoll and dextran), percoll and iodinated compound
used and each have advantages and disadvantages (Pertoft, 2000).  
Enzyme assays, immunoprobing western blots and electron microscopy have been widely 
used to assess the purity of fractions resulting from subcellular fractiona
important step to confirm that the fractionation method is suitable for a sp
(Huber et al., 2003). For example, succinate dehydrogenase (SDH) is k
enzyme from the Krebs cycle and constitutes complex II of the ETC on the 
IMM (Ackrell, 2000). Cytochrome c is a protein also bound to the IMM where it perfor
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marker chosen was lamin, a cytoskeletal protein exclusively found in the nucleus of
and cleaved in apoptosis (Goldberg et al., 1999). Although the subcellu
procedure adapted produced only three fractions (mitochondrial, cytoplasm
the presence of lysosomes and endoplasmic reticulum was also investigated
marker chosen was lysosomal-associated-membrane protein 2 (LAMP2),
membrane of lysosomes as revealed by their name (Chang et al., 2002). The endoplasm
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 present on the 
ic 
reticulum chosen marker was NADPH-cytochrome c reductase, which was used in a study 
 
tochondrial proteome using a proteomic approach 
 
 all the proteins 
s (Govorun and 
ns. The primary 
rticular sample 
ure to a certain 
 determine how 
. This approach is called protein-network 
al transduction 
 studied under 
ed to separate 
dentification by 
employed, for example, 2-dimensional-gel electrophoresis (2DE) or blue-native-PAGE, 
both combined with matrix-assisted-laser-desorption ionisation mass spectrometry 
(MALDI-TOF) (Scheffler et al., 2001), or 1D-SDS-PAGE combined with liquid 
chromatography-mass spectrometry (LC-MS) (Gaucher et al. 2004). Two-dimensional gels 
were first devised by O’Farrell in 1975 and have since then been widely used over the 
by Fujiki and colleagues (1982). 
3.1.3 Studying the mi
3.1.3.1 Proteomics techniques 
 
Proteomics is a large-scale study which involves making an inventory of
present in an organism and analysing the interaction between these protein
Archakov, 2002). The proteomics approach has four principal applicatio
role is mining; that is, identifying all proteins present in a sample. Another application is 
protein expression profiling; that is, the identification of a protein in a pa
given its function in a particular state of the organism or cell or under expos
drug, chemical or physical stimulus. Moreover, proteomics can be used to
proteins interact with each other in a living system
mapping and can be used to discover certain protein involved in sign
pathways. The last application, is mapping protein modifications, which involves 
identifying and localizing different modified forms of proteins, usually
various chemical, drug or physical conditions (Liebler, 2002). 
Proteomics includes a wide range of high throughput technologies devis
complex mixtures of proteins or digested peptides followed by protein i
mass spectrometry (Govorun and Archakov, 2002). Gel based methods have been widely 
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decades. Typically, proteins from a complex mixture are separated using isoelectrofocusing 
(IEF) as a first step followed by SDS-PAGE as a second dimension. Re
then eluted and subjected to proteolytic digestion (Aebersold et al., 1987) o
(Rosenfeld et al., 1992). Digested peptides can then be processed through 
order to get a mass list that should correspond to one protein peptide prof
al., 2001). Other techniques also widely used consist of digesting the protein m
and then fractionating the peptides using a range of chromatographic te
methods are commonly called the Shotgun proteome techniques. Th
normally involve 2-dimensional liquid chromatography combined with
spectrometry (2D-LC-MS/MS), also known as MudPit technology (Sta
2004), or isotope coded affinity tags (ICAT) generally combined with LC
and Archakov, 2002). Proteomics techniques genera
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 tandem mass 
syk and Huber, 
-MS (Govorun 
lly allow the study of protein mixtures 
of up to 1,000 proteins. So, for cellular studies, it has then been well documented that 
es the complexity of the sample and allows a more 
comprehensive analysis (Lopez and Melov, 2002).  
teomic research 
 due to the fact 
ertain level of 
that there were about 1,000-
1,500 proteins forming the mitochondrial proteome (Taylor et al., 2003b). Although a wide 
variety of techniques have been used, and a combination of them all would probably be 
ideal, 2DE is the most commonly employed technique for studying the mitochondrial 
proteome, due to its high resolution capacity (Govorun and Archakov, 2002).  
 
 
 
 
 
 
 
fractionating the cell reduc
 
3.1.3.2 The mitochondrial proteome 
 
Mitochondria have been one of the most widely studied organelles for pro
(Bailey et al., 2005). This interest in the mitochondrial proteome is partly
that mitochondria are relatively easily separated, although with a c
contamination (Taylor et al., 2003b). It was originally thought 
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3.1.4 Aims of the chapter 
analysis of the 
o the proteome 
l features of PD 
 using 
nrichment and 
ptimised, based on subcellular fractionation 
ere monitored 
ved by 2DE following a protocol modified from O’Farrell (1975). Buffer conditions 
ure of proteins. 
imise variability 
 was to evaluate protein profile changes in the mitochondrial proteome 
following differentiation of neuroblastoma cells. Thus, proteins in mitotic and differentiated 
cells were compared using 2DE followed by peptide mass fingerprinting for potential spot 
identification. 
 
 
 
The overall objective of this chapter was to develop methods for the 
mitochondrial proteome of neuroblastoma cells. A study of changes t
following treatment with toxins that could mimick some of the biochemica
would then follow (see chapter V).  Included in this objective was the choice of
mitotic versus differentiated cells. 
First, a protocol for the isolation of mitochondria with acceptable e
contamination with other organelles was o
using differential centrifugation. Enrichment and contamination levels w
using a range of enzymatic and antibody-based methods. 
Once a satisfactory protocol was devised, the resultant mitochondrial fractions were 
resol
were optimised based on the resolution, solubility and staining of the mixt
The reproducibility of such gels was then analysed and measures to min
devised. 
A final aim
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homogenisation the same protocol for differential centrifugation was applied for the two 
 
tion following 
toma cells 
2.2.1.3) prior to 
 (refer to section 
r protein in the 
nd 2.2.7). The 
was normalised 
ment. 
tein recovery in the mitochondrial fraction in the two different 
drial fraction of 
Y5Y cells. The 
ochondria in the mitochondrial fraction compared to total extract was 5.5-
fold in the N2a cells and 3.5-fold in the SH-SY5Y cells, which was not significantly 
different between the two cell lines.  
Because the recovery of mitochondrial proteins by subcellular fractionation was more than 
doubled in the mouse N2a cells, these cells were used in the following experiments using 
mitochondrial fractions. 
 
 
The first step was to optimise the mitochondria isolation protocol for neu
by optimising each step of the protocol. Preliminary experiments designed
efficiency of homogenisation showed that a glass-glass homogeniser was
than a teflon-glass homogeniser and that the percentage of lysed cells f
homogenisation was 50 to 75 % total cells (lysed plus unlysed cells)
neuroblastoma cells and 65-80 % in human SH-SY5Y neuroblastoma cells (d
shown). This percentage lysis was considered as acceptable as increasing
homo
cell lines. 
3.2.1 Comparison of protein recovery in the mitochondrial frac
subcellular fractionation in mitotic N2a and SH-SY5Y neuroblas
 
Mouse N2a and human SH-SY5Y cells were grown to 80 % confluency as observed by 
microscopy in growth medium and cells were counted (refer to section 
homogenisation using an haemocytometer  and subcellular fractionation
2.2.4). Protein recovery and the relative presence of mitochondrial marke
mitochondrial fraction were determined (refer to sections 2.2.3, 2.2.4 a
mitochondrial marker protein distribution, as measured by SDH activity, 
against the total cell extract in each case (given a value of 1) in order to assess enrich
Table 3.1 compares the pro
cell lines. The protein content per 106 cells recovered in the mitochon
mouse N2a neuroblastoma cells was significantly higher than with SH-S
enrichment of mit
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 ia (μg / 106 c
ochondria 
hment compared to 
total extracts 2 
Mitochondr l protein 
ells 1
Mit
enricrecovery ) 
Mouse N2a cells 5.3 ± 12.1 5.5 ± 1.97 6
Human SH-SY5Y cells 23.9 ± 6.7 * 3.5 ± 1.24 
Table 3.1: Protein recovery in the mitochondrial fractions from mitotic mouse N2a 
counted followed 
 of the resultant 
s divided by the 
5 when compared 
 was measured in 
drial fractions from each type of cells. Mitochondrial enrichment is expressed as mean 
specific activity normalised against the specific activity of the total extract (given a value of 1) ± 
with a two-tail 
rentiated mouse N2a 
 
wing 
 cell states was 
edium. For the 
ncubated either in fresh growth medium (mitotic 
erentiated state, 
owed by protein estimation (section 2.2.3) of each resulting 
fraction (nuclear, cytoplasmic and mitochondrial).  
Table 3.2 compares the protein recovery in the mitochondrial fraction from the two 
different cellular states. Protein recovered was similar for both states, being around 150-200 
μg protein / 106 seeded mitotic cells and a lower, but not significant, range of 130-180 μg 
protein / 106 seeded differentiated cells. 
 
 
 
 
and human SH-SY5Y cells 
Mitotic mouse N2a and Human SH-SY5Y neuroblastoma cells were detached and 
by subcellular fractionation as described in section 2.2.4. 1 Protein estimation
mitochondrial fraction was carried out (section 2.2.3). The protein content wa
number of 106 cells originally extracted (μg / 106 cells). All * values ± SEM p<0.0
to N2a cells using a paired t-test with a two-tail distribution (n ≥ 7). 2 SDH activity
the mitochon
SEM. All * values p<0.05 when compared to N2a cells using a paired t-test 
distribution (n ≥ 5) 
 
3.2.2 Subcellular fractionation using mitotic and diffe
neuroblastoma cells 
3.2.2.1 Comparison of protein recovery in the mitochondrial fraction follo
subcellular fractionation in mitotic and differentiated mouse N2a cells 
 
A comparison of subcellular fractionation in mitotic versus differentiated
undertaken. Cells were seeded and left to recover for 24 hours in growth m
next 24 hours, the cells were further i
state), or in serum free medium supplemented with 0.3 mM dbcAMP (diff
see section 2.2.1.3 and 2.2.1.6 for further details). Cells were then extracted and subjected 
to subcellular fractionation foll
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 mitotic and 
he cells in growth 
 24 hours, mitotic 
P for 24 hours, 
1 Protein 
estimation of the various fractions was carried out (section 2.2.3). The protein content was divided 
 brackets: protein content in 
the fraction as a percentage of the total in the three subfractions together. (n = 6 for nucleus; n = 10 
for cytoplasm; n = 16 for mitochondria).  
 cells 
action (nucleus, 
itochondria) normalised to corresponding total extract activities. There 
ficant compared 
cantly different 
 the two states. 
itotic 
1.4 and 2.4-fold 
rentiated cells, 
hrome c, in the 
 and differentiated 
cells. Cytochrome c was highly enriched in the mitochondrial fraction from both mitotic 
(7.9-fold increase) and differentiated cells (13.3-fold increase). For both cellular states, 
cytochrome c was found at very low levels in the cytoplasmic fraction. Finally, as for SDH 
activity, reactivity with the anti-cytochrome c antibody was slightly enriched in the nuclear 
fraction. No significant difference was observed between mitotic and differentiated cells. 
 
 p
 (μg
ed
lasm
very (μ
s see
ochondria protein 
ecovery (μg / 106 
cells seeded) 1 
Nuclear
recovery
rotein 
 / 106 
Cytop
reco
cells se ed) 1 cell
 protein 
g /106 
Mit
r
ded) 1 
Mitotic 
ce
N
lls  (4 ± 49 
2a 369 ± 28 2 %) 332 (38 %) 177 ± 28 (20 %) 
Table 3.2: Protein recovery in the mitochondrial fractions from
differentiated mouse N2a neuroblastoma cells 
N2a cells were seeded as explained in section 2.2.1.3 followed by incubation of t
medium for 24 hours. Cells were either further incubated in growth medium for
state, or incubated in serum free medium supplemented with 0.3 mM dbcAM
differentiated state. Cells were then extracted and subjected to subcellular fractionation. 
Differentiated 
N2acells 225 ± 27 (35 %) 258 ± 41 (40%) 157± 26 (25 %) 
by the number of 106 cells originally seeded (μg / 106 seeded cells). In
 
3.2.2.2 Mitochondrial markers in fractions from mitotic and differentiated
 
Figure 3.1A shows the presence of SDH activity in each subcellular fr
cytoplasm and m
was a 5.5-fold enrichment of SDH in the mitochondrial fraction from mitotic cells and a 
4.5-fold enrichment for differentiated cells. These enrichments were signi
to total extracts for both cellular states and the enrichment was not signifi
between
SDH activity in the cytoplasmic fraction was low (0.28) compared to total extract in m
cells and not detected in the differentiated cells. SDH activity was enriched 
in the nuclear fraction compared to total extract in mitotic and diffe
respectively. 
Figure 3.1B shows the presence of another mitochondrial marker, cytoc
different subcellular fractions compared to total extract in both mitotic
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 level in each fraction 
using differential 
ty of SDH in the 
ifferentiated cells. 
Enrichment  = (specific enzyme activity of fraction / specific enzyme activity of total extract) 
  enzyme specific activities were expressed in Δabsorbance/minute/ug protein 
B. Anti-cytochrome c antibody was used to detect the presence of cytochrome c in the different 
subcellular fractions and the total extract of a) mitotic cells and b) differentiated cells. The digitized 
blots were quantified using the AIDA image analyzer software and the average intensity in each 
fraction compared to the total extract ± SEM for mitotic (n = 3) and differentiated (n = 18), 
tabulated in (c).  
All * values p<0.05 when compared to total extract using a paired t-test with a two-tail distribution 
ndria 
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 Nucleus Cytoplasm Mitocho
 
 
Figure 3.1: Succinate dehydrogenase activity and cytochrome c protein
co pare
Mitotic and differentiated mouse N2a neuroblastoma cells were fractionated 
centrifugation.  
A. SDH activity was used as a mitochondrial marker. The graph shows the activi
m d to total extract from mitotic and differentiated cells 
three subcellular fractions compared to total extract for both mitotic and d
(mitotic: n = 11; differentiated = 4) 
Mitotic cells 3.93 ± 1.87 0.66 ± 0.41 * 7.89 ± 4
c) 
.99 
Differentiated cells 1.91 ± 0.95 0.52 ± 0.13 * 13.34 ± 4.59 * 
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Following the observations showing that mitochondrial recovery and enrichm
similar in both mitotic and differentiated N2a cells, only the data for the dif
are presented her
 - 75 - 
ent were 
ferentiated cells 
e as an example for the investigation of presence of contamination in the 
mitochondrial fraction. 
 
phate dehydrogenase (GAPDH) protein levels were higher in the 
cytoplasmic fraction compared to other fractions and were low in the mitochondrial and the 
nucl
 
Figure 3.2B shows the presence of the nuclear marker lamin in each subcellular fraction 
from nuclear fraction (35.5-fold) and was of 
low-abundance in the cytoplasmic and mitochondrial fractions. 
Figure 3.3A shows the presence of LAMP2 in the different fractions and indicates high 
lyso the cytoplasm (4.4-fold enrichment compared to the total extract). 
Lysosomes were also enriched in the mitochondria (2.3-fold) whilst depleted in the nuclear 
me found in microsomes. Figure 3.3B shows 
that NADPH-cytochrome c reductase activity was mainly present in the cytoplasmic 
fraction compared to other subcellular fractions. The nuclear fraction was slightly 
contaminated with the microsomal marker. The specific activity of the microsomal marker 
was significantly reduced in the mitochondrial fraction compared to total extract showing a 
low level of contamination. 
3.2.2.3 Cytoplasmic marker in fractions from differentiated cells 
 
Glyceraldehydes-3-phos
ear fractions (figure 3.2A). 
3.2.2.4 Nuclear marker in fractions from differentiated cells 
 
 differentiated cells. Lamin was enriched in the 
 
3.2.2.5 Lysosomal markers in fractions from differentiated cells 
 
somal content in 
fraction. 
 
3.2.2.6 Microsomal marker 
 
NADPH-cytochrome c reductase is an enzy
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 Nucleus Cytoplasm Mitochondria
 Total 
extract 
Nuclear 
fraction 
Cytoplasmic 
fraction 
Mitochondrial 
fraction 
37 kDa 
A. Detection of GAPDH in each fraction 
Lamin densitometry 35.50 ± 9.18 * 0.68 ± 0.26 0.85± 0.18 
 
Figure 3.2: GAPDH and lamin A/C protein levels present in each fraction c
extract 
ompared to total 
ial centrifugation 
PDH and lamin were detected in the various subcellular fractions by probing western blots 
with anti-GAPDH antibody (A, n = 13) and anti-lamin A/C antibody (B, n = 14).  
The digitized blots were quantified using the AIDA image analyzer software and expressed relative 
to total extract (given a value of 1). The tables show the average intensity change in each fraction 
compared to total extract  ± SEM.  
All * values p<0.05 when compared to total extracts using a paired t-test with a two-tail 
distribution. 
 
Mitochondria  Nucleus Cytoplasm
Diff .9 ± 0.33 0.15 ± 0.06 * erentiated cells 0.25 ± 0.18 * 0
B. Detection of lamin in each fraction 
Total 
extract 
Nuclear 
fraction 
Cytoplasmic 
fraction 
Mitochondrial 
fraction 
7  kDa 
65 kD
4
a 
 
Differentiated mouse N2a neuroblastoma cells were fractionated using different
and GA
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me c reductase activity in each 
toma cells were fractionated using differential centrifugation. 
A image analyzer 
software and expressed relative to total extract (given a value of 1). The table shows the average 
enrichment in each fraction compared to the total extract ± SEM.  
B. NADPH-cytochrome c reductase activity was used as an endoplasmic reticulum marker. The 
graph shows the specific activity of NADPH-cytochrome c reductase in the three subcellular 
fractions compared to the total extract (n = 9).  
Specific enzyme activities are expressed in Δabsorbance/minute/ug protein 
All * values p<0.05 when compared to total extract using a paired t-test with a two-tail distribution 
 
 
N C Mitochondria
 
 
 
Figure 3.3: LAMP 2 protein level and NADPH-cytochro
fraction compared to total extract from differentiated cells 
Differentiated mouse N2a neuroblas
A. LAMP2 was detected in the various subcellular fractions by probing western blots with anti-
LAMP2 antibody (n =17). The digitized blots were quantified using the AID
 ucleus ytoplasm 
Differentiated cells 0.45 ± 0.21 4.44 ± 2.3 * 2.31 ± 2.24 
0.48
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B. NADPH-cytochrome c reductase activity in each fraction 
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Cytoplasmic 
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A. Detection of LAMP2 in each fraction 
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3.2.3 Optimisation of 2D-gel electrophoresis  
al fraction were 
MW). This was 
 proteins with a 
s showed similar biochemical marker 
optimisation of 
r. Pictures were 
 aligned to one 
ent 
r detergent choice, 50 μg protein 
were chosen; nevertheless, for practicability, further analysis of sample preparation and 
buffer optimisation, lower amounts of proteins were used leading to two different groups of 
studies. The issue of protein loading will be discussed in section 3.2.3.3. 
 
Following subcellular fractionation, proteins contained in the mitochondri
separated relative to their isoelectric point (pI) and their molecular weight (
performed using 2DE. Since many mitochondrial proteins are membrane
basic pI, the isoelectro-focusing (IEF) buffer prior to the first dimension conditions needed 
optimisation. As mitotic mitochondrial fraction
enrichment to differentiated cells, all mitochondrial samples used for the 
2DE and its reproducibility were from untreated mitotic cells.  
Pictures of each gel were taken using Fujifilm FLA-5100 image scanne
transferred to Samespots software (Progenesis) and each gel image was
chosen gel (called reference). The statistical package allowed choosing the best alignm
features. When the 2DE was based on a mini-gel system fo
 
3.2.3.1 Sample preparation 
 
- Choice of detergent 
The first step of 2DE is lysis of mitochondrial preparations prior to IEF pro
An important consideration is the choice of detergents, the precipitation 
inclusion of chaotropic agents. 
Three different detergents were tested for their ability to enhance
mitochondrial proteins. The non ionic detergent Triton-X-100 (1.5% [w/v]) was first 
compared to the zwitterionic detergent CHAPS (4% [w/v]), both in the p
Figures 3.4A and B show a representative profile for the triplicate gels an
were exclusive to each group of gels. Table 3.3 shows the number of spots reso
tein separation. 
method and the 
 separation of 
resence of urea. 
d the spots that 
lved on each 
gel and the total spot volume as calculated by the Samespot software. The two detergent 
buffers revealed approximately the same number of spots, but different profiles; using 
Triton-X-100, basic proteins were enriched but there was a reduced number of acidic 
proteins. When CHAPS was used as a detergent, proteins across the pI range were revealed, 
including a number of acidic proteins. Thus, for broad range, acidic and neutral pI 
CHAPTER III ESTABLISHING METHODS 
 
investigations, the zwitterionic detergent CHAPS seemed to be more suitab
X-100. The total spot volume as calculated by the Samespot software relate
the staining was from one gel to another. As the total spot volume was m
replicate 3 from the CHAPS group (table 3.3) than the other replicates in th
can be sug
 - 79 - 
le than Triton-
s to how strong 
uch higher with 
e same group, it 
gested that the staining was stronger; however the number of spots was similar 
for the 3 gels.   
 
ration
specification
Re Tosp
volu  
Spot no. 
de
Average spot 
no. ± SEM 3 
Sample 
prepa  
 
plicate 
no. 
tal 
ot 
me 1 tected 
2 
1 6.8 x  395  108
2 5.8 x  376  108A. CHAPS
8
394 ± 13  
3 12.2 x 10 412 
1 5.0 x 108 396 
2 6.5 x 108 294 B. Triton 
3 4.3x 108 403 
375 ± 43 
Table 3.3: Effects of CHAPS and triton-X-100 detergents on spot number and total 
y 2DE using IEF 
tes. One replicate 
3.4. 
1 Total spot volume: Sum of the volume (calculated intensity) of each spot calculated by the 
Samespot software. 
tergent and using 
anufacturers (Calbiochem) as a more powerful agent for solubilising membrane 
proteins if used in combination with thiourea. Figure 3.4C shows a representative image for 
a set of triplicate gels. Although the basic pI range of the gel looked similar to the CHAPS 
gel, the acidic and neutral parts of the gel were fuzzy and weakly stained. Consequently, 
CHAPS remained the detergent of choice for broad spectrum, acidic and neutral pI 
analyses. 
 
spot volume resolved on 2DE 
50 μg mitochondria isolated from mitotic N2a neuroblastoma were fractionated b
buffers containing A. 4% CHAPS / 8 M urea, B. 1.5% triton / 8 M urea  in triplica
of each group of gels is shown in figure 
2 Total number of spots detected in each gel using the Samespot software. 
3 Average number of spot in each group of samples (triplicates using CHAPS as de
Triton-X-100 as detergent) ± SEM (n = 3). 
 
 
Another zwitterionic detergent, ASB-14, was tested compared to CHAPS. This is described 
by m
CHAPTER III ESTABLISHING METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
HAPS, Triton-X-
100 and ASB-14) in the IEF buffer in 2DE analysis 
50 μg mitochondria isolated from mitotic N2a neuroblastoma were fractionated by 2DE using IEF 
buffers containing A. 4% CHAPS / 8 M urea, B. 1.5% triton / 8 M urea or C. 4% ASB-14 / 6 M 
urea / 2 M thiourea. Circled spots in A and B represents spots exclusive to each gel. The square in C 
shows the area where the most changes were observed between CHAPS (A) and ASB-14 gels (C). 
Representative gel shown here (n = 3). Total spot numbers and total spot volume resolved on each 
gel shown in table 3.3. 
MW: Molecular weight markers. Only pI 4-9 ranges of the gels are shown here. 
 
 
 
 
 
 
 
 
 
 
A. 4 % CHAPS kDa B. 1.5 % Triton 
 
 
 
 
 
Figure 3.4: Differences in spot detection using three different detergents (C
p                      9 4        9 
37 
25
20 
I 4 
50 
 100 
 150
   75 
C. 4 % ASB-14MW kDa 
150 
100 
75 
50 
37 
25 
20 
          pI 4      9 
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- Influence of acetone precipitation for sample preparation 
Acetone precipitation has been widely used to concentrate proteins but 
excess detergents, lipids and salts (Englard and Seifter, 1990). Figure 3.5A 
3.4 shows that acetone precipitation of samples prior to adding the IEF 
effect on the resolution and spot number of proteins on 2DE. However
volume was decreased in the three replicates showing an effect on stain
which
also to remove 
and B and table 
buffer had little 
, the total spot 
ing efficiency, 
 could be due to a decrease in protein recovery. For reproducible analysis, samples 
were not acetone precipitated as it could be a source of variability to add another step to the 
protoc
 
ple 
paration 
cation 
Replica Total spot volume 1 
 
detected 2 
Average spot 
no. ± SEM 3 
ol. 
Sam
pre
specifi
te no. Spot no.
1 5.5  395  x 108
2 6.3 x 108 257  A. CHAurea 
PS / 
3 6.0 x 108 347 
333 ± 50 
 
1 2.5 x 108 322  
2 2.1 x 108 347 
C. Acetone 
3 2.8 x 10  316 
8 ± 12 precipitation / 
CHAPS / urea  8
32
1 3.1 x 108 272 
2 2.1 x 108 309 B. CHAPS / thiourea  3 6.8 x 108 218 
266 ± 32 
Table 3.4: Effects of CHAPS and triton-X-100 detergents on spot number and total 
 resolved on 2DE 
lastoma were fractionated by 2DE using IEF 
buffers containing A. 4% CHAPS / 8 M urea, (no acetone precipitation ), or B. 4 %CHAPS / 8 M 
urea following acetone precipitation of mitochondrial pellet, or C. 4 % CHAPS / 6 M urea / 2 M 
thiourea (no acetone precipitation).  One replicate of each group of gels is shown in figure 3.5. 
1 Total spot volume: Sum of the volume (calculated intensity) of each spot calculated by the 
Samespot software.  
2 Total number of spots detected in each gel using the Samespot software. 
3 Average number of spot in each group of samples ± SEM (n = 3). 
 
spot volume
20 μg mitochondria isolated from mitotic N2a neurob
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on by 2DE and of thiourea 
inclusion in the IEF buffer on spot detection  
20 μg mitochondria isolated from mitotic N2a neuroblastoma were fractionated by 2DE using IEF 
buffers containing A. 4 % CHAPS / 8 M urea, B. 4 % CHAPS / 8 M urea following acetone 
precipitation of mitochondrial pellet or C. 4 % CHAPS / 6 M urea / 2 M thiourea (no acetone 
precipitation was performed for both groups). Circled spots in A to C represents spots exclusive to 
each gel. Representative gel shown for each group (n = 3). Spot numbers and total spot volume 
resolved on each gel shown in table 3.4. Only pI 4-9 ranges of the gels are shown here. 
pI 4             9 
150
100
75
50
37
25
20
kDa
A. 4 % CHAPS / 8 M urea 
 
 
 
 
 
 
 
B. Influence of acetone 
 
 
 
 
 
Figure 3.5: Influence of acetone precipitation prior to fractionati
pI 4             9
precipitation
  9 
C. 4 % CHAPS / 6 M urea / 2 M 
thiourea 
  4    
kDa 
150 
100 
75 
50 
37 
25 
20 
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- Influence of thiourea  
Thiourea is known to help the solubilisation of proteins. Figure 3.5A and C
representative gels using CHAPS / urea with or without thiourea. Severa
seemed to be more enriched without thiourea. The main difference w
horizontal streaking of acidic proteins when thiourea was present. Moreove
spots resolved on each gel was lower with thiourea and the total spot volum
in 2 out of the three replicates showing an effect on staining efficiency, wh
to a decrease in
 show images of 
l basic proteins 
as a consistent 
r, the number of 
e was decreased 
ich could be due 
 protein recovery (table 3.4) during the 2DE protocol. Consequently, for 
broad pI 3-10 range and acidic to neutral pI ranges, urea without thiourea was chosen as the 
t. solubilising agen
 
- Protein loading 
Two different protein loadings were analysed using CHAPS / urea in the IEF buffer. The 
number of spot was slightly reduced when using less protein material (20 μg as opposed to 
50 μ table 3.3A and 3.4A), nevertheless, the total spot volume was 
similar in both groups. 
Glycerol was used to increase buffer viscosity in the equilibration buffer and to improve the 
h glycerol led to 
own). 20% (v/v) 
 
The decision was therefore to use no acetone precipitation, CHAPS combined with urea but 
no thiourea in the first dimension, and 20% glycerol in the equilibration buffer for optimal 
resolution  of mitochondrial proteins. 
g protein; compare 
 
3.2.3.2 Equilibration conditions 
 
transfer of proteins from the IPG strip to the second dimension. Too muc
fuzzy separation of the proteins in the second dimension (figure not sh
glycerol was then used in the subsequent protocol.  
CHAPTER III ESTABLISHING METHODS 
 
 - 84 - 
3.2.4 Reproducibility of mini 2D-gel electrophoresis  
he overall method 
s important to 
ost variable. For 
er staining was used and spots were not saturated (for significance of 
this,
 
ith another set. 
licates of both sets were run in the same tank, 
leaving one replicate of each set in a separate tank. Nevertheless, both tanks were run in 
me power pack. As discussed below, the variability between tanks 
 
Following optimisation of 2DE buffer conditions the reproducibility of t
needed to be assessed. To improve the reproducibility between gels, it wa
determine which steps were the most reproducible and which were the m
these analyses silv
 see section 3.2.5). 
3.2.4.1 Intra-sample reproducibility 
 
In general each set of samples was composed of triplicates run in parallel w
(total of six gels). For practical reasons, dup
parallel linked to the sa
was not discernable. 
 
- Same sample, same day 
Triplicates of a sample were electrophoresed the same day (figure 3.6). The
spot was normalised to the total sp
 volume of each 
ot volume in each gel so that the normalised volume of 
 1 was the most 
cted by the total 
pot number was 
nesis). The fold 
is between each 
intensity by less 
aried by less than 3-fold between gels. 
Interestingly, although there was a higher difference in staining intensity between replicate 
1 and 3, the fold changes seemed to be smaller than between gels 1 and 2 showing that 
normalising to total spot volume was efficient. Additionally, replicate 3 was the replicate 
run on the different tank in parallel to the other replicates showing that the variability 
between tanks did not reflect on the reproducibility between gels. 
 
each spot could be compared between gels. Figure 3.6 shows that replicate
intensely stained gel and replicate 3 staining intensity was the lowest, refle
spot volume calculated by Samespot software (shown in table 3.5); but s
not necessarily correlated with spot volume. 
 A gel to gel analysis was undertaken using Samespots software (Proge
change of each spot between gels was calculated and comparative analys
gel is shown in table 3.6. Between 77 and 91 % of spots varied in relative 
than 2-fold and between 92 and 97 % of the spots v
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Figure 3.6: Triplicate gels electrophoresed in parallel 
Mitochondria isolated from mitotic N2a neuroblastoma were fractionated by 2DE in triplicate in 
parallel using IEF buffer containing A. 4 % CHAPS / 8 M urea. Spot numbers and total spot volume 
resolved on each gel are shown in table 3.5 and comparative analysis between gels compared to the 
average reference gel is shown in table 3.6. Only pI 4-9 ranges of the gels are shown here 
 
A. Replicate 1 
pI 4     9 
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by 2DE in parallel 
E using 
te gel is shown in figure 3.6. 
he volume (calculated intensity) of each spot calculated by the 
Samespot software. 
2 Total number of spots detected in each gel using the Samespot software. 
3 Average number of spot ± SEM (n = 3). 
el
pared Min 
Average 
3 
an
4 
1-2-
ld 
change 
5 
2-3-
fol
change 
5 
3-5-
fold 
change 
5 
> 5-
fold 
change 
5 
 
Table 3.5: Gel properties of the same sample electrophoresed 
Mitochondria isolated from mitotic N2a neuroblastoma were fractionated in triplicate by 2D
IEF buffer containing 4 % CHAPS / 8 M urea. Each replica
1 Total spot volume: sum of t
 
 
G
com
s 1 Max 2 Medi  fo d 
Gel 
rsus 
el 
1.003 7.23 1.68 1.39 78 % 15 % 6 % 1 % 
1 
ve
g 2 
Gel 2 
versus 
gel 3 
1.002 11.072 1.81 1.45 77 % 15 % 10 % 3 % 
Gel 1 
versus 
gel 3 
1.017 4.48 1.48 1.36 91 % 6 % 3 % 0 % 
Table 3.6: Reproducibility between triplicates of the same sample electrophoresed by 
d in triplicate by 2DE using 
figure 3.6. The fold 
changes between each spot volume between 2 gels were calculated from the normalized volume as 
measured by Samespot software. 
1 Lowest –fold change calculated between the 2 gels compared 
2 Highest–fold change calculated between the 2 gels compared 
3 Average of all the –fold changes of each spot from one gel to another  
4 Median of all the –fold changes of each spot from one gel to another 
5 Percentage of spots that showed a –fold change in the range analysed between two gels 
 
 
 
 
 
Repli volume 
spo
Spot no. 2 
Average no. 
spot ± SEM 
3 
2DE in parallel 
Mitochondria isolated from mitotic N2a neuroblastoma were fractionate
IEF buffer containing 4 % CHAPS / 8 M urea. Each replicate gel is shown in 
cate 
Total 
t 1 
1 5.73  321 x 108
2 3.4 x 10  350 8
3 2.9 x 108 240 
304 ± 40 
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- Same sample run on a different day 
2DE of two sets of triplicates of the same sample were electrophoresed 
days. Each set of three gels was grouped, the volumes of each group we
averaged groups were analysed against each other using Samespots softw
97 % of the spots were previously shown to vary in relative intensity by 
only spots showing a change of more than 3-fold in intensity were annotated (Figure 3.7). 
on two separate 
re averaged and 
are. Since 92 to 
less than 3-fold, 
Only 9 spots varied by more than 3-fold, these were of low intensity and differences 
between gels are likely to be  due to detection limits. 
 
 section. Figure 3.8A shows spots that varied in 
intensity by more than 3-fold, the numerical data are reported in figure 3.8B. Although 9 
e changes were 
ld change between spots. 
 
From the latter results, the best way of analysing two different samples would be to run as 
many samples as possible in parallel. 
3.2.4.2 Inter-sample reproducibility 
 
Two samples prepared on different days were subjected to 2DE in triplicate. The data were 
analysed in the same way as in the previous
spots varied in relative intensity by more than 3-fold, as previously, th
smaller, not exceeding 5.3-fo
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Spot 
number 
ge of norm
umes of gel
m 1
verage o al 
volumes of gels 
from d
Fold change
Avera al A
vol s 
fro  day 1  
f no mr
a 1y 2  
1 870 ± 146 271 ± 3.2 2* 176 
2 232 ± 18 62 ± 3.8 2*  9 
3 71 ± 7 11 ± 6.3 2*  2 
4 57 ± 6 5 ± 10.6 2*  2 
5 201 ± 113 58 ± 12 3.5 2 
6 52 ± 9 184 ± 96 3.5 3 
7 40 ± 5 197 ± 41 4.9 3 
8 338 ± 50 1204 ± 65 3. 6 3* 
9 94 ± 51 355 ± 77 3.8 3* 
Figure 3.7: Map of a 2DE showing expression changes between replicates of the same sample 
re prepared. The 
ophoresed on 2DE (12 % polyacrylamide) on two different days. The six gels 
ts software from Progenesis. The gel images were grouped and 
averaged per day. The two averages were compared showing the spots that changed by more than 3-
fold (spots 1 to 9 in A). MW: Molecular weight markers. The numerical data are shown in B. 
1 Average of normalised volumes (n = 3) ± SEM. 
2 Fold decrease = Average of normalised volumes from sample 1 gels / Average of normalised 
volumes from sample 2 gels. 
3 Fold increase = Average of normalised volumes from sample 2 gels / Average of normalised 
volumes from sample 1 gels. 
All * values p<0.05 using ANOVA test. 
 
electrophoresed on different days 
Six replicates of the same mitochondrial fraction from mitotic N2a cells we
triplicates were electr
were analysed using Samespo
1
5
23
4
6 7 8
9
250 
100 
75 
50 
37 
25 
20 
kDa 
pI 3      10 
A. Change ween gels from same sample electrophoresed on a different day 
MW 
B. Numerical data showing t  betwe s represented in A 
s bet
h se change en gel
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nges between replicates of different samples 
triplicates were 
% polyacrylamide) in parallel. The six gels were analysed using 
es were grouped and averaged per sample. The 
two averages were compared showing the spots that changed of more than 3-fold (spots 1 to 9 in 
A). MW: Molecular weight markers. The data is shown in table B. 
1 Average of normalised volumes (n = 3) ± SEM. 
2 Fold decrease = Average of normalised volumes from sample 1 gels / Average of normalised 
volumes from sample 2 gels. 
3 Fold increase = Average of normalised volumes from sample 2 gels / Average of normalised 
volumes from sample 1 gels. 
All * values p<0.05 using ANOVA test. 
Spot 
number 
ge of nor
mes of ge
 sample 1
erage o al 
es of gels 
from sam 1 
Fold change
100 
1 5 
2
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Figure 3.8: Map of a 2DE showing expression cha
electrophoresed in parallel 
Three replicates of the same mitochondrial fraction from mitotic N2a cells were prepared. This was 
repeated with a fraction prepared on a different day. The two pairs of 
electrophoresed on 2DE (12 
Samespots software from Progenesis. The gel imag
Avera mal Av
volu ls volum
from 1 
f norm
ple 2
1 139 ± 179 287 ± 4.0 2* 1  63 
2 688 ± 86 187 ± 3.7 2  44 
3 519 ± 150 409 ± 3.7 2* 1   13  9
4 457 ± 68 128 ± 3.6 2*  18 
5 232 ± 18 77 ± 11 3.0 2* 
6 272 ± 21 83 ± 5 3.3 2* 
7 57 ± 6 11 ± 2 5.3 2* 
8 126 ± 36 402 ±118 3.2 3* 
9 112 ± 11 475 ± 193 4.2 3* 
pI 3       10 
kDa 
150
75 
50 
37 
25 
20 
250 
MW 
A. Changes between gels from different samples electrophoresed in parallel 
B umeri ng t twee represented in A . N ca wil data sho he  bechanges n gels 
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3.2.5 Reproducibility of large 2D-gel electrophoresis  
cm gels since it 
i-system (7 cm 
on experiments 
he key 
owed horizontal 
larly with high 
s absent on gels. 
spots than with 
ic profiles 
arative analysis 
wed a 4 to 5-fold 
variability with large gels (data not shown) compared to 2 to 3-fold with mini gels (table 
6 s needed higher amount of proteins and for the above reasons, 
detailed comparisons in subsequent chapters involved the use of mini-gels. 
as the stain was 
vity of the stain 
quickly making quantitative analysis difficult.  
Figure 3.10 shows 3-dimensional images of silver stained spots which are saturated (a) and 
non-saturated (b) with silver on the same gel. The saturated spot showed a truncated shape, 
showing that the intensity reported for this spot would be lower than what it should have 
been compared to other unsaturated spots. 
 
 
Preliminary experiments were run using 17 cm IEF strips and 17 cm by 17 
was expected that resolution would be better than when using the min
strips). However, the latter was not found to be the case, so optimizati
shown in section 3.2.2 and 3 were all undertaken using mini-gels (7 cm strips). T
reasons for using the  mini-system for the main analyses are given below.  
An example of large 2DE is shown in figure 3.9. Large gels often sh
streaking, particularly at the basic end and vertical streaking, particu
molecular weight proteins. Moreover, some acidic proteins were sometime
In the present study, these gels were inconstant and did not show more 
mini-gels (up to 350 spots observed). Furthermore, the reproducibility of proteom
on large gels tended to be lower than of mini-gels. For example, in a comp
using Samespots software of one to one gel, the majority of the spots sho
3. ). Because the large gel
 
3.2.6 Choice of staining method 
 
Using mini-2DE gels instead of large-gels improved the staining pattern 
more homogenous all over the gel. Nevertheless, despite the high sensiti
(0.2 to 0.6 ng), silver stain had a narrow linear range (1 to 10 ng) and saturated relatively 
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ferentiated mouse N2a 
neuroblastoma 
120 μg of mitochondrial sample from differentiated N2a cells were resolved on a large 2D-gel 
electrophoretic system (17 cm by 17 cm). 1. Horizontal streaking of the basic spots, 2. vertical 
streaking of high molecular weight spots and 3. ATP synthase β-subunit is less abundant, whereas it 
has been shown in mini-gel studies to be highly abundant. MW: Molecular weight markers. 
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Figure 3.9: Large-scale 2DE of mitochondrial proteins from dif
pH 3        10 
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SyproRuby (Molecular Probes) is a fluorescent stain. It is said to be as sensitive as silver 
stain (0.25 ng to 0.5 ng) and has a greater linear range (0.25 ng to 1000 n
testing showed that staining with this dye was more homogenous over th
did not saturate as quickly as silver stain (data not shown). In order to c
stains, five gels of a sample were stained with SyproRuby followed by sil
3.11 shows one representative gel stained with both stains, consecutively. In the five gels, 
arou
 - 92 - 
g). Preliminary 
e whole gel and 
ompare the two 
ver stain. Figure 
nd 96 % of all spot intensities showed less than 2-fold difference, compared to 86 % 
titative data not 
To conclude, silver staining was adequate for visualising spots but staining with SyproRuby 
 occurring between two different samples. 
3.2.7 Summary of 2D-gel electrophoresis optimisation 
 shows the optimised c
gory misatio  
from the silver stained gels (consistent with data from table 3.6, quan
shown). 
was more reproducible for quantifying changes
 
 
Table 3.7 onditions used in the present project. 
 
cate Opti n Comment
Detergent APS tain with ASB-14 CH Some acidic proteins did not sand Triton-X-100 
Solubility 8M Urea Thiourea increased the variability even though tter the solubility was be
Sample 
aration 
le
cipitated 
Acetone precipitation did not improve gel 
d increase the prep
Samp  not profiles and adding a step coul
variabpre ility 
Equilibration r  spots fuzzy 20 % glyce ol 30 % glycerol made the
Reproducibility Different samples on the same run 
Reproducibility was better when gels were run in 
parallel 
Size Mini gels More reproducible, mass spectrometry efficiency equivalent, needed less sample 
Stain SyproRuby Staining more homogenous, more reproducible, less saturation due to a larger linear range  
Table 3.7: Summary of the results for the optimisation of 2D-gel electrophoresis 
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. 
 
2DE followed by 
from spots were observed using Progenesis Samespots software: 
a) a saturated spot of glutamate oxaloacetate transaminase 2 (41.2 kDa, pI 9.0) and b) a non 
saturated spot of ATP synthase δ-subunit (19 kDa, pI 5.88) from a mitochondrial fraction from 
mouse N2a neuroblastoma resolved on 2DE. 
 
 
 
 
 
Differences in spot detection using silver stain compared to SyproRuby 
Five different replicates of gels were consecutively stained with SyproRuby (A) followed by silver 
stain (B). The five replicates for each stain were grouped and spot densities were averaged using 
Progenesis Samespots software. The pictures show a representative pofile. Yellow spots are spots 
that have densities decreasing by more than 2-fold compared to the average of the five gels. Green 
spots are spots that have densities increasing by more than 2-fold compared to the average. Blue 
spots are spots that are changed by less than 2-fold (increase or decrease) compared to the average 
gel. 
 
 
Figure 3.10: 3-dimensional image of two different spots from a large 2DE 
120 μg mitochondrial fractions from mitotic mouse N2a cells were run on a large 
silver stain. 3-dimensional images 
a) b) 
 
 A. SyproRuby stained gel 
 
 
 
 
 
 
Figure 3.11: 
kDa 
150 
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  75 
  50 
  37 
  25 
  20 
      4        9 
B. Silver stained gel 
pI 4     9
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3.2.8 Mass Spectrometry 
E profiles using 
f mitochondrial 
ent. Five of the 
ous in the cell 
ely of spot 9 
 3.12. This spot had a positive match to ATP synthase, F1 complex α-
subunit isoform 1 with a significant identification score as calculated by the Mascot 
 
differentiated 
ar differentiation in mouse N2a neuroblastoma cells increased the variability of 
samp act that not all cells differentiate at the same rate and only 
around 20-40 % of total cells in a sample actually produce axon-like processes (Flaskos et 
ypical morphology of 
N2a neuroblastoma cells when they were differentiated with 0.3 mM dbcAMP in serum 
free medium for 24 hours compared to mitotic cells grown in growth medium (containing 
10 % serum, refer to section 2.2.1.1 and 2.2.1.6). Differentiated cells expressed a different 
morphological phenotype from mitotic cells. Axon-like processes were extended from the 
cell body and cells were more ovoid in shape, typical of differentiated neuronal cells. 
 
 
Figure 3.12 and table 3.8 show the spots that have been identified from 2D
peptide mass fingerprinting. Sixteen out of twenty-one proteins were o
origin, mainly matrix. Outer and inner membrane proteins were also pres
identified proteins were not specific to mitochondria but three were ubiquit
and the other two were normally found in the endoplasmic reticulum. Figure 3.13 shows an 
example of protein identification using peptide mass fingerprinting, nam
shown in figure
database (score > 54). 
3.2.9 Mitochondrial proteome changes between mitotic and 
phenotypes 
 
Cellul
les. This was due to the f
al., 1998). 
 
3.2.9.1 Morphological changes 
 
Mouse N2a neuroblastoma cells were differentiated and characterised in-house using 0.3 
mM dbcAMP (De Girolamo et al., 2000). Figure 3.14 shows the t
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ptide 
plex β-subunit (ATPase-β) 
plex α-subunit isoform 1 (ATPase-α) 
itochondrial F0 complex subunit d (ATPase-δ) 
C2) 
 
75) 
 
erase, mitochondrial precursor 
 oxaloacetate transaminase 2, mitochondrial (GOT2) 
ofolate dehydrogenase / cyclohydrolase, mitochondrial 
1 ubunit alpha, mitochondrial 
18. Electron transfer flavoprotein subunit alpha, mitochondrial 
Outer membrane interacting proteins from other cellular compartments: 
1. 78 kDa glucose-regulated protein precursor (GRP 78) 
7. Protein disulfide isomerase A3 precursor 
11. Putative β-actin 
Ubiquitous proteins: 
3. Heat shock cognate 71 kDa protein (Hsc70) 
5. Stress-induced-phosphoprotein 1 (STIP1) 
 H+ transporting mitochondrial F1 com
 
 
Figure 3.12: 2DE (pI 3-10) stained with SyproRuby showing spots identified following pe
mass fingerprinting 
Inner mitochondrial membrane proteins: 
8. ATP synthase, H+ transporting mitochondrial F1 com
9. ATP synthase,
21. ATP synthase, H+ transporting m
20. Prohibitin (BAP32 homolog) 
Outer mitochondrial proteins: 
16. Voltage-dependent-anion channel protein 2 (VDA
 19. Voltage-dependent-anion channel 1 (VDAC1) 
Mitochondrial matrix 
2. Aconitate hydratase, mitochondrial precursor
4. Stress-70 protein, mitochondrial precursor (GRP
6. 60 kDa Heat shock protein, mitochondrial precursor (Hsp60)
10. Fumarate hydratase, mitochondrial 
12. δ(3,5)-δ(2,4)-dienoylCoA isom
13. Glutamate
14. bifunctional methylenetetrahydr
15. Malate dehydrogenase, mitochondrial precursor (MDH) 
7. Electron transfer flavoprotein s
1 4
6
2 
7
5
9 8
11
3
12
13
15
16
19 20
21
kDa 
116.25 
66.3 
45 
23.6 
18 
pI      3                  9 
10 
14 
17 18 
 
 
Spot 
symbol 1 
c
number 3 
 
coverage  weight 
l 
pI 
Subcellular 
location Protein identification 
2 Ac ession Score 4 % sequence 5
Molecular Theoretica
1 78 kDa glucose-regulated  P20029 142 29 % 72 kDa 
ER-
interacting 
with OMM precursor
5.07 
2 se,   Q99K10 2 Matrix 
Aconitate hydrata
mitochondrial 69 3 % 86 kDa 8.08 
3 ate 71 in P630 2 Ubiquitous 
Heat shock cogn
prote
kDa 17 83 7 % 71 kDa 5.37 
4 protein, rial P38647 Matrix 
Stress-70 
mitochond 57 18 % 74 kDa 5.91 
5 otein 1  Q60864 Ubiquitous 
Stress-induced-
phosphopr 79 20 % 63 kDa 6.40 
6 roitochondrial P63038 Matrix 
60 kDa Heat shock p
m
tein, 113 27 % 61 kDa 5.91 
7 me P27 1 3
ER-
interacting 
with OMM 
Protein disulfide iso
A3 
rase 773 34 6 % 57 kDa 5.88 
8 
+ 
chondrial 
ubun
P56480 189 51 % 56 kDa 5.25 IMM 
ATP synthase, H
transporting mito
F1 complex β-s it  
9 m 1 Q03265 IMM 
ATP synthase, F1 complex 123 42 % 60 kDa 9.19 α-subunit isofor
10 sl P978 1 4 Matrix 
Fumarate hydrata e, 07 03 3 % 54 kDa 9.12 mitochondria
11 Putative β-actin P60710 120 24 % 42 kDa 5.78 Ubiquitous 
12 δ(3,5)-δ(2,4)-dienoylCoA isomerase, mitochondrial  O35459 60 14 % 36 kDa 7.60 Matrix 
13 Glutamate oxaloacetate P05202 89 22 % 41 kDa 9.00 Matrix 
 
Table 3.8: Protein identification of spots from 2DE (gel image in figure 3.12) 
1 Refers to circled spots figure 3.12 
2 Using the Mascot database http://www.matrixscience.com 
3 Accession number from the Protein Knowledgebase UniProtKb: http://www.uniprot.org 
4 Protein score greater than 54 are significant according to the Mascot database search software when comparing SwissProt database 
5 Coverage of all peptide sequences matched to the identified protein sequence 
 
 
ase 2, 
ndrial 
transamin
mitocho
14 
ydrofo
nase / 
olase, 
l 
P18155 160 30 % 38 kDa 8.98 Matrix 
bifunctional 
methylenetetrah
dehydroge
cyclohydr
late 
mitochondria
15 na P08 1 4 Matrix Malate dehydroge se 249 01 3 % 36 kDa 8.93 
16 ent-anion 2 Q609 1 4 OMM 
Voltage-depend
channel protein 30 25 2 % 32 kDa 7.44 
17-18 
ansfer 
 al
rial  
Q99 1 Matrix 
Electron tr
flavoprotein subunit
mitoch
pha, 
ond
LC5 65 7 % 35 kDa 8.62 
19 ent-an1 Q60932 OMM 
Voltage-depend ion 
channel 196 81 % 30 kDa 8.62 
20 3 P67778 IMM 
Prohibitin (BAP
homolog) 
2 169 21 % 30 kDa 5.22 
21 
ATP synthase, H+ 
transporting mitochondrial Q9DCX2 97 
F0 complex subunit d  
31 % 19 kDa 5.88 IMM 
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Figure 3.13: Example of MALDI-TOF analysis and protein identification of spot 9 from figure 
3.12 
Mitochondrial fraction was electrophoresed by 2DE (pI 3-10) followed by silver staining. Spot 9 
(figure 3.12) was picked, trypsinised and processed via MALDI-TOF mass spectrometry. The 
peptide mass list obtained was transferred to the Mascot database giving a significant positive 
identification. A. Mass spectrum obtained by MALDI-TOF. B. Identity probability of spot 9 as ATP 
synthase subunit alpha.  
 
 
A. Mass spectrum of spot 9 obtained by MALDI-TOF analysis 
B. Mascot database results for spot 9 identification 
1000 1500 2000 2500 3000 3500
1553.89
861.11
855.13 1673.09
2338.55877.21
1625.05859.50 2309.53
1627.141067.22 2465.66
2753.93
 
 
 
Match to: ATPA_MOUSE Score: 123 Expect: 8.1e-09 
ATP synthase subunit alpha, mitochondrial OS=Mus musculus GN=Atp5a1 PE=1 
Nominal mass (Mr): 59830; Calculated pI value: 9.22 
Number of mass values matched: 16 
Sequence Coverage: 40% 
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pared to mitotic 
Mouse N2a neuroblastoma cells were seeded then grown for 24 hours. a) Growth medium was 
chan ours: mitotic cells. b) Alternatively, growth medium was 
replaced by serum free medium with 0.3 mM dbcAMP for 24 hours: differentiated cells. 
Objective x 400, bar = 20μm. 
g to investigate 
blastoma were 
 from a mitotic 
n had not been 
n differentiated 
. These changes were quantified using the Samespots software and are 
shown in table 3.3. Nine spots showed significant changes. Most of them were decreasing 
in levels, indicating a lower level expression of those proteins in the post-mitotic state. 
Table 3.3 also shows that two of those proteins were identified. Stress-70 protein was 
significantly increased following differentiation. Moreover, aconitate hydratase level was 
significantly decreased. 
 
 
a) b) 
Figure 3.14: Differentiated mouse N2a neuroblastoma cell morphology com
cell morphology 
ged and cells incubated for 24 more h
 
3.2.9.2 Changes in the mitochondrial proteome 
 
Since mitochondria have been implicated in differentiation, it was interestin
whether the mitochondrial proteome changed when mouse N2a neuro
differentiated. Figure 3.15 shows a representative mitochondrial proteome
sample resolved on a large 2DE (please note – at this stage optimisatio
conducted). Circles highlight spots that showed significant changes betwee
and mitotic cells
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ots changing in 
rowing in growth 
m while 0.3 mM dbcAMP in serum free medium was used to differentiate the cells. 
Mitochondria from mitotic samples and from differentiated samples were isolated using differential 
centrifugation. 200 μg samples were run onto 12 % polyacrylamide resolving large-scale 2DE using 
pI 3-10 strips (17 cm) and silver stained gels were compared using Samespots Progenesis software. 
Circled spots represent spots that changed in intensity level between mitotic and differentiated 
samples using a paired t-test (n = 3).  
A. Full image of the gel from mitotic sample. B. Enlarged image of the squared area from mitotic 
sample. C. Enlarged image of the squared area from differentiated sample. MW: molecular weight 
markers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Large-scale 2DE (pI 3-10) stained with silver stain showing sp
levels when cells are differentiated compared to mitotic cells 
Mouse N2a neuroblastoma cells were grown for 24 hours. Mitotic cells were left g
mediu
9 
9
B. Mitotic state C. Differentiated 
state 
18  18 
pI 7.7   8.2 pI 7.7   8.2 
kDa kDa 
1 
2 3 
5 4 
7 
6 
8 
9 
A. Protein mitochondrial profile following differentiation of N2a cells 
150 
100 
75 
50 
37 
25 
20 
kDa 
15 
pI 3          10
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itotic cells 
ore details on the 
d error of the mean 
m differentiated samples / Average of 
normalised volumes from mitotic samples. 
4 Percentage decrease = - Average of normalised volumes from mitotic samples / Average of 
normalised volumes from differentiated treated samples. 
* Statistically significant increases p < 0.05 using a paired t-test. 
** Statistically significant increases p < 0.1 using a paired t-test. 
 
o
ymb
1 
ein
identificatio
vera
rmal
um
ferentiated 
ample
A
o
itotic  3 
+/- % change 
compared to 
mitotic 4 
 
n 2 
A
no
vol
dif
ge 
ised 
es in  nvolumes in  
verage 
rmalised Sps
t 
ol Prot
s 3 m  sampless
1 S ess-70 pro 29 ± 4854 ± 500 + 20 % * tr tein 58 489 
2  33 ± 1 1902 ± 128 - 43 % ** 13 591 
3 Aconitate hydratase 299 ± 2361 - 82 % 
** 1 104  ± 151 
4  02 ± 1 1038 ± 119 - 29 % * 8 32 
5  1687 ± 2464 ± 116 - 46 % *  74 
6  752 ± 4250 - 54 % ** 2 534  ± 212 
7  577 ± 29 1120 ± 386 - 94 % * 
886 ± 187 1734. ± 386 - 96 % ** 8  
5386 ± 384 - 37 % * 9  2271 ± 541 
Table 3.9: Quantitative analysis of spots showing significant changes in differentiated
cell profiles compared to m
Normalised density obtained using Samespot software (Progenesis) .  
1 Spot symbols confer to figure 3.15. 
2 Proteins identified by peptide mass fingerprinting. For accession numbers and m
Mascot database results refer to table 3. 
3 Average of normalised volumes (n = 3) ± Standar
4 Percentage increase = + Average of normalised volumes fro
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3.3  DISCUSSION 
3.3.1 Purity of subcellular fractions 
mouse N2a cells 
ount of 
ant, mouse N2a 
erence was not 
ceptable for the 
hat the level or 
 assessment of 
d higher using 
viously reported 
 from primary 
5Y neuronal cell line and had no enrichment of a 
e total extract. 
wing a percoll / 
ecreased due to 
al markers was 
 a low fraction 
d to total extract 
01), which was 
 
differentiated cells. To remove lysosomes, preliminary experiments were conducted 
involving pelleting the mitochondria through a sucrose cushion. Unfortunately, the yield of 
protein was too low for use in proteomics protocols (data not shown). This problem was 
also mentioned by Cox and Emili (2006) who suggested that gradient fractionation 
necessitated much more starting material with increased time and cost. In the present work, 
 
 
A comparative analysis revealed that mitochondrial protein recovery from 
was double that  from human SH-SY5Y cells using the present protocol. As the am
protein needed for further analysis, using a proteomic approach, was import
neuroblastoma cells were chosen for further analysis.  
Even though protein recovery seemed higher in mitotic cells, the diff
significant making both mitotic and differentiated states of N2a cells ac
present study. Analysis of biochemical markers in each fraction showed t
activity of mitochondrial markers were higher in the mitochondrial fraction, which was not 
significantly different between mitotic and differentiated cells. Indeed,
enrichment of mitochondria was around 5-fold using SDH activity an
cytochrome c as a marker. This enrichment was higher than observed in pre
studies. For example, Almeida and Medina (1997) isolated mitochondria
neurons estimating a 3.7-fold enrichment in mitochondria based on citrate synthase activity. 
Scheffler et al. (2001) used the SH-SY
mitochondrial marker (cytochrome c oxidase activity) compared to th
However, in their study, a purer mitochondrial extract was produced follo
metrizamide two-step gradient, and mitochondrial activity may have been d
further fractionation (damage due to extra steps).  
In the present project, the presence of cytoplasmic, nuclear and microsom
negligible compared to the high enrichment of mitochondrial markers. Only
of the cytoplasmic marker was found in the mitochondrial fraction compare
in differentiated cells, which was slightly higher than in Scheffler et al. (20
expected as they used a percoll / metrizamide gradient.  
Lysosomal proteins were also enriched by 2-fold in the mitochondrial fraction from
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it was decided to opt for high recovery of mitochondria despite the risk of lysosom
contamination. It was felt that because 2DE tends to resolve the high-abu
lysosomal proteins should be in the background of the gels. Moreover, it wa
although there was a 2-fold enrichment of lysosomal proteins in the mitoch
the enrichment of lysosomal markers was higher in the cytoplasmic fracti
 - 103 - 
al 
ndance proteins, 
s observed that, 
ondrial fraction, 
on compared to 
was negligibly 
tion was called 
 that it contained the majority of the 
with the crude 
 fraction, this fraction was 
al proteins. The 
nce of unbroken 
wn).  
fraction was adequate for further study. Even 
aminated with lysosomes, it seemed unlikely to be a 
problem for 2DE analysis since low-abundance proteins are not always observed on 2DE 
ique is not used 
ty (Govorun and 
ydrophobic and 
ecting how they 
tric field, particularly in the IEF step. Consequently, it has 
been proposed that each laboratory should optimise 2DE methods to the best performance 
for each type of sample used (Rabilloud et al., 2007). In the present project, each step was 
devised to obtain a mitochondrial profile that resolved as many spots as possible in a 
reproducible manner. A compromise between these two characteristics has sometimes been 
necessary.  
total extract (4.4-fold). This indicated a dominant presence of lysosomal proteins to the 
cytoplasmic fraction compared to the mitochondrial fraction. 
Overall, the cytoplasmic fraction following differential centrifugation 
contaminated with mitochondrial and nuclear fractions. Although the frac
“cytoplasmic fraction”, it is worth mentioning
endoplasmic reticulum and lysosomal proteins which was consistent 
fractionation in the study of Scheffler and colleagues (2001).  
Although a high enrichment of lamin was observed in the nuclear
contaminated with cytoplasmic, microsomal, lysosomal and mitochondri
presence of all the fractions in the nuclear fraction indicated possible prese
cells in the homogenate, estimated to be between 25 and 50 % (data not sho
To conclude, it was felt that the mitochondrial 
if the mitochondrial fraction was cont
and proteins were identified prior to further validation. 
 
3.3.2 2DE: optimization and reproducibility 
 
Although 2DE has been widely used in many different studies, the techn
routinely in laboratories due to a lack of automation and low reproducibili
Archakov, 2002). Moreover, different samples used have different ionic, h
molecular weight compositions, which can be a source of variability, aff
behave when applied to an elec
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It is well known that mitochondria are membrane rich organelles, with a m
hydrophobic proteins (Reifschneider et al., 2006). One limitation of the pr
sample preparation for the first dimension of 2DE. As the voltage is very h
residual salts and ionic compounds had to be removed. Consequently, 
agents and detergents used in the sample buffer could not be ionic, whi
more efficient for the solubilisation of highly hydrophobic molecules (Rabilloud 
2007). On the other hand, non ionic and zwitterionic detergents could be us
commonly used detergents in each category were tested: Triton-X-10
respectively (Rabilloud et al., 2007). With Triton-X-100, some low-a
proteins seemed to be more intensely stained, but the staining of acidic pro
The latter was of great importance since acidic proteins included ATP syn
(ATPase-β), which is an inner mitochondrial membrane protein. Chaotropic agents such as 
urea and thiourea solubilise proteins by breaking non-covalent interactions 
molecules in a system, causing protein unfolding (Rabilloud et al., 2007). A
X-100 has been shown to be more efficient with thiourea (Rabilloud et al., 
present study; data not shown) and although acidic spots seemed to appear, 
intense or as well resolved as with CHAPS. Other zwitterionic deterge
family, for example ASB-14, are thought to be more efficient and the
increasing over the last few years, ASB-14 has been shown to solubilise me
more efficiently, if used in combination with thiourea (Luche et al., 2003), but in the 
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ajority of 
esent study was 
igh in IEF, any 
any solubilising 
ch generally are 
et al., 
ed and the most 
0 and CHAPS, 
bundance basic 
teins was weak. 
thase β-subunit 
between various 
lthough Triton-
2007 and in the 
they were not as 
nts of the same 
ir use has been 
mbrane proteins 
B-14 combined 
imilar to results 
or the 
pI 3-10 2DE. 
 with IEF and mass spectrometry, 
acetone precipitation has widely been used prior to 2DE (Mastro and Hall, 1999). In the 
present study, precipitating samples with acetone prior to IEF did not improve resolution 
and the staining seemed to be less intense than without acetone precipitation. Moreover, it 
was thought that adding a step could increase variability to the procedure so it was decided 
that, for comparative studies, acetone precipitation would not be used. 
 
present study, although basic proteins seemed to be better resolved with AS
with thiourea than with CHAPS, acidic proteins were barely detectable, s
shown with Triton-X-100. CHAPS remained, therefore, the detergent of choice f
analysis of mitochondrial proteome from mouse N2a neuroblastomas using 
To remove residual lipids and salts that could interfere
CHAPTER III ESTABLISHING METHODS 
 
When Merril et al. (1979) used silver stain for the first time they introduced, at the tim
most sensitive non-radioactive protein stain for 2DE. It was a lot more
Coomassie brilliant blue stain with a detection limit of 1 ng compared to
2002). Silver staining was also compatible with mass spectrometry; howev
variability was high and the staining was not always uniform over the wh
2002), which was also observed in the present study (discussed below). The stain can be 
semi-quantitative if glutaraldehyde is used in the sensitizing step of the st
showing a more uniform staining all over the gel, but not being compatib
spectrometry (Patton, 2002). Nevertheless, in the present project, althou
seemed to improve when using glutaraldehyde, the variability between ge
(data not shown). Another limitation of silver stain, with or without aldeh
linear dynamic range for quantitation of spot intensities. Indeed, the linear range is only one 
order of magnitude (Lopez et al., 2000) leading to saturation of the stain (wi
protein / spot) prior to the apparition 
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e, the 
 sensitive than 
 10 ng, (Patton, 
er, the gel to gel 
ole gel (Patton, 
aining protocol, 
le with mass 
gh the staining 
ls was still high 
ydes, is the low 
th around 60 ng 
of lower-abundance spots. An alternative to silver 
stain is the use of fluorescent dyes. SyproRuby has a similar detection limit to silver (0.5-1 
ting with spots 
 reproducibility 
protocol, it was 
ple or replicate 
llel showed that 
ote that changes 
t day compared 
t samples electrophoresed in parallel. This showed that, although subcellular 
fractionation reproducibility was relatively low, as shown by high SEMs with the protein 
recovery and the markers data, the 2DE protocol was a greater source of variability for the 
mitochondrial proteome profile itself. On the other hand, when SyproRuby was used, 95 % 
of the spots showed a change in intensity by less than 2-fold change, improving the 
reproducibility. 
 
ng) and a linear dynamic range of three orders of magnitude, satura
containing over 2 μg protein (Lopez et al., 2000).  
 
In previous studies, one of the limitations of 2DE was described as the low
of the method (Dani and Dencher, 2008). Following optimization of the 
important to assess the reproducibility between gels for the same sam
samples, initially using silver staining. Replicates of samples run in para
approximately the same number of spots was revealed and around 80 % of these spots 
varied in intensity by less than 2-fold, and around 95 % by less than 3-fold. Changes over 
the 3-fold threshold were then minimal. It was, however, interesting to n
were slightly more significant when the same sample was run on a differen
to differen
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To conclude, to reduce variability when comparing samples (treatments versus controls), it 
was deemed necessary to 
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run samples in parallel for the IEF step and for the SDS-PAGE 
step and to stain with SyproRuby. 
3.3.3 Integrity of mitochondrial fractions on 2DE 
oblastoma cells 
x and inner and 
hment of intact 
ing enrichment 
 some evidence 
he endoplasmic 
ct sites between 
007). Moreover, 
DE profiles of 
drial proteome. 
ious studies of 
mples, Kruft et 
rabidopsis with 
 the majority of 
04) studied the 
and observed up 
protein, again in agreement with previous studies (Kruft et al., 2001; Scheffler et al., 2001 
and Fukada et al., 2004). This limitation could be due to the fact that most of the 
mitochondrial proteins are membrane proteins and extraction of peptides from the gel might 
be difficult due to the low solubility of some of these proteins. Moreover, many proteins 
were of basic pI. Such proteins, by their chemical composition, could be rich in lysine 
 
 
The 2DE profile of the mitochondrial proteome from mouse N2a neur
included proteins from all three compartments of the mitochondria (matri
outer mitochondrial membranes). This provides clear confirmation of enric
mitochondria in the mitochondrial fraction. It also agrees with the data show
of SDH and cytochrome c described earlier. On the other hand, there was
for the presence of non-mitochondrial proteins such as GRP78, β-actin, STIP1 and protein 
disulfate isomerase A3, which could be indicative of contamination by t
reticulum. Interestingly, GRP78 and STIP1 are proteins found in the conta
the mitochondria and the endoplasmic reticulum (Hayashi and Su, 2
proteins that are not specific to mitochondria were also present in 2
mitochondria in other studies (Fukada et al., 2004; Scheffler et al., 2001). Thus, the N2a 
mitochondrial fraction was considered suitable for analysis of the mitochon
Up to 400 spots were visualised with the majority showing molecular weights between 20 
and 60 kDa and pI values between 5 and 8. This is similar to prev
mitochondrial proteomes from different sources, even from plants. For exa
al. (2001) visualised up to 600 spots in the mitochondrial proteome from A
the majority between 30 and 60 kDa and pI 4.5 and 8. Scheffler et al. (2001) analysed the 
mitochondrial proteome from human SH-SY5Y neuronal cells and observed
spots between 20 and 80 kDa and pI 5 to 8. Moreover, Fukada et al. (20
mitochondrial proteome from NSC34 mouse spinal cord-neuronal cell line 
to 600 spots with a majority between 25 and 70 kDa and pI 4.5-8.  
Only about two-third of the spots analysed (21 / 32) led to a positive identification of the 
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residues and when cleaved by trypsin, the most widely used proteas
spectrometry, produce many small peptide fragments, which woul
identification difficult. This problem would also be exacerbated when the b
of low molecular weight. Another limitation for mass spectrometry in the pr
that the limited amount of ma
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e for mass 
d render their 
asic proteins are 
esent study was 
terial loaded onto each gel might lead to spots with too low 
 
tion 
itotic state. One 
, although they 
 differentiate cultured cells in 
 cell cycle arrest 
g in elongation 
 
 
wed significant 
large-2DE, it is 
ve been missed. 
to increase and 
ation. Stress-70 
e. 
gical changes in 
ifferentiation of 
r mitochondrial 
 relation to an 
increase in enzyme activities, inferring a more efficient use of enzymes with less protein.  
Stress-70 protein has been implicated in apoptosis by protecting against cell death (Xu et 
al., 2009). It was observed that the differentiation process in different cell lines shared 
similarities with the apoptotic process with a slight release of cytochrome c but no 
activation of caspase-3 combined with a rearrangement of Bcl2 proteins and lower 
protein content to allow identification.  
3.3.4 Changes in the mitochondrial proteome following cell differentia
 
One of the characteristics of neurons in the brain is that they are in a post-m
of the difficulties with using secondary neuroblastoma cultures is that
express some neuronal properties, they are mitotic and also express different characteristics 
compared to post-mitotic cells. Methods have been devised to
vitro. For example, serum withdrawal supplemented with dbcAMP induces
in mouse N2a neuroblastoma cells (Prashad and Rosenberg, 1976), resultin
of axon-like processes due to changes in cytoskeletal protein arrangements. 
In the present study, we investigated whether the differentiation process had direct effects
on the mitochondrial proteome profile of N2a cells. Nine proteins sho
changes in levels following differentiation, but, due to the variability of 
likely that these changes are not exclusive and that other changes may ha
Two of the nine spots were identified: stress-70 protein was observed 
aconitate hydratase was observed to decrease following cellular differenti
protein is a mitochondrial heat shock protein and aconitase is a Krebs cycle enzym
Several studies have shown that differentiation of cells leads to morpholo
mitochondria. For example, Moyes and colleagues (1992) showed that d
3T3 fibroblasts led to changes in cristae structure formed by the inne
membrane. They observed that the volume of cristae was decreasing in
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or study of the 
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n blot analysis. 
e composition, it was decided that 
subsequent analyses would be conducted on differentiated cells. 
 
 
mitochondrial potential (in keratin
mitochondria to the differentiation process. 
In the present study, designed to choose the most suitable cellular state f
mitochondrial proteome, changes in expression levels of stress-70 protei
were not validated using an alternative detection method such as wester
Since differentiation led to distinct changes in proteom
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CHAPTER IV EFFECTS OF MPTP ON CELL VIABILITY 
 
4.1.1.1
4.1.1.2
4.1 INTRODUCTION 
 
4.1.1 Effects of MPTP on cell viability and mitochondrial activity in mouse N2a 
neuroblastoma cells 
 
 MPTP-mediated sub-cytotoxic effects 
 
An important step in studying the effects of MPTP on the mitochondrial proteome of 
mouse N2a neuroblastoma cells was to establish concentrations of the toxin that 
produced effects on the cell and the mitochondria prior to cell death. De Girolamo and 
colleagues (2000) previously used sub-cytotoxic concentrations of MPTP on mouse 
N2a neuroblastoma cells resulting in changes in cytoskeletal proteins. In particular, 
neurofilaments were modified in response to MPTP resulting in changes in axon 
outgrowth and cell morphology prior to cell death. Song and colleagues (1997) have 
also used sub-cytotoxic concentrations of MPTP on human SH-SY5Y neuroblastoma 
cells that did not affect cell viability but resulted in changes in cell morphology, 
cytoskeleton organisation and mitochondrial structure. The objective of these studies 
using sub-cytotoxic concentrations aimed to decipher the pathways involved in MPTP 
toxicity prior cell death as this may lead to a better understanding of the 
neurodegenerative process involved in PD.  
 
 Monitoring cell viability following MPTP treatment in mouse N2a 
neuroblastoma cells 
 
Several assays to study cell viability have been designed to monitor a wide range of 
essential cellular characteristics, such as membrane integrity (e.g. LDH release and 
trypan blue exclusion), metabolic activity (e.g. MTT reduction), protein content (e.g. 
Coomassie blue assay) or DNA synthesis (e.g. 3H-thymidine assay).  
De Girolamo et al. (2000) used one of the commonly used methods to monitor cell 
membrane integrity, the trypan blue exclusion assay, to establish whether the 
concentrations of MPTP used were sub-cytotoxic. The trypan blue dye is able to enter 
cells that had lost their membrane integrity and are then considered to be dying or dead, 
whilst healthy cells remain trypan blue dye-impermeable. This constitutes a rapid and 
relatively inexpensive way of checking cell permeability and cell membrane integrity. 
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Metabolic activity can also be an indicator of cell viability. For example, Amazzal et al. 
(2007) used both the trypan blue exclusion and MTT reduction assays for cell viability 
markers. The MTT assay was developed for cytotoxic assessment by Mosmann (1983). 
The tetrazolium salt MTT is cleaved by various dehydrogenase enzymes. The resulting 
coloured product concentration was proportional to the dehydrogenase enzyme 
activities present in each cell and can be measured spectrophotometrically. 
Assessment of cellular ATP content could also be considered as a metabolic activity 
assay as it monitors cellular energy. De Girolamo and colleagues (2001) used the bio-
luminescent ATP assay to monitor ATP presence in N2a neuroblastoma following 
MPTP treatment. In this bio-luminescent assay, ATP presence was monitored based on 
the capacity of the luciferase enzyme to catalyse the formation of a luminescent product 
in a proportional manner. 
 
 Monitoring mitochondrial activity following MPTP treatment in mouse N2a 
neuroblastoma cells 
 
Since the main objective of the present study was the analysis of the effects of MPTP on 
the mitochondrial proteome, it was necessary to establish whether the sub-cytotoxic 
concentrations used had an effect on mitochondrial activity. 
Although not entirely specific to mitochondria, the ATP assay can be sometimes used as 
a measure of mitochondrial activity since these organelles are thought to produce most 
of the cellular ATP (Mootha et al., 2003). Then, a change in extra-mitochondrial ATP 
production would not have a huge effect on mitochondrial ATP levels. Moreover, the 
major site of action of MPTP was observed to be the inhibition of the ETC via its 
metabolite, MPP+ (Ramsay et al., 1987) leading to mitochondrial ATP production 
reduction (Ramsay et al., 1987). Consequently, the ATP assay could be considered as a 
measure of mitochondrial activity.  
Another marker of mitochondrial activity is the assessment of mitochondrial membrane 
potential. As the ETC transfers protons through the IMM, it creates an electrical 
potential that polarises mitochondrial membranes. The fluorescent JC-1 assay was 
developed by Cossarizza and colleagues (1993). They used the JC-1 dye, a lipophilic 
cation that had the capacity to enter mitochondria. The dye was observed to aggregate in 
active polarised mitochondria and to form J-aggregates that emitted an orange-red 
signal at 590 nm when excited at 490 nm. Interestingly, when mitochondrial membrane 
potential collapsed, the dye could leave depolarised mitochondria as a monomeric form 
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that emitted a green signal at 530 nm when excited at 490 nm. The ratio of aggregated 
dye signal over monomeric dye signal can be measured and provide a relatively specific 
marker of mitochondrial activity.  
 
4.1.2 Investigation of cell death pathways 
 
Whether neurodegeneration in PD has necrotic or apoptotic features has been the focus 
of a number of studies producing conflicting results involving both necrotic and 
apoptotic markers depending on models and toxin concentrations used (reviewed in 
Barzilai and Melamed, 2003). Two different studies by He and colleagues (2008) and 
Novikova et al., (2006) have shown that in a mouse model, neurodegeneration due to 
acute MPTP treatment of mice did not show typical apoptotic markers, while injections 
of subacute or chronic treatments showed apoptotic markers (e.g. nuclear condensation, 
presence of apoptotic bodies).  
It was therefore important in the present study to investigate whether early cell death 
markers were present following sub-cytotoxic MPTP treatment in mouse N2a 
neuroblastoma cells and the potential role of mitochondria if such markers were present. 
 
 Cellular markers of necrosis 
 
As previously described (section 1.3.2), necrosis was originally observed to be a 
passive, energy-independent type of cell death. One of the identified causes was calcium 
overload leading to its typical cellular characteristics: induction of mitochondrial 
permeability transition, osmotic swelling of mitochondria, rupture of the OMM, loss of 
energy, cell swelling, disruption of plasma membrane and release of cytoplasmic 
content into the extracellular environment (Kajta et al., 2004).  
However, studies have recently demonstrated that other types of necrosis could occur in 
different models of study. For example Niquet et al. (2006), studied a neuronal death 
pathway in primary cortical cultures, in which cells showed a necrotic morphology but 
with some features of the apoptotic pathway (caspase-3 activation, DNA 
fragmentation). Moreover, Boujrad et al. (2007) described a “programmed necrosis” 
that was mediated by apoptosis inducing factor found in the mitochondrial IMS and 
released in apoptotic cell death. 
Typically, cell lysis is the most used characteristic for studying necrotic cells. 
Membrane exclusion assays (e.g. trypan blue) and cytoplasmic content release assays 
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(e.g. lactate dehydrogenase) are often used as necrotic markers. Moreover, 
mitochondrial membrane potential and cytochrome c release can be monitored as 
mitochondrial health markers but are not specific to necrotic cell death as they also 
occur in apoptosis (Halestrap et al., 2000). 
 
 Cellular markers of apoptosis 
 
Apoptosis is a programmed and active process of the cell leading to death (also 
described in section 1.3.1). As opposed to necrotic cell death, typical characteristics are 
cell shrinkage leading to apoptotic body formation, nuclear and cytoplasmic 
condensation, chromatin fragmentation and intact cell membrane integrity (Orenius et 
al., 2004).  
Any protein involved in the apoptotic cascade can be used as markers of apoptotic cell 
death (e.g. Bcl2 family proteins, caspases, mitochondrial proteins that can be released to 
the cytoplasm). Many have been used for the study of MPTP-induced cell death. The 
protein levels and mRNA levels of Bcl2-family proteins, particularly the anti-apoptotic 
Bcl2 and pro-apoptotic Bax proteins, have been widely used as a marker of the cell 
death pathway (Yang et al., 1998). Many cleaved caspases have been studied, 
depending on the pathway involved in the particular projects. Caspase-3, for example, 
has been widely used as it is activated in both extrinsic and intrinsic pathways and is the 
most central effector caspase along with its analog caspase-7 (Hartmann et al., 2003; 
Bilsland et al., 2002). To distinguish between the mitochondrial-dependent pathway 
with other apoptotic pathways, caspase-2 can be used as it is an initiator of the 
mitochondrial-dependent pathway (Orrenius et al., 2004). Moreover, caspase-2 activity 
has been linked to MPP+ toxicity (for example in Sanz et al., 2008). Morphologically, 
DNA fragmentation and chromatin condensation have also widely been used as 
apoptotic markers (Novikova et al., 2006), although they are not pathway specific. 
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4.1.3 Aims of the chapter 
 
The pathways involved in MPTP-induced neurodegeneration have not been fully 
resolved. Investigating MPTP-induced cell death in mouse N2a neuroblastoma cells 
may add important insights into these pathways. It has previously been shown that 
morphological and biochemical changes occurred prior to cell death following sub-
cytotoxic exposure to MPTP in differentiating mouse N2a neuroblastoma cells (De 
Girolamo et al., 2000). Sub-cytotoxic concentrations of MPTP were used in this thesis 
to study early markers of neurodegeneration and more particularly of mitochondrial 
dysfunction. Consequently the primary objective of this chapter was to establish sub-
cytotoxic MPTP concentrations using a variety of assays, namely monitoring cell lysis, 
metabolic activity and mitochondrial activity. This would establish the parameters for 
further studies to identify markers of neurodegeneration covered in subsequent chapters. 
Both necrosis and apoptosis have been observed in MPTP-induced neurodegeneration 
(Bilsland et al., 2002; Lotharius et al., 1991). Both pathways have common and 
different characteristics. A secondary objective of this chapter was to investigate 
whether early markers of cell death were observed using these sub-cytotoxic 
concentrations. Mitochondrial involvement was monitored by investigating 
mitochondrial potential, cytochrome c release and caspase-2 cleavage. Caspase-3 
cleavage and activity were also used as an overall marker of apoptosis. These markers 
could give clues on which pathways are involved in MPTP-induced neuronal cell death 
and whether mitochondria are involved in this process. 
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4.2 RESULTS 
 
4.2.1 Assessment of effects of MPTP on N2a neuroblastoma cell viability 
 
In order to establish cytotoxic and sub-cytotoxic MPTP concentrations in mouse N2a 
neuroblastoma cells, cellular morphology, cell membrane integrity, metabolic activity, 
cellular energy level and mitochondrial membrane potential were monitored following 
exposure of the toxin over time. 
 
 Cellular morphology 
 
Mouse N2a neuroblastoma cells were pre-differentiated in serum free medium 
supplemented with 0.3 mM dbcAMP for 16 hours prior to treatment with different 
MPTP concentrations (0 to 2 mM MPTP). The morphology of cells was then observed 
using an inverted microscope and pictures were taken following 24 (figure 4.1) and 48 
hour (figure 4.2) treatments. 
At 24 hours, control cells showed ovoid cell bodies with axon-like processes (figure 
4.1A). Following 10 μM MPTP treatment for 24 hours, cells looked similar to controls 
except that cells exhibited fewer axon-like processes (figure 4.1B). Morphological 
changes became more evident following 100 μM MPTP for the same time-point 
compared to controls (figure 4.1C). Axon-like processes were generally shorter at this 
concentration and gradually deteriorated as the concentration of MPTP increased (figure 
4.1C to 4.1E). Very short or no axon-like processes were observed following 24 hours 
exposure to 1 mM MPTP (figure 4.1E). However, with this treatment, cell bodies 
seemed to maintain membrane integrity when compared to cell bodies observed 
following 2 mM MPTP treatment (figure 4.1F). Indeed, 2 mM MPTP treatment 
exhibited cell death morphology characterised by reduction in cell volume, spherical 
cell shape and loss of membrane integrity. 
Following 48 hours, control cells had similar morphology compared to controls for the 
24 hour time-point (figures 4.1A and 4.2A). Morphological changes were highly 
apparent following 10 μM MPTP treatment with virtually no axon-like processes and a 
few cell bodies with reduced volume (figure 4.2B). Following treatments with higher 
concentrations of MPTP, a mixture of morphologies could be observed. Some cells 
showed intact membrane while others exhibited loss of membrane integrity.  
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24 hour time-point 
B. 10 μM MPTP A. Control (0 μM MPTP) 
D. 500 μM MPTP 
F.2 mM MPTPE. 1 mM MPTP
C. 100 μM MPTP 
 
Figure 4.1: Morphological changes of mouse N2a neuroblastoma cells following exposure 
to MPTP for 24 hours   
Cells were differentiated with 0.3 mM dbcAMP for 16 hours prior to treatment with a variety of 
MPTP concentrations for 24 hours: A. 0 μM; B. 10 μM; C. 100 μM; D. 500 μM; E. 1 mM; F. 2 
mM MPTP (× 400 magnification). Scale bars represent 20 μM. Arrow shows an example of a 
cell which has lost membrane integrity. 
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48 hour time-point 
B. 10 μM MPTP A. Control (0 μM MPTP) 
D. 500 μM MPTP 
F. 2 mM MPTPE. 1 mM MPTP
C. 100 μM MPTP 
 
Figure 4.2: Morphological changes of mouse N2a neuroblastoma cells following exposure 
to MPTP for 48 hours   
Cells were differentiated with 0.3 mM dbcAMP for 16 hours prior to treatment with a variety of 
MPTP concentrations for 48 hours: A. 0 μM; B. 10 μM; C. 100 μM; D. 500 μM; E. 1 mM; F. 2 
mM MPTP (× 400 magnification). Scale bars represent 20 μM. 
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This became more apparent as the concentration of MPTP increased from 100 μM to 2 
mM MPTP (figure 4.2C to F). 
 
 Cell membrane integrity  
 
To assess the extent of cell death caused by exposure to MPTP and establish sub-
cytotoxic concentrations, cell membrane integrity was measured using the trypan blue 
exclusion assay as a marker of cell viability (refer to section 2.2.2.2).  
Following 24 hours treatment, no decrease in cell viability was observed using the 
trypan blue exclusion assay with concentrations up to 1 mM compared to control (figure 
4.3A). Concentrations greater than 1 mM showed a significant decrease in cell 
membrane integrity. Following 2 mM MPTP exposure for 24 hours, there was 60 % cell 
death. With 5 mM MPTP, no viable cells were observed. This showed that MPTP was 
cytotoxic at concentrations greater than 2 mM (figure 4.3A). 
At a later time-point of 48 hours, cells were more sensitive to MPTP at lower 
concentrations. 10 μM killed over 20 % of the cells which increased with increasing 
MPTP concentrations in a concentration-dependent manner (figure 4.3A).  
 
 MTT reduction assay  
 
As an alternative method of monitoring cell viability, the cellular metabolic activity was 
assayed using the MTT reduction assay (refer to section 2.2.2.3).  
Following 24 hours treatment, no decrease in cell viability was observed using the MTT 
reduction assay with concentrations up to 1 mM compared to control (figure 4.3B). 
However, concentrations greater than 1 mM showed a significant decrease in MTT 
reduction. Following 2 mM and 5 mM MPTP exposure for 24 hours, there was a 40 % 
and 85 % decrease, respectively (figure 4.3B). 
After 48 hours exposure, cells were more sensitive to MPTP with 10 μM significantly 
decreasing cell viability by 35 %. Metabolic activity (as measured by MTT reduction) 
was reduced to 40 % by 100 μM to 1 mM MPTP whilst concentrations of 2 and 5 mM 
MPTP resulted in viability being reduced to 20 % and 5 %, respectively (figure 4.3B). 
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Figure 4.3: Effects of different concentrations of MPTP on cell viability using two 
different assays in differentiated N2a cells following 24 hour and 48 hour treatments 
Cells were differentiated in serum free medium containing 0.3 mM dbcAMP for 16 hours. 
Different MPTP concentrations (0 to 5 mM) were then added to the medium for 24 hours 
(black) and 48 hours (striated) A. Trypan blue exclusion assay was measured. Control 
percentage of viable cell values were 53.3 ± 4.3 at 24 hours (n = 4) and 50.6 at 48 hours (n = 1) 
and B. MTT reduction assay was also measured. Control mean absorbance values were A570nm = 
0.611 ± 0.095 at 24 hours and A570nm = 0.610 ± 0.081 at 48 hours (n ≥ 7). 
Results are expressed as mean % viability / reduction ± SEM. Statistical analysis was carried 
out using the paired t-test with a two-tail distribution. All * values p<0.05 when compared to 
respective controls. 
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4.2.1.5
 Cellular ATP content  
 
ATP levels were investigated as a complementary measure of metabolic activity (refer 
to section 2.2.2.5) and more particularly a measure of oxidative phosphorylation, as it 
accounts for most of the cellular ATP production.  
MPTP caused a dose- and time-dependent decrease in ATP levels, with 1 mM MPTP 
producing 50 % depletion of ATP compared to control following 24 hours exposure and 
10 μM MPTP producing 50 % depletion following 48 hours exposure (figure 4.4). 
Following 24 hours exposure, ATP levels were reduced with concentrations as low as 
10 μM MPTP – which resulted in 25 % loss of ATP levels.  
 
 Mitochondrial potential  
 
Specific mitochondrial activity was measured by monitoring mitochondrial membrane 
integrity using the JC-1 fluorescent dye (refer to section 2.2.2.4). This dye fluoresces 
red within mitochondria when they are active and green within the cytoplasm when 
mitochondria depolarise and become inactive. Pictures were taken using a confocal laser 
microscope (figure 4.5A). Control cells showed a strong red signal evenly distributed in 
the cell body, in axon-like processes and corresponding to active, healthy and evenly 
distributed mitochondria (figure 4.5A a to c). Quantification of JC-1 signal using Leica 
confocal software and calculation of active / inactive mitochondria showed a ratio of 
around 1 (figure 4.5B). Following 1 mM MPTP treatment for 24 hours, no axonal 
mitochondria could be observed, consistent with previous morphological observations 
of axonal loss. JC-1 aggregates remained present in the cell body but not as evenly as 
the controls compared to the green signal (figure 4.5A d to f). Compared to controls, the 
green signal was more apparent in the overlay image (Figure 4.5A c and f). Individual 
red dots representing mitochondria looked bigger in a minority of the cells indicating 
mitochondrial swelling. Moreover, active / inactive mitochondria ratio decreased by 20 
% but this drop was not significant indicating that some mitochondria became inactive 
but the majority were still active in each cell (figure 4.5B). Following 2 mM MPTP 
treatment, individual dots looked bigger, indicating mitochondrial swelling in most of 
the cells (figure 4.5A g to i). The active / inactive mitochondria ratio was significantly 
decreased by 40 % indicating a depolarisation of mitochondria at this concentration 
compared to controls (figure 4.5B). 
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Figure 4.4: Effects of different concentrations of MPTP on ATP levels in differentiated 
N2a cells following 24 hour and 48 hour treatments 
Cells were differentiated in serum free medium containing 0.3 mM dbcAMP for 16 hours. 
Different MPTP concentrations (0 to 2 mM) were then added to the medium for 24 hours 
(black) and 48 hours (striated) and cellular ATP levels were measured using the vialight 
bioluminescent assay.  
Results are expressed as mean % ATP level ± SEM. Statistical analysis was carried out using 
the paired t-test with a two-tail distribution. All * values p<0.05 when compared to respective 
controls. (n ≥ 6 for 24 hours, n ≥ 3 for 48 hours). 
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Figure 4.5: Effects of different concentrations of MPTP on mitochondrial membrane 
potential in mouse N2a neuroblastoma cells following 24 hours treatment 
Cells were differentiated in serum free medium containing 0.3 mM dbcAMP for 16 hours. 
Different MPTP concentrations (0 to 2 mM) were then added to the medium for 24 hours and 
stained with 10 μM JC-1 fluorescent dye (refer to section 2.2.2.4). A. Cells were visualized by 
confocal laser microscopy (×630 magnification). Scale bars represent 20 μM. White arrows 
represent swollen mitochondria.  
B. Red and green signal intensities were measured using Leica Confocal Software. Results are 
expressed as mean red / green (active / inactive) ratio ± SEM. Statistical analysis was carried 
out using the paired t-test with a two-tail distribution. All * values p<0.05 when compared to 
respective controls. 
a, d and g show diffused dye from inactive mitochondria; b, e and h show active mitochondria 
and c, f and I show overlay images. 
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4.2.2  Effects of MPTP on apoptosis markers 
 
Apoptosis can be detected by assessing a variety of characteristics including typical cell 
morphology, cleavage of apoptotic markers and release of mitochondrial molecules to 
the cytoplasm. STS (staurosporine) has been observed to induce apoptosis in many 
models including mouse N2a neuroblastoma cells (Bronisz et al., 2002). For the 
purpose of the present study, 1 μM STS for 4 hours was used as a positive control of 
apoptosis. 
 
 Apoptotic morphology 
 
Following pre-differentiation, cells treated with 1 μM STS for 4 hours presented a 
mixture of morphological changes. Most of the cells exhibited swollen elongated cell 
bodies with longer axon-like processes  compared to controls. The axon-like processes 
formed a connecting network between the cells. Accompanying these elongated shaped 
cells, some small detached cells with intact membranes were present in the medium 
indicating a minority of the cells had entered into late apoptosis (figure 4.6B). 
Cells treated with 1 mM MPTP for 2 hours also showed elongated swollen cell bodies 
compared to controls (figure 4.6C and D).  
Mouse N2a neuroblastomas treated with 1 mM MPTP for 4 and 8 hours resembled, 
control cells (figure 4.6E and F; 8 hour data not shown). Following 24 hours exposure 
to 1 mM MPTP treatment, the cells had round intact cell bodies but short or virtually no 
axon-like processes (figure 4.6G and H). 
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Treatments and time-points 
D. 1 mM MPTP at 2 hours
F. 1 mM MPTP at 4 hoursE. Control at 4 hours
A. Control at 0 hours B. 1 μM STS at 4 hours 
C. Control at 2 hours
H. 1 mM MPTP at 24 hoursG. Control at 24 hours
 
Figure 4.6: Time-course of morphological changes of N2a neuroblastoma cells due to 1 
mM MPTP treatment as compared to staurosporine, inducer of apoptosis. 
Cells were differentiated with 0.3 mM dbcAMP for 16 hours prior to treatment with either 
MPTP or STS. Pictures were taken over a time course of 24 hours: A. Control at time zero; B. 1 
μM STS for 4 hours; C. Control at 2 hours; D. 1mM MPTP at 2 hours E. Control at 4 hours; F. 
1mM MPTP at 4 hours; G. Control at 24 hours; H. 1mM MPTP at 24 hours. 
Scale bars represent 20 μm. 
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4.2.2.4
 
 Procaspase-2 cleavage  
 
To further investigate whether apoptosis, and more particularly mitochondrial-
dependent-apoptosis, was involved in MPTP-induced toxicity, caspase-2 cleavage was 
measured using a western blotting approach (refer to section 2.2.6 for protocol).  
The anti-caspase-2 antibody recognised two different bands in the samples (figure 
4.7A). The 48 kDa band represents the inactivated procaspase-2 whilst the 32 kDa band 
represents the active cleaved caspase-2. In controls, inactive caspase-2 predominated, 
although a basal level of caspase-2 was cleaved (active form). Following STS-induced 
apoptosis, caspase-2 was mainly cleaved showing a high activation of caspase-2. 
Following treatment with 1 mM MPTP, the procaspase-2 isoform was predominant at 
all the time-points studied, similar to controls (figure 4.7A). This showed that no 
significant activation of caspase-2 was occurring during a time-course using 1 mM 
MPTP treatment. 
 
 Cytochrome c release 
 
Cytochrome c is normally present in the mitochondrial fraction. Upon an apoptotic 
stimulus, e.g. which can be initiated by cleavage of caspase-2 in some models, 
cytochrome c is released into the cytoplasm (Garrido et al., 2006). Figure 4.7B shows 
the levels of cytochrome c in the cytoplasm following different treatments. Compared to 
controls, cytochrome c release was significantly increased following STS-induced 
apoptosis. Following 1 mM MPTP treatments cytochrome c release was not 
significantly increased. 
 
 Cleaved caspase-3 
 
Caspase-3 is an effector caspase, which, upon a stimulus via other caspases, can be 
activated by cleavage and subsequently cleaves other targets (Katjta, 2004). The 
presence of active / cleaved form of caspase-3 was measured using an antibody that 
recognised only the cleaved caspase-3. Cleavage was only observed at a high level 
following treatment with STS. No detectable level of cleaved caspase-3 was seen with 1 
mM MPTP using the western blot technique (figure 4.7C). 
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Figure 4.7: Detection of apoptotic markers in differentiated N2a neuroblastoma cells by 
western blot analysis 
Differentiated mouse N2a neuroblastoma cells were fractionated using differential 
centrifugation (refer to methods section 2.2.4). Anti-pro- and cleaved caspase-2 (A), anti-
cytochrome c (B) or anti-cleaved caspase-3 antibodies (C) were used to detect the presence of 
each respective protein in the cytoplasmic fractions; and detection by HRP-conjugated antibody 
with ECL substrates was carried out as described in section 2.2.6.2. 
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4.2.2.5 Caspase-3/7 activation 
 
Caspase-3/7 activation was also investigated using a fluorimetric assay (see section 
2.2.12). This assay relies on the ability of active caspase-3-like proteases to cleave a 
fluorogenic substrate, DEVD-AMC, whose cleavage releases a fluorophore that can be 
measured using a fluorimeter (Garcia-Calvo et al., 1998).  
Caspase-3/7 activity was significantly increased following STS treatment compared to 
controls (figure 4.8A and B). This was in accordance with caspase-3 cleavage shown 
using western blotting in figure 4.7C.  
Following treatment with different concentrations of MPTP for 24 hours, only 10 μM 
MPTP showed a significant increase in caspase-3/7 activity, whilst higher MPTP 
concentrations had no activating effect (figure 4.8A). The use of 1 mM MPTP treatment 
over a 48 hour time-course, resulted in a transient increase of caspase-3/7 activity at 2 
hours, not detected by cleaved capsase-3 western blot analysis (figure 4.7C).  
To further validate these increases in caspase-3/7 activity shown using the fluorimetric 
assay, a caspase inhibitor specific to caspase-3 and caspase-7 was used, DEVD-CHO. 
Figure 4.9 shows the in vivo effects of the caspase-inhibitor alone on cell viability using 
an MTT reduction assay. Only a high concentration of the inhibitor, 200 μM 
significantly decreased cell viability. Concentrations lower than 200 μM caused no 
significant cell death in N2a neuroblastoma. Figure 4.10A shows the effects of different 
concentrations of caspase-3/7 inhibitor (0 to 50 μM) on control and STS-induced 
apoptotic samples. Indeed, even 5 μM DEVD-CHO added one hour prior to STS 
treatment was sufficient to decrease the caspase-3/7 increase induced by STS. 
Following these results, 5 μM DEVD-CHO were used for further analysis. Treatment 
with 1 mM MPTP for 2 hours, 10 μM MPTP for 24 hours and 1 μM STS for 4 hours led 
to increased levels of caspase-3/7 activity (figure 4.10B) similarly to previously seen 
(figure 8A and B). When 5 μM specific caspase 3/7 inhibitor was added 1 hour prior to 
treatments, these increases in caspase-3/7 activity were completely inhibited in all three 
different treatments, further validating caspase-3/7 activity increases observed 
previously (Figure 4.10B).  
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Figure 4.8: Effects of different concentrations and time-points of MPTP on caspase-3/7 
0.3 mM dbcAMP for 16 hours. A. 
Different MPTP concentrations (0 to 2 mM) were then added to the medium for 24 hours 
(black). B. 1 mM MPTP was then added to th medium and cells extracted at different time-
points. 1 mM STS for 4 hours was used as a positive control (stripes) (A and B). Caspase-3/7 
activity was measured.  
Results are expressed as mean % caspase activity ± SEM. Statistical analysis was carried out 
using the paired t-test with a two-tail distribution. All * values p<0.05 when compared to 
respective controls (n ≥ 3). 
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igure 4.9: Effects of different concentrations of caspase-3/7 inhibitor on cell viability in 
differentiated N2a cells following 25 hours exposure 
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A. Effects of Ac-DEVD-CHO on caspase-3-like activity in mouse N2a cells 
B. Effects of Ac-DEVD-CHO on MPTP-induced caspase-3-like activity 
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Figure 4.10: Inhibition of caspase-3/7 activity due to MPTP neurotoxicity 
A. Mitotic cells were treated with different caspase-3/7 inhibitor (DEVD-CHO) concentrations 
(0 to 50 μM) in duplicate one hour prior treating with or without 1 μM STS for 4 hours (n = 2). 
B. Cells were differentiated in serum free medium containing 0.3 mM dbcAMP for 16 hours. 5 
μM caspase-3/7 inhibitor (DEVD-CHO) were added to the medium for 1 hour. MPTP (10 μM 
for 24 hours and 1 mM for 2 hours) or STS (1 μM for 4 hours) treatments were then added to 
the medium. Cells were then extracted and caspase-3/7 activity was measured (A and B).  
Results are expressed as mean % caspase activity ± SEM. Statistical analysis was carried out 
using the paired t-test with a two-tail distribution. All * values p<0.05 when compared to 
respective controls. All ● values p<0.05 when compared to respective treatment with no 
inhibitor (n ≥ 3). 
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4.3.1.1
4.3 DISCUSSION 
 
4.3.1 MPTP effects on cell viability and mitochondrial activity of N2a 
neuroblastoma 
 
A variety of assays were used in order to establish the effects of different concentrations 
of MPTP on energy production, mitochondrial activity and cell viability. The results of 
these assays are summarised in table 4.1. 
 
 Establishment of MPTP sub-cytotoxic concentrations  
 
The trypan blue exclusion and MTT reduction assays measured two different cell 
characteristics to monitor cell viability. The former was based on cell integrity and the 
latter on cellular metabolic activity. Both assays showed similar results, suggesting that 
cell viability was not compromised by treatment for 24 hours with concentrations up to 
1 mM MPTP and was significantly decreased following 2 mM MPTP treatment or 
higher (table 4.1). Cell viability was significantly decreased following 10 μM MPTP 
exposure for 48 hours (table 4.1). Since cell death was observed with low 
concentrations of MPTP at this later time-point, the 48 hour time-point was not 
considered suitable for investigating sub-cytotoxic effects in this particular study.  
Although cell viability was not affected by up to 1mM MPTP at 24 hours, cell 
morphological changes were evident with 10 μM MPTP, and were increasing with 100 
μM and 1 mM MPTP treatments. Similar studies were carried out by De Girolamo et al. 
(2000), although they used co-differentiating cells while the present study used 
differentiated cells. Using a trypan blue assay, they observed that cell viability was not 
affected by MPTP concentrations up to 10 μM following 24 hour treatments. Moreover, 
axons, defined as cell processes greater than two cell bodies in length, were 
significantly reduced at these sub-cytotoxic concentrations. In a subsequent study, De 
Girolamo et al. (2001) also measured cell viability using an MTT assay and found, 
contrary to the present study, a decrease in cell viability with concentrations from 50 
μM to 400 μM MPTP following a 24-hour exposure. Although this was significant, the 
decrease was only small (10-15 % cell death).  
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assay 24 hour time-point 48 hour time-point 
Morphology 
Reduction in axonal processes 
from 10 μM MPTP and cell 
death from 2 mM MPTP 
treatment 
Change in cell body shape, 
reduction in axonal processes 
and cell death observed from 
10 μM MPTP treatment 
MTT 
reduction and 
trypan blue 
exclusion 
assays 
Cell viability reduced following 
treatment with concentrations 
greater than 1 mM MPTP 
Cell viability reduced with 
concentrations as low as 10 μM 
MPTP. 
ATP 
ATP levels reduced by 25 % 
with MPTP concentrations as 
low as 10 μM, depletion of 
ATP increased as MPTP 
concentration increased 
ATP levels reduce by 50 % 
with MPTP concentrations as 
low as 10 μM. ATP levels 
depleted by 80 % following 2 
mM treatment 
JC-1 stain 
Swollen mitochondria unevenly 
present in cell bodies starting 
with 1 mM MPTP and  more 
obvious with 2 mM MPTP 
compared to controls. 
Mitochondrial membrane 
potential decreased with these 
concentrations. 
 
Table 4.1: Summary of the toxicity assays used to assess MPTP effects on 
differentiated N2a neuroblastoma cells 
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4.3.1.2
These disparities showed that the differentiated N2a neuroblastoma model used in the 
present study was slightly more resistant to MPTP than in the co-differentiating model 
used by De Girolamo et al. (2001). Indeed, de Araujo and Huber (2007) observed a 
rearrangement of cytoskeletal proteins in neuronal cells during the differentiation 
process. These observations may suggest a greater ATP demand during the early 
differentiation as opposed to the late differentiation process. 
 
 Effects of MPTP on mitochondrial activity 
 
ATP levels were also affected by sub-cytotoxic concentrations of MPTP, being reduced 
by 25 % and 50 % with 10 μM and 1 mM MPTP, respectively, at 24 hours. Depletion of 
ATP by more than 50 % was needed to decrease cell viability, observed with 2 and 5 
mM MPTP for 24 hours. This suggested that a reduction in ATP levels alone was not 
sufficient to lead to cell death unless it was reduced by more than 50 %. Consistent with 
this observation, following 48 hours MPTP treatment, 10 μM MPTP was sufficient to 
reduce ATP levels to below 50 % and lead to cell death.  
It has been well established that MPTP, via its metabolite MPP+, inhibits complex I of 
the ETC (Ramsay et al., 1987; refer section 1.4 for a more detailed description). Singer 
and colleagues (1988) have shown that treatment with MPP+ leads to ATP depletion in 
nigrostriatal neurons. Wu and colleagues (1990) found consistent results in hepatocytes 
showing that ATP levels were depleted only with MPP+ and not MPTP when MAO 
inhibitors were used, signifying a main role for MPP+ and its ability to inhibit complex I 
in ATP depletion. Moreover, it was shown that ATP depletion was happening prior to 
cell death and in a MPTP dose-dependent manner in hepatocytes (DiMonte et al., 1986) 
and in rat brain synaptosomes (Scotcher et al., 1990), consistent with the data retrieved 
in the present study. 
 
Mitochondrial permeability transition leading to mitochondrial depolarisation has been 
observed to be regulated by membrane voltage. Calcium overload, increase in ROS, 
decrease of adenine nucleotides and increase in inorganic phosphates have all been 
shown to induce mitochondrial transition (Cassarino and Bennett, 1999). A direct 
consequence of mitochondrial transition is the opening of a transition pore which 
challenges the integrity of the mitochondrial double membrane. 
The mitochondrial membrane potential was measured using the JC-1 dye and showed 
that mitochondria were depolarised with 2 mM MPTP. Whether depolarisation occurred 
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in mitochondria with lower concentrations, for example following 1 mM MPTP 
treatment for 24 hours was not obvious as the active / inactive mitochondria ratio 
decreased by only 20 % and was not significant compared to controls. A minority of the 
cells showed swollen mitochondria following 1 mM MPTP treatment while a majority 
exhibited this phenomenon when exposed to 2 mM MPTP. Mitochondrial swelling has 
previously been observed in MPP+ treated cortical neurons (Han et al., 2003b) and can 
be a typical characteristic of mitochondrial calcium overload, also previously observed 
in PD study models (Chiueh et al., 1993).  
Cytochrome c release and release of other pro-death molecules to the cytoplasm has 
been observed to be one of the consequences of mitochondrial transition and 
depolarisation (Norenberg and Rao, 2007). In the present study, cytochrome c release 
was not obvious compared to controls using sub-cytotoxic concentrations, supporting 
the observation that mitochondria were not significantly depolarised using 1 mM MPTP 
treatment. 
Cassarino and colleagues (1999) were the first to show that MPP+-induced toxicity 
could occur via the opening of the transition pore using isolated mitochondria consistent 
with other studies relating a role of ETC inhibitors to mitochondrial transition pore 
opening (refer to section 1.3.4). More recently, Lee and colleagues (2006) have partially 
inhibited MPP+-induced mitochondrial transition pore opening using cyclosporin A (a 
known inhibitor of the transition pore) in PC12 cells. In the present study, mitochondrial 
pore opening was observed in MPTP-induced toxicity in mouse N2a cells following a 
24 hour exposure to a high concentration (2 mM) parallel to apparent cell death. 
 
Following these data, it was accepted that treatment with 1 mM MPTP for 24 hours led 
to morphological changes, ATP depletion, minor non-significant mitochondrial changes 
but no decrease in cell viability. Consequently, further study of the mitochondrial 
proteome will be investigated mainly using 1 mM MPTP for 24 hours. 
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4.3.2 Markers of MPTP-induced cell death in mouse N2a neuroblastoma  
 
Molecular pathways involved in neuronal cell death that occur in PD have been widely 
studied. Markers of necrosis and apoptosis, the main death pathways, have both been 
observed in PD mimetic models. Before the early 1990s, only necrotic markers, mainly 
morphologic, had been observed in models. Since then, different apoptotic markers 
have been observed in MPTP or MPP+ treated in vivo and in vitro models (reviewed in 
Du et al., 1997) including in human PD brains (Hartmann et al., 2000). The question of 
whether neurodegeneration occurs via necrosis or apoptosis is still open although 
several studies tend to show that both can happen, depending on the model of study 
used. For example, He and colleagues (2008) have been using two different models of 
study in which they induced non apoptotic cell death by acute MPTP treatment in mice 
and induced apoptosis by sub-acute treatment of mice with MPTP. Chee and colleagues 
(2005) have observed both apoptotic and necrotic characteristics following treatment of 
mouse dopaminergic cells using MPP+.  
In the present project, the MTT reduction assay showed that the overall cellular 
metabolic activity was maintained until exposure to 2 mM MPTP for 24 hours in mouse 
N2a neuroblastoma cells. The trypan blue exclusion assay, representing cell membrane 
integrity, as a measure of necrosis, showed similar results to the MTT assay. Two 
hypotheses could be drawn from these data: (a) there was no cell death with MPTP 
treatments with concentrations equal or lower than 1 mM for 24 hours and only necrosis 
occurred in the present model, (b) a minority of cells died of non-necrotic cell death, 
which was not detected by the MTT reduction assay due to compensatory metabolic 
activation of surviving neuronal cells. Since early apoptosis has been observed using 
sub-acute concentrations of MPTP (Du et al., 1997), it was interesting to check whether 
apoptotic markers were present using the sub-cytotoxic concentrations previously 
established. 
Western blot analysis showed that there was no significant increase of cleavage of 
caspase-2 and caspase-3 using different time-points of 1 mM MPTP treatment. 
Cytochrome c release was not increased using the same treatment. These results showed 
that there was no evidence of activation of the mitochondrial-dependent apoptotic 
pathway using sub-cytotoxic concentration of MPTP. These results were consistent with 
the JC-1 mitochondrial depolarisation assay which showed no significant depolarisation 
of mitochondria with concentrations of MPTP lower than 1 mM following 24 hour 
treatment, indicating that no opening of the transition pore occurred. This is in 
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agreement with a previous study that monitored J-aggregate formation in N2a cells 
following 10 μM MPP+ treatment and observed no significant effects (De Girolamo et 
al., 2001). 
Interestingly, using a specific fluorigenic substrate Ac-DEVD-AMC, caspase-3-like 
activity was transiently evident with either a low concentration MPTP (10 μM) for 24 
hours (chronic exposure) or short acute exposures (2 hours) with 1 mM MPTP. This 
activity could be inhibited using an inhibitor of caspase-3 activity, Ac-DEVD-CHO 
demonstrating specificity of the assay for a caspase-3-like activity. Both substrates, Ac-
DEVD-AMC, and inhibitor, Ac-DEVD-CHO, have shown specificity for both caspase-
3 and caspase-7. Whether other caspases can interact with this substrate and inhibitor 
has not been described in the literature. Since caspase-3 was not cleaved and detected 
using the western blot approach, it could be postulated that caspases other than caspase-
3 were transiently activated following low concentration MPTP treatment. Apoptotic 
markers in MPTP treated cell lines have already been documented (Chee et al., 2005; 
Liu et al., 2008). However no study showed the activation of caspase-3 protease or 
other apoptotic markers prior to cell death using sub-cytotoxic concentrations. Using 
cytotoxic concentrations, caspase-3-like activation has been found in PC12 following 
MPTP treatment (Shimoke et al., 2003). In this particular study, the authors did not 
check which caspase was activated. Sanz et al. (2008) showed that MPP+ could induce 
caspase-2 activity via a p53-induced pathway in SH-SY5Y cells using cytotoxic 
concentrations. Another study confirmed the involvement of apoptosis in MPTP-
induced cell death in rat PC12 cells via increased Bax/Bcl2 ratio mRNA expression (Liu 
et al., 2008). Contradictory studies have been obtained showing that caspase-3 might 
not be involved in MPTP-induced apoptosis using different models. Indeed, using a 
mouse MN9D dopaminergic cell line, Chee and colleagues (2005) showed that caspase-
3 and -9 were not activated in MPP+-induced toxicity but caspase-2, -8, -6 and caspase-
7 were cleaved in the same model. They also showed the involvement of mitochondria 
using cytotoxic concentrations since cytochrome c release occurred. In the present 
study, cytochrome c release following cytotoxic conditions (over 1 mM MPTP for 24 
hours) has not been investigated; cytochrome c release could be expected in mouse N2a 
cells, since opening of the pores occurred at higher MPTP concentrations but this needs 
to be measured. 
Activation of caspase-7 without caspase-3 cleavage has previously been observed in 
other pathological studies. For example, Lovastatin, an inducer of apoptosis, induced 
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caspase-7 activation but not caspase-3 in a cell line derived from prostate cancer 
(Marcelli et al., 1998).  
The transient activity of a caspase-3-like protease without caspase-2 cleavage or 
cytochrome c release to the cytoplasm coincides with the hypothesis that sub-cytotoxic 
concentrations of MPTP might trigger an extrinsic apoptotic pathway. As inferred by 
the MTT reduction and trypan blue exclusion assays, whether this activation of caspase-
3-like protease was sufficient or not to lead to cell death prior to mitochondrial 
depolarisation has not been shown in the present study. 
Other interesting observations have been made using the differentiated N2a cell model. 
Indeed, a basal level of cytochrome c release was observed in control cells. It has 
previously been observed that cytochrome c was released into the cytoplasm during cell 
differentiation of some types of cells (Garrido et al., 2006). This is likely to be a 
consequence of serum withdrawal (a known activator of apoptosis; Martin et al., 1988) 
which is required in the differentiation of cell. However, this is minimalised in this 
model by the addition of dbcAMP (Prashad and Rosenberg, 1978). 
Additionally, following transient activation of caspase-3-like activity, levels of caspase 
activity were lower than controls. An explanation could be: the endogenous level of 
pro-caspase was limited and its activation led to depletion of the pro-form leading to a 
decrease in activity as the substrate levels were down.  
 
Along with the establishment of a model to study mitochondrial proteome using sub-
cytotoxic concentrations of MPTP, the data produced in the present chapter, 
accompanied with already established molecular events from previous studies, has 
given some new insights in MPTP-induced toxicity in mouse N2a neuroblastoma cells 
(Figure 4.11). 
Interestingly, ATP depletion occurred prior to mitochondrial membrane depolarisation 
consistent with the study from Wu and colleagues (1990) in hepatocytes, showing that 
ATP depletion occurred prior to mitochondrial depolarisation and was a cause and not a 
consequence. The mitochondrial transition has been observed to occur with low adenine 
nucleotide concentrations (Cassarino and Bennet 1999). This ATP depletion occurred as 
morphological changes were observed as well as concomitant activation of a caspase-3 
and/or caspase-7. It is worth mentioning that MPTP-induced toxicity has been shown to 
occur accompanied by ROS production and increased calcium levels (Chiueh et al., 
1993), although it was not investigated in the present model. However, the 
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mitochondrial swelling observed does suggest that calcium overload might be 
happening in these cells.  
In addition to ATP depletion, usually accompanied by increased oxidative stress and 
calcium concentrations, this chapter showed that an early marker of apoptosis was 
activated following low concentrations of MPTP but did not directly lead to 
mitochondrial depolarisation or significant cell death. However, higher concentrations 
of MPTP led to significant cell death with necrotic features linked to mitochondrial 
potential loss. This two-step death pathway is in accordance with previous studies on 
MPTP-treated mice by He and co-workers (2008) and studies using rotenone, another 
complex I inhibitor, in dopaminergic cell cultures (Hartley et al., 1994). 
The apoptotic pathway has been observed to be an ATP-dependent process. An 
exacerbated depletion of ATP could be inhibiting the apoptotic process explaining why 
caspases were seen to be activated early in the MPTP treatment-course but not at later 
time-points when ATP levels were depleted by more than 30 % compared to controls. 
Eguchi et al. (1997) showed, using Jurkat and Hela cells, that the cellular ATP 
concentrations were important for cells to either undergo apoptosis or necrosis. Indeed, 
they proposed that apoptosis occurred only when enough ATP was present in the cells; 
following large depletion of ATP, cell underwent necrosis. However, a more recent 
study proposed that ATP depletion-induced by ETC inhibition did not lead to apoptosis 
in dopaminergic neurons but the ROS produced via ETC inhibition was the trigger of 
the cell death pathway (Watabe and Nakaki, 2007) being in disagreement with the 
former cited study. 
To verify the two-step cell death hypothesis (ROS-dependent or not), it would be 
interesting to further characterise both steps. For example, western blot analysis using 
an anti-caspase-7 antibody and other caspases could be interesting to uncover which 
caspase is really activated using low concentrations of MPTP. Moreover, the protein 
and mRNA levels of Bcl2-familly proteins could be monitored to assess whether 
apoptosis is happening or whether the transient caspase activation is part of another 
pathway. 
Finally, cytochrome c release and other markers of cell death should be monitored at 
higher concentration than 1 mM MPTP for 24 hours to uncover which type of necrotic 
cell death pathway occurs following treatment with cytotoxic concentrations of MPTP. 
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Figure 4.11: Flow chart representing the molecular events induced by different 
concentrations of MPTP for 24 hours  observed in the present study 
Grey writing: molecular events shown in previous studies 
1 Langston et al., 1983; 2 Ramsay et al., 1987 
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5.1 INTRODUCTION 
 
5.1.1 Proteomic approaches to a study of the mitochondrial proteome 
 
The development of proteomic approaches has precipitated marker discovery research 
in the last few decades by allowing the study of complex mixtures at once (Anderson 
and Anderson, 1982). Proteomic approaches of relevance to PD have only emerged in 
the last half decade. Most of the studies have concentrated on total cell extracts from 
different models of neurodegeneration, including the use of toxins mimicking PD in cell 
lines (e.g. Jin et al., 2006; Lee et al., 2003) and in animals (De Iuliis et al., 2005; Zhao 
et al., 2007), the use of genetically modified animal models (Palacino et al., 2004) and 
the use of post-mortem neurons from human patients (Basso et al., 2004; Werner et al., 
2008). However, despite the evidence of mitochondrial dysfunction in PD (Gandhi and 
Wood, 2005), only a few studies have focused on the mitochondrial proteome. 
As previously described elsewhere (section 3.1.3), it has been proposed that a reduction  
in complexity, such as fractionation of samples, was essential to increase efficiency of 
proteomic studies and observation of low-abundant proteins (Lopez and Melov, 2002) 
and that mitochondria were ideal organelles as the number of proteins they contain is 
estimated around 1,000, which is the limit of detection of gel-based and 
chromatography-based proteomic approaches (Taylor et al., 2003b).  
 
5.1.2  Molecular markers linking mitochondrial dysfunction and Parkinson’s 
disease 
 
The links between mitochondrial dysfunction and Parkinson’s disease are numerous (as 
described in section 1.1.2). For example, abnormal mitochondrial morphology has been 
observed in MPTP treated SH-SY5Y cells (Song et al., 1997) showing distorted cristae 
structure and a swollen appearance. In the present study, mouse N2a neuroblastoma 
cells also showed swollen mitochondria (refer to chapter IV section 4.2.1.5). Moreover, 
using a proteomic approach, Jin et al. (2005) studied the mitochondrial proteome 
following MPTP exposure to mice. Using a shotgun strategy followed by LC-MS/MS, 
they identified more than 300 mitochondrial proteins of which around 100 showed 
differences in abundance between MPTP treated samples compared to controls. This 
study showed that many proteins involved in most functions of mitochondria were 
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altered in MPTP-induced toxicity, consistent with the mitochondrial dysfunction 
hypothesis. 
 
Additionally, the use of different models of study allowed the observation of other 
markers of mitochondrial protein dysfunction. For example, the levels of proteins and 
enzyme activities associated with oxidative phosphorylation have been linked to 
neurodegeneration. Complex I inhibition can lead to PD-like symptoms (Langston et 
al., 1983). This led to the observation that ATP production was reduced linked with 
dysregulation of ATP synthase protein levels (Ferrer et al., 2007). 
PD has been linked to high mitochondrial oxidative stress and low antioxidant defences 
(Fukae et al., 2007). The pathways involved in oxidative stress generation by 
mitochondria have previously been described in section 1.2.5. 
Chaperone proteins have also been involved in mitochondrial dysfunction in PD. A 
particular example is the genetic link between chaperone DJ-1 and neurodegeneration. 
Loss of DJ-1 function reproduced PD features in human and animal models (Abou-
Sleiman et al., 2006). This was linked with increased oxidative stress and re-localisation 
of the protein to the mitochondria (Zhang et al., 2005). Prohibitin, also thought to have 
a chaperone activity, has been observed to decrease in substantia nigra of PD patients 
(Ferrer et al., 2007). Heat shock proteins have been considered to have a protective role 
in PD (Freyaldehoven and Ali, 1996). 
Another hallmark of PD was the modulation of phosphorylating kinases. In particular, 
two mitochondrial kinases have been linked with genetic cases of the 
neurodegeneration. PINK1, a threonine kinase found in the mitochondrial membrane, 
and leucine-rich-repeat kinase (LRRK)-2 have been found to partially interact with the 
OMM (Henchcliffe and Beal, 2008). Dysregulation of both kinases has been an 
important clue that phosphorylation pathways, including mitochondrial signalling 
pathways could be involved in PD.  
 
5.1.3 Signaling pathways in Parkinson’s disease 
 
Modulations in kinase activity indicate that the cellular phosphoproteome can be 
altered. There have been several reports that phosphorylation pathways are involved in 
PD. A recent study showed that GSK3-β was found in Lewy bodies in post-mortem 
samples of PD patients (Nagao and Hayashi, 2009). Focusing on the effects of MPTP 
on phosphorylation kinases, mitogen-activated protein kinases (MAPKs), have been 
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strongly linked to neurodegeneration. For examples, MPTP or its metabolite MPP+ 
activated JNK in B65 cells (Saporito et al., 2000) and mouse N2a neuroblastomas (De 
Girolamo and Billett, 2006) and p38 in mice (Karunakaran et al., 2008). Moreover, 
inhibition of GSK3-β was observed to be protective against MPTP in dopaminergic 
neurons (Wang et al., 2007).  
 
5.1.4 Study of the mitochondrial phosphoproteome 
 
Although protein phosphorylation in mitochondria was observed a long time ago 
(Burnett and Kennedy, 1954), the significance of phospho-signaling in the organelle has 
been more widely studied in the past decade (reviewed in Horbinski and Chu, 2005). 
Over 60 mitochondrial proteins have been identified to be phosphorylated and 25 
kinases and 8 phosphatases have been located in mitochondria (listed in Pagliarini and 
Dixon, 2008). Signalling kinases and phosphatases found in mitochondria include 
tyrosine kinases, serine / threonine kinases and protein tyrosine phosphatases. A few 
signaling molecules are specific to mitochondria, for example, the pyruvate 
dehydrogenase complex, PINK1, a dual-specific protein tyrosine phosphatase (called 
PTMT1) and the translocase of the inner mitochondrial membrane 50 (TIM50) 
(reviewed in Pagliarini and Dixon, 2008). Nevertheless, most of the signaling kinases 
and phosphatases have been found ubiquitously in the cell with specific function 
depending on subcellular localisation (Horbinski and Chu, 2005). These include PKA, 
found in the IMM and thought to promote complex I activity and cell survival; Akt, 
generally linked to cell survival and found in mitochondrial membranes mostly and also 
in the matrix, has a role in the phosphorylation of ATP synthase-β subunit; GSK3-β, 
also found in mitochondria with a pro-apoptotic role; protein kinase C (pKC) found in 
the IMM and cristae and thought to have a pro-apoptotic role and to inhibit 
mitochondrial function; and a variety of MAPKs including the MAPK kinase 1 
(MEK1), the extracellular-signal regulated protein kinase (ERK) 1/2, p38 and JNK 
(reviewed in Horbinski and Chu, 2005). Although most of the phosphorylated proteins 
observed in the mitochondria are phosphorylated via serine / threonine residues, 
tyrosine phosphorylation has also been observed in mitochondria and has been 
increased with oxidative stress stimuli (reviewed in Salvi et al., 2005). 
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5.1.5 Approaches to the study of the phosphoproteome 
 
Although over 50 % of proteins can undergo phosphorylation, accounting for up to 
100,000 phosphorylation sites in mammalian cells, phosphoproteins normally account 
for 1-2 % of total proteins (Reviewed in Reinders and Sickmann, 2005). So, despite a 
growing research interest in phosphorylation, there is a need for highly sensitive and 
high-throughput methods. Different methods for the study of the phosphoproteome have 
been developed (reviewed in Delom and Chevet, 2006). Gel-based methods remain the 
simplest approaches, often combined with different detection methods such as western 
blotting. The most sensitive approach is the use of 32P or 33P radioactive labelling. 
However, it tends to be replaced with safer and more convenient methods (Reinders and 
Sickmann, 2005). Dyes specific to phosphoproteins have recently been developed. An 
example is the fluorescent ProQ Diamond dye (Molecular Probes) which has a 
sensitivity in the order of nanogram and it has a broad linear spectrum allowing 
quantitative proteomics. This dye can be used to compare two samples, as experimented 
by Hoper et al. (2006), studying the effects of calcium on mitochondrial matrix 
phosphoproteome. Other advantages are the fact that it is compatible with other stains 
(e.g. total protein stains) and also with mass spectrometry (Reinders and Sickmann, 
2005). Western blotting approaches are also possible using antibodies specific to 
phospho-amino acids such as anti-phospho-tyrosine, -threonine and -serine antibodies. 
However, such approaches depend on the sensitivity of the antibody used and 
availability of the phosphorylated sites on the protein (Reinders and Sickmann, 2005). 
Other methods exist, including the enrichment of phosphoproteins or peptides using 
fractionation techniques. Although these methods are more difficult to optimise than 
gel-based methods, they can be more sensitive and quantitative (Baumann and Meri, 
2004). A disadvantage of these approaches is the need for more starting material, which 
is restricted when using cell culture models. 
 
5.1.6 Aims of the chapter 
 
In order to contribute to uncovering molecular events involved in PD-induced 
mitochondrial dysfunction, methods for study of the mitochondrial proteome, including 
the optimisation of 2DE (refer to chapter III) and establishment of sub-cytotoxic 
concentrations of MPTP on mouse N2a neuroblastoma cells (refer to chapter IV) have 
been developed.  
 - 144 - 
CHAPTER V            EFFECTS OF MPTP ON THE MITOCHONDRIAL PROTEOME 
 
The main aim of the present study was to investigate the effects of MPTP on the 
mitochondrial proteome of mouse N2a cells, using 2DE. Attempts were made to 
identify proteins whose levels were altered using peptide mass fingerprinting, and 
validation included the use of western blotting. 
In addition to the changes in protein levels, post-translational modifications have been 
implicated in PD, supported by the observation of increased oxidative stress inducing 
increase in protein, lipid and nucleotide oxidation but also contributing to modulations 
in kinases and phosphatases (Jenner et al., 1992; Nagao and Hayashi, 2009). As 
previously reviewed, many kinase activities have been targeted by MPTP toxicity, some 
of which have been localised in mitochondria (section 5.1.3-4). A further aim was to 
study the effects of MPTP on the mitochondrial phosphoproteome using different 
approaches including antibody-based methods and gel-electrophoresis followed by 
specific staining of phosphoproteins. Modulations in the phosphoproteome would 
complement the discovery of potential markers of mitochondrial dysfunction and 
molecular pathways involved in the process.  
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5.2.1.1
5.2 RESULTS 
 
5.2.1 MPTP effects on the mitochondrial proteome from differentiated mouse 
N2a neuroblastoma cells 
 
The effects of sub-cytotoxic concentrations of MPTP on the mitochondrial proteome 
were studied using 2DE. Isolated mitochondria were further analysed by separating 
mitochondrial proteins via their charge and their molecular mass, consecutively. 
Triplicates of paired samples, one control paired to one treatment (cells treated with 1 
mM MPTP for 24 hours), were run in parallel and images were taken (as described in 
section 2.2.8.5) and analysed using the Samespots software (Progenesis). Each gel 
image was aligned to one control chosen gel (called reference). The statistical package 
allowed choosing the best alignment features. Each treatment gel was paired with its 
corresponding control gel. Spots showing a change in level between control and 
treatment with a p < 0.1 using a paired student t-test were selected. Such spots are 
circled in figures 5.1 and 5.2.  
 
 pI 3-10 analysis 
 
Using pI 3-10 strips for the first dimension of 2DE, a total of 19 spots were observed to 
vary in levels following treatment with sub-cytotoxic concentrations of MPTP, of which 
10 had a p < 0.05. These 19 spots are highlighted in figure 5.1 and are labelled with a 
letter for non-identified proteins and with a number for identified proteins according to 
previous designation used in section 3.2.8 (figure 3.12). Quantitative analysis is shown 
in table 5.1. The fold changes were quite low varying between 17 % and 115 % (table 
5.1). Most of these proteins showed an increase in level following treatment and five 
showed a decrease. 
Out of the 19 proteins, 6 were identified by peptide mass fingerprinting (refer to section 
3.2.8 and figures 3.12-13 and table 3.8). The six identified proteins all showed an 
increase in level (table 5.1). These were ATP synthase F1 complex α-subunit isoform 1 
(spots 9), electron transfer flavoprotein subunit alpha (spot 18), fumarate hydratase 
(spots 10), malate dehydrogenase (spot 15), glutamate oxaloacetate transaminase 2, 
(GOT2) (spot 13) and voltage-dependent-anion channel 1 (VDAC1) (spot 19).  
Interestingly, most of the proteins changing in levels using pI 3-10 strips were relatively 
high abundance proteins with basic isoelectric points (pI) (around pI 8.5 to 9.5). It can 
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5.2.1.2
be hypothesised that changes in levels of low-abundance proteins were not detected 
using these broad range pI strips.  
Spots B and E were both in the smear of high abundance proteins indicating that they 
could be isoforms or post-translationally modified proteins of these high abundance 
proteins. Spot B was in the proximity of a spot previously identified as 60 kDa heat 
shock protein (spot 6 from figure 3.12) but slightly more basic. Similarly, spot E was at 
proximity of a spot previously identified as β-actin (spot 11 from figure 3.12). 
 
 pI 5-8 analysis 
 
In order to observe changes in low-abundance proteins, the use of narrower pI strips 
was the next step. Moreover, the use of such strips could be useful for observing 
different isoforms of the same protein (e.g. the observation of isoforms around spots B 
and E, both between pI 5.7 to 6). 
Using a similar approach to section 5.2.1.1, mitochondrial proteins were separated using 
2DE using pI 5-8 strips and treatments were compared to controls using the Samespots 
software.  
Up to 13 spots showed changes in levels (figure 5.2), all but one increasing. The 
percentage changes were similar to those observed with the broad range pI 3-10 strips, 
varying from 27 to 74 % change (table 5.2). 
Three of the proteins, whose levels were increased were identified as 60 kDa heat shock 
protein (Hsp60), Stress-induced phosphoprotein 1 (STIP1) and ATP synthase F0 
complex subunit-δ (refer to figure 3.12). Moreover, spot N, an acidic spot in the 
proximity of the spot previously identified as heat shock cognate 71 kDa protein 
(Hsc70, spot 1 in figure 3.12-13 and table 3.8) was observed to increase in levels 
indicating a possible involvement of Hsc70 in MPTP toxicity.  
None of the spots observed to change in levels using the pI 3-10 strips were observed 
using pI 5-8 strips. In the pI 5-8 region, more spots were observed to change; some were 
of lower abundance than observed using pI 3-10 strips. 
The basic form of Hsp60 shown to significantly increase in section 5.2.1.1 did not show 
significant changes in levels despite being well focused compared to gels resolved using 
pI 3-10 strips. The spot previously identified as β-actin was not focussing well using pI 
5-8 strips, making the quantitative analysis difficult for this protein. 
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Figure 5.1: Mini 2D-electrophoretogram (pI 3-10) stained with SyproRuby showing spots 
changing in levels in MPTP treated differentiated N2a cells 
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM 
MPTP or not (controls) for 24 hours. Subcellular fractionation was then carried out. 50 μg 
proteins from mitochondrial fractions for each treatment were fractionated by 2DE (pI 3-10 
strips and 12 % resolving gel) and visualized using SyproRuby. Pictures of gels were compared 
using Samespots Progenesis software. Circled spots represent spots that significantly (p < 0.1) 
changed in density level between 1 mM MPTP and control samples following a student paired t-
test (n = 3). Numerical data are represented in table 5.1. 
Letters represent spots showing significant changes between treatments and controls but that 
have not been identified. 
Digits represent spots showing significant changes between treatments and controls that have 
been identified using MALDI-TOF mass spectrometry (refer to figure 3.12 for example and 
table 3.8). 
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Spot 
symbol 
1 
Protein 
identification 2 
Average 
normalised 
volumes in 
control samples 3
Average 
normalised 
volumes in 
treated samples 3 
+/- % change 
compared to 
controls 4 
A  583.81 ± 66.68 438.42 ± 24.30 - 33 % † 
B In the smear of Hsp60 576.48 ± 87.29 413.31 ± 50.62 - 40 % 
† 
C  1428.41 ± 148.13 1709.37± 136.06 + 20 % † 
9 
ATP synthase, F1 
complex α-
subunit isoform 1 
5381.89 ± 756.76 4595.48 ± 696.56 - 17 % † 
D  212.38 ± 12.98 250.05 ± 11.20 + 18 % * 
E In the smear of putative β-actin 473.30 ± 19.98 713.80 ± 42.51 + 51 % 
* 
10 Fumarate hydratase 1123.07 ± 70.35 1437.70 ± 128.52 + 28 % 
† 
F  205.69 ± 39.53 407.11 ± 51.45 + 98 % * 
13 
Glutamate 
oxaloacetate 
transaminase 2 
5559.19 ± 915.92 6899.94 ± 628.47 + 24 % * 
G  442.34 ± 42.46 277.48 ± 33.27 - 59 % * 
H  1077.13 ± 248.56 1589.04 ± 178.86 + 48 % * 
15 Malate dehydrogenase 2416.24 ± 210.98 3757.51 ± 70.02 + 56 % 
* 
18 
Electron transfer 
flavoprotein 
subunit α 
802.37 ± 27.45 1193.65 ± 37.60 + 49 % * 
I  509.11 ± 43.11 756.48 ± 72.92 + 49 % † 
19 
Voltage-
dependent-anion 
channel 1 
3954.00 ± 453.73 5122.56 ± 766.40 + 30 % † 
J  520.65 ± 40.80 336.60 ± 41.10 - 55 % * 
K  385.77 ± 76.98 828.86 ± 134.53 +115 % * 
L  603.25 ± 82.27 710.00 ± 108.54 + 18 % † 
M  487.09 ± 89.22 606.93 ± 63.36 +25 % † 
Table 5.1: Quantitative analysis of spots showing significant changes in MPTP 
treated profiles compared to controls (pI 3-10 analysis) 
Normalised density obtained using Samespot software (Progenesis) .  
1 Spot symbols confer to figure 5.1. 
2 Proteins identified by peptide mass fingerprinting. For accession numbers and more details on 
the Mascot databse results refer to table 3.2. 
3 Average of normalised volumes (n = 3) ± Standard error of the mean 
4 Percentage increase = + Average of normalised volumes from MPTP samples / Average of 
normalised volumes from control samples 
4 Percentage decrease = - Average of normalised volumes from control samples / Average of 
normalised volumes from MPTP treated samples 
* Statistically significant changes p < 0.05 using a paired t-test 
† Statistically significant changes p < 0.1 using a paired t-test 
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Figure 5.2: Mini 2D-electrophoretogram (pI 5-8) stained with SyproRuby showing spots 
changing in levels in MPTP treated differentiated N2a cells  
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM 
MPTP or not (controls) for 24 hours. Subcellular fractionation was then carried out. 50 μg 
proteins from mitochondrial fractions for each treatment were fractionated by 2DE (pI 5-8 strips 
and 12 % resolving gel) and visualized using SyproRuby. Pictures of gels were compared using 
Samespots Progenesis software. Circled spots represent spots that significantly (p < 0.1) 
changed in density level between 1 mM MPTP and control samples following a student paired t-
test (n = 3). Numerical data are represented in table 5.2. 
Letters represent spots showing significant changes between treatments and controls but that 
have not been identified. 
Digits represent spots showing significant changes between treatments and controls that have 
been identified using MALDI-TOF mass spectrometry (refer to figure 3.12 for example and 
table 3.8). 
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Spot 
symbol 
1 
Protein 
identification 2 
Average 
normalised 
volumes in 
control samples 3
Average 
normalised 
volumes in 
treated samples 3 
+/- % change 
compared to 
controls 4 
N In the smear of Hsc70 453.62 ± 60.89 761.21 ± 90.71 + 68 % 
† 
O  393.98 ± 28.92 510.64 ± 33.67 + 30 % † 
5 Stress-induced-phosphoprotein 1 1564.27 ± 385.70 2094.72 ± 375.71 + 34 % 
† 
6 60 kDa Heat shock protein 3040.35 ± 150.44 3863.02 ± 160.79 + 27 % 
† 
P  301.93 ± 44.39 389.34 ± 36.70 + 29 % * 
Q  426.15 ± 63.48 555.41 ± 49.78 + 30 % * 
R  1121.52 ± 103.41 1648.35 ± 103.75 + 47 % † 
S  135.76 ± 9.22 82.26 ± 14.02 - 65 % * 
T  849.65 ± 142.41 1163.51 ± 137.07 + 37 % * 
U  413.47 ± 34.24 572.04 ± 47.89 + 38 % * 
V  425.64 ± 58.80 540.28 ± 31.39 + 27 % * 
W  788.81 ± 124.67 1374.59 ± 189.30 + 74 % * 
21 ATP synthase, F0 complex subunit d 3871.90 ± 447.06 5530.40 ± 613.96 + 43 % 
* 
Table 5.2: Quantitative analysis of spots showing significant changes in MPTP 
treated profiles compared to controls (pI 5-8 analysis) 
Normalised density obtained using Samespot software (Progenesis)   
1 Spot symbols confer to figure 5.2. 
2 Proteins identified by peptide mass fingerprinting 
3 Average of normalised volumes (n = 3) ± Standard error of the mean 
4 Percentage increase = + Average of normalised volumes from MPTP samples / Average of 
normalised volumes from control samples 
4 Percentage decrease = - Average of normalised volumes from control samples / Average of 
normalised volumes from MPTP treated samples 
* Statistically significant changes p < 0.05 using a paired t-test 
† Statistically significant changes p < 0.1 using a paired t-test 
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5.2.1.3
5.2.1.4
 pI 7-10 
 
A similar 2DE approach with pI 7-10 focusing strips was used. Due to a high variability 
between replicates, no change could be observed using the Samespots software. 
Nevertheless, since the alignment between the gel images was poor, changes were 
probably occurring but could not be detected. A typical gel image using pI 7-10 strips is 
shown in figure 5.3. 
 
 Validation of markers 
 
A few proteins that showed changes in levels following MPTP treatment and that were 
identified using peptide mass fingerprinting were further investigated using a western 
blot approach. The four selected proteins were 60 kDa heat shock protein (Hsp60), heat 
shock cognate 71 kDa protein (Hsc70), glutamate oxaloacetate transaminase 2 (GOT2) 
and voltage-dependent anion channel 1 (VDAC1). 
 
- Heat shock proteins 
 
a) Hsp60: 60 kDa heat shock protein 
 
Figure 5.4 shows the western blot probed using an anti-Hsp60 antibody. The levels of 
Hsp60 were high in the mitochondrial and nuclear fractions (probably due to 
mitochondrial contamination) and low in the cytoplasmic fraction (figure 5.4A).  
An upregulation was observed in all fractions but significant only in the mitochondrial 
fraction (Figure 5.4B). A small increase was observed in the total extract probably 
because there was no enrichment of the protein compared to total proteins. 
The use of 2-dimensional western blot analysis showed that the anti-Hsp60 antibody 
recognised at least three distinct forms of Hsp60 (figure 5.4C). The main form is the 
middle one, showing a net increase in intensity compared to the two other ones 
following MPTP treatment. 
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Figure 5.3: Mini 2D-electrophoretogram (pI 7-10) stained with SyproRuby showing spots 
changing in levels in MPTP treated differentiated N2a cells  
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM 
MPTP or not (controls) for 24 hours. Subcellular fractionation was then carried out. 50 μg 
proteins from mitochondrial fractions for each treatment were fractionated by 2DE (pI 7-10 
strips and 12 % resolving gel) and visualized using SyproRuby. Gel profiles were too variable 
to observe significant changes. Representative electrophoretogram from a 1 mM MPTP treated 
sample. 
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Figure 5.4: Changes in 60 kDa heat shock protein (Hsp60) levels in various subcellular 
fractions following 1 mM MPTP treatment for 24 hours  
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM 
MPTP for 24 hours or not (controls). Subcellular fractionation was then carried out.  
A. 20 μg protein from each fraction for each treatment were fractionated by 1D-SDS-PAGE (12 
% resolving gel) and then transferred onto a nitrocellulose membrane. Blots were stained with 
copper (refer to section 2.2.6.1) to check for protein loading before probing with anti-Hsp60 
antibody (1 in 5,000 dilution) followed by the ECL detection procedure (refer to section 2.2.6.2) 
B. Densitometry of each band was quantified using Aida software. Each band was compared to 
total protein. The histogram bars represents % Hsp60 / total protein ratio versus controls.  
* p<0.05 against control using a paired t-test with a two-tailed distribution (n = 4). 
C. 2D-blots of 50 μg protein from mitochondrial fractions labeled with the same anti-Hsp60 
antibody as used in A. 
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b) Hsc70: Heat shock cognate 71 kDa protein 
 
Figure 5.5 shows the western blot analysis using anti-Hsc70 antibody. Hsc70 protein 
was present in all fractions (figure 5.5A). A significant increase in level was observed in 
the mitochondrial fraction only (Figure 5.5A and B). No change was observed in the 
total extract, the nuclear fraction and the cytoplasmic fraction.  
The use of 2-dimensional western blot analysis showed that the anti-Hsc70 antibody 
recognised two forms of Hsc70 (figure 5.5C). The acidic form was almost absent in the 
control and its detection was greatly increased following 1 mM MPTP treatment for 24 
hours. 
 
- GOT2: Glutamate oxaloacetate transaminase 2 
 
Figure 5.6 shows the western blot analysis using anti-GOT2 antibody. The levels of 
GOT2 were high in the mitochondrial and nuclear fractions (probably due to 
mitochondrial contamination) and low in the cytoplasmic fraction (figure 5.6A). An 
increase in level was observed in all fractions, as well as in the total extract, but 
significant only in the mitochondrial and nuclear fractions (Figure 5.6B). 
The use of 2-dimensional western blot analysis showed that the anti-GOT2 antibody 
recognised one spot with increased intensity following 1 mM MPTP treatment for 24 
hours but no changes were observed on the shape of the spot (figure 5.6C). 
 
- VDAC1: Voltage-dependent anion channel 1 
 
Figure 5.7 shows the western blot analysis using anti-VDAC1 antibody. The levels of 
VDAC1 were high in the mitochondrial and nuclear fractions (probably due to 
mitochondrial contamination) and low in the cytoplasmic fraction (figure 5.7A). An 
increase in level was observed in cytoplasmic and mitochondrial fractions as well as in 
the total extract but significant only in the mitochondrial fraction probably due to a high 
variability in the cytoplasmic fraction (Figure 5.7B). Interestingly, a significant decrease 
in intensity was observed in the nuclear fraction. 
The use of 2-dimensional western blot analysis showed that the anti-VDAC1 antibody 
recognised up to 7 distinct spots. The two spots observed at the far right end of the blot 
probably corresponded to non focused VDAC1 protein, leaving up to 5 well focused 
spots. The overall intensity seemed to be increased following treatment with 1 mM 
MPTP for 24 hours. 
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Figure 5.5: Changes in heat shock cognate 71 kDa protein (Hsc70) in various subcellular 
fractions following 1 mM MPTP treatment for 24 hours  
Mouse N2a neuroblastoma were differentiated for 16 hours in serum free medium supplemented 
with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM MPTP for 24 hours 
or not (controls). Subcellular fractionation was then carried out.  
A. 20 μg protein from each fraction for each treatment were fractionated by 1D-SDS-PAGE (12 
% resolving gel) and then transferred onto a nitrocellulose membrane. Blots were stained with 
copper (refer to section 2.2.6.1) to check for protein loading before probing with anti-Hsc70 
antibody (1 in 10,000 dilution) followed by the ECL detection procedure (refer to section 
2.2.6.2) B. Densitometry of each band was quantified using Aida software. Each band was 
compared to total protein. The histogram bars represents % hsc70 / total protein ratio versus 
controls. * p<0.05 against control using a paired t-test with a two-tailed distribution (n = 3). 
C. 2D-blots of 50 μg protein from mitochondrial fractions labeled with the same anti-Hsc70 
antibody as used in A. 
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Figure 5.6: Changes in glutamate oxaloacetate transaminase 2 (GOT2) in various 
subcellular fractions following 1 mM MPTP treatment for 24 hours  
Mouse N2a neuroblastoma were differentiated for 16 hours in serum free medium supplemented 
with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM MPTP for 24 hours 
or not (controls). Subcellular fractionation was then carried out. 
A. 20 μg protein from each fraction for each treatment were fractionated by 1D-SDS-PAGE (12 
% resolving gel) and then transferred onto a nitrocellulose membrane. Blots were stained with 
copper (refer to section 2.2.6.1) to check for protein loading before probing with anti-GOT2 
antibody (1 in 500 dilution) followed by the ECL detection procedure (refer to section 2.2.6.2) 
B. Densitometry of each band was quantified using Aida software. Each band was compared to 
total protein. The histogram bars represents % GOT2 / total protein ratio versus controls.  
* p<0.05 against control using a paired t-test with a two-tailed distribution (n = 7 for 
mitochondrial fractions, n = 3 for other fractions ). C. 2D-blots of 50 μg protein from 
mitochondrial fractions labeled with the same anti-GOT2 antibody as used in A. 
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Figure 5.7: Changes in voltage-dependent anion channel 1 (VDAC1) levels in various 
subcellular fractions following 1 mM MPTP treatment for 24 hours  
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM 
MPTP for 24 hours or not (controls). Subcellular fractionation was then carried out.  
A. 20 μg protein from each fraction for each treatment were fractionated by 1D-SDS-PAGE (12 
% resolving gel) and then transferred onto a nitrocellulose membrane. Blots were stained with 
copper (refer to section 2.2.6.1) to check for protein loading before probing with anti-VDAC1 
antibody (1 in 1,000 dilution) followed by the ECL detection procedure (refer to section 2.2.6.2) 
B. Densitometry of each band was quantified using Aida software. Each band was compared to 
total protein. The histogram bars represents % VDAC1 / total protein ratio versus controls.  
p<0.05 against control using a paired t-test with a two-tailed distribution (n = 8 for 
mitochondrial fractions, n = 5 for other fractions ). C. 2D-blots of 50 μg protein from 
mitochondrial fractions labeled with the same anti-VDAC1 antibody as used in A. 
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5.2.2.1
5.2.2 Effects of MPTP on the phosphoproteome 
 
The phosphoproteome can be studied using a range of methods. In the present study, 
two different approaches were used to investigate whether MPTP had an effect on the 
phosphorylation state of the cell and, more particularly, of the mitochondrial proteins. 
 
 Study of the phosphoproteome using western blot analysis 
 
The first approach used to investigate the effects of MPTP on the phosphoproteome was 
a western blot-based analysis using a range of antibodies directed against 
phosphorylated residues.  
 
- Phosphoserine antibody 
 
Figure 5.8A shows serine phosphorylation in various subcellular fractions from control 
and MPTP treated cells. The three fractions showed different profiles to one other: 
overall, the level of serine phosphorylation was lower in the mitochondrial proteins 
compared to other fractions. The total extract profile was similar to the profile from the 
cytoplasmic fraction indicating that most serine phosphorylation involved cytoplasmic 
proteins.  
Changes in serine phosphorylation following treatment with MPTP were present in all 
subfractions. Nevertheless, only changes observed in the mitochondrial fraction were 
quantified using Aida Analyser software by measuring the intensity of each band 
normalised to protein loading represented by copper stain (figure 5.8B) and comparing 
MPTP treatments with respective controls. As shown by the table in figure 5.8C, 4 
bands showed changes in intensity. Serine phosphorylation was increased following 
treatment with sub-cytotoxic concentrations of MPTP. 
Bands 1, 2 and 3 appeared to be specific to mitochondria, whereas band 4 seemed to be 
also found in the cytoplasm.  
Interestingly, the major change in serine phosphorylation following MPTP treatment 
was observed in the nuclear fraction with a large decrease in serine phosphorylation of 
band 5 which corresponded to an increase in serine phosphorylation of a protein with 
the same molecular weight in the cytoplasmic fraction (figure 5.8A). Although changes 
in phosphorylation were observed following MPTP treatment, no protein identification 
of these proteins was carried out. 
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C. Quantitative changes in serine phosphorylation in 
mitochondrial proteins  
 
Band no. 
+/- % change 
compared to 
controls 
1 + 77 % † 
2 + 66 % * 
3 + 90 % 
4 + 107% * 
 
 
 
 
 
Figure 5.8: Detection of proteins phosphorylated via a serine amino acid in various 
subcellular fractions in cells treated with 1 mM MPTP for 24 hours compared to controls 
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM 
MPTP for 24 hours or not (controls). Subcellular fractionation was then carried out. 20 μg 
protein from each fraction for each treatment were fractionated by 1D-SDS-PAGE (12 % 
resolving gel) and then transferred onto a nitrocellulose membrane. Blots were stained with 
copper (refer to section 2.2.6.1) to check for protein loading (B). This was followed by probing 
with anti-phosphoserine antibody (1 in 500 dilution) followed by the ECL detection procedure 
(refer to section 2.2.6.2) (A). Densitometry of each band was quantified using Aida software. 
Each band was compared to total protein and expressed as % phosphoserine / total protein ratio 
versus controls (C). * p < 0.05 and † < 0.1 against control using a paired t-test with a two-tailed 
distribution (n =3). 
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In order to observe more changes in the mitochondrial proteome and assist in the 
identification of proteins, mitochondrial fractions were electrophoresed using 2DE, 
transferred onto a nitrocellulose membrane and probed with the same anti-
phosphoserine antibody as used for 1D-western blot analysis. The resultant 
mitochondrial serine phosphoproteomes are shown in figure 5.9. As already mentioned, 
following the 1-dimensional study, serine phosphorylation was, in general, increased in 
the mitochondrial fractions following MPTP treatment. More particularly, two main 
areas showed changes in serine phosphorylation with one around 75 kDa (annotated as 
circle 1) and one around 50 kDa (circle 2) (Figure 5.9b). Interestingly, circle 1 
corresponds to the area where Hsp70 family proteins are focused indicating a potential 
role of serine phosphorylation in Hsp70 family protein function following MPTP 
treatment, notably GRP75 protein and Hsc70. 
 
- Phosphothreonine phosphorylation 
 
Figure 5.10A shows the effects of treatment with 1 mM MPTP for 24 hours on 
threonine phosphorylation in subcellular fractions from mouse N2a cells. The three sub-
fractions showed different profiles. Strongly stained bands are observed in all three 
fractions and all contribute to the profile in the total extract; in this case, the total extract 
profile does not match the profile of the cytoplasm. 
As before, only changes observed in the mitochondrial fraction were quantified using 
the Aida Analyser software by measuring the intensity of each band normalised to 
protein loading represented by copper stain (figure 5.10B) and comparing MPTP 
treatments with respective controls. Bands 1 and 2 showed a decrease in threonine 
phosphorylation, while band 3 showed an increased level (figure 5.11C). Band 1 and 2 
appeared to also be present in the cytoplasmic fraction, while band 3 seemed to be 
specific to mitochondria (figure 5.10A).  
Although changes in phosphorylation were observed following MPTP treatment, no 
protein identification of these proteins was carried out. 2D-western blot analysis was not 
possible due to the low sensitivity of the antibody using this approach, despite the 
strong staining obtained on the 1D-blots. 
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Figure 5.9: 2D-blot detection of proteins phosphorylated via a phosphoserine amino acid 
in mitochondrial fractions from cells treated with 1 mM MPTP for 24 hours compared to 
controls 
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM 
MPTP for 24 hours (B) or not (controls) (A). Subcellular fractionation was then carried out. 50 
μg protein from each fraction for each treatment were fractionated by 2DE (pI 3-10; 12 % 
resolving gel) and then transferred onto a nitrocellulose membrane. Blots were stained with 
copper (refer to section 2.2.6.1) to check for protein loading (a) before probing with anti-
phosphoserine antibody (1 in 200 dilution) (b) followed by the ECL detection procedure (refer 
to section 2.2.6.2). Circles show area of potential changes between treated and untreated 
samples. 
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 C. Quantitative changes in threonine phosphorylation in 
mitochondrial proteins  
 
Band no. 
+/- % change 
compared to 
controls 
1 - 27 % † 
2 -51 % † 
3 + 47 % * 
 
 
 
 
Figure 5.10: Detection of proteins phosphorylated via a threonine amino acid in various 
subcellular fractions in cells treated with 1 mM MPTP for 24 hours compared to controls 
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM 
MPTP for 24 hours or not (controls). Subcellular fractionation was then carried out. 20 μg 
protein from each fraction for each treatment were fractionated by 1D-SDS-PAGE (12 % 
resolving gel) and then transferred onto a nitrocellulose membrane. Blots were stained with 
copper (refer to section 2.2.6.1) to check for protein loading (B). This was followed by probing 
with anti-phosphothreonine antibody (1 in 500 dilution) followed by the ECL detection 
procedure (refer to section 2.2.6.2) (A). Densitometry of each band was quantified using Aida 
software. Each band was compared to total protein and expressed as % phosphothreonine / total 
protein ratio versus controls (C). * p < 0.05 and † < 0.1 against control using a paired t-test with 
a two-tailed distribution (n =3). 
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- Tyrosine phosphorylation 
 
Figure 5.11A shows the effects of treatment with 1 mM MPTP for 24 hours on tyrosine 
phosphorylation in subcellular fractions from mouse N2a cells. The three subfractions 
showed similar levels of tyrosine phosphorylation but different profiles, although the 
nuclear fraction was similar to the mitochondrial fraction. This might be due to the 
mitochondrial contamination in the nuclear fraction, also indicating that tyrosine 
phosphorylation might be low in the nucleus compared to the mitochondria.  
Changes in tyrosine phosphorylation following treatment with MPTP were present in all 
subfractions. Nevertheless, only changes observed in the mitochondrial fraction were 
quantified (figure 5.11C). The levels of three bands were altered following MPTP 
treatment; bands 1 and 2 showed an increase in tyrosine phosphorylation, while band 3 
showed a decreased level. Band 1 appeared to be also present in the cytoplasmic 
fraction, while bands 2 and 3 seemed to be specific to mitochondria.  
Although changes in phosphorylation were observed following MPTP treatment, no 
protein identification of these proteins was carried out. 2D-western blot analysis was not 
possible due to the low sensitivity of the antibody using this approach. 
 
5.2.2.2 Study of the phosphoproteome using SDS-PAGE analysis 
 
The second approach for the study of the mitochondrial proteome was using a 
fluorescent dye reactive with all phosphorylated proteins called ProQ Diamond 
phosphoprotein stain (Molecular Probes). 
 
- 1D-SDS-PAGE 
 
Figure 5.12 shows triplicate pairs of mitochondrial samples, MPTP treatment versus 
control, stained with ProQ Diamond for phosphorylated proteins (figure 5.12A) 
followed by SyproRuby stain (Molecular probes) for all proteins (Figure 5.12.B). 
The phosphoprotein profile was different to the total protein profile showing the 
specificity of each stain, whilst different replicates were very similar to each other.  
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 A. Phosphotyrosine detection 
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C. Quantitative changes in tyrosine phosphorylation in 
mitochondrial proteins 
 
 
Band no. Change fold (n ≥ 2) 
1 + 47 % 
2 + 24 % * 
3 - 15 %  
 
 
 
Figure 5.11: Detection of proteins phosphorylated via a tyrosine amino acid in various 
subcellular fractions in cells treated with 1 mM MPTP for 24 hours compared to controls 
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM 
MPTP for 24 hours or not (controls). Subcellular fractionation was then carried out. 20 μg 
protein from each fraction for each treatment were fractionated by 1D-SDS-PAGE (12 % 
resolving gel) and then transferred onto a nitrocellulose membrane. Blots were stained with 
copper (refer to section 2.2.6.1) to check for protein loading (B). This was followed by probing 
with anti-phosphotyrosine antibody (1 in 500 dilution) followed by the ECL detection procedure 
(refer to section 2.2.6.2) (A). Densitometry of each band was quantified using Aida software. 
Each band was compared to total protein and expressed as % phosphotyrosine / total protein 
ratio versus controls (C). * p < 0.05 and † < 0.1 against control using a paired t-test with a two-
tailed distribution (n =3). 
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Figure 5.12: Detection of phosphorylated proteins in mitochondrial fractions following 1 
mM MPTP treatment for 24 hours using 1D-SDS-PAGE 
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM 
MPTP for 24 hours or not (controls). Subcellular fractionation was then carried out. 50 μg 
protein from triplicate mitochondrial fractions for each treatment were fractionated by 1D-SDS-
PAGE (12 % resolving gel) followed by staining with A. ProQ Diamond for the detection of 
total phosphorylated proteins, B. Sypro Ruby for the detection of total proteins. 
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No obvious reproducible changes were observed in the three replicates using ProQ 
Diamond (figure 5.12A) following 1 mM MPTP treatment. This was contrary to the 
western blot analysis using a series of phospho-antibodies. However, there were so 
many phosphorylated proteins using the fluorescent dye, that changes in levels of one 
protein was more difficult to observe than when using phospho-specific antibodies with 
their restricted activities.  
 
- 2D-SDS-PAGE 
 
In order to observe more effects of MPTP on the mitochondrial phosphoproteome, 2DE 
from treated and untreated samples were stained using ProQ Diamond prior to being 
stained with Sypro Ruby.  
 
a) pI 3-10 
 
Figure 5.13 shows a typical 2D-electrophoretogram following ProQ Diamond stain. The 
picture showed that, in general, phosphorylated proteins were represented as trails of 
spots. This is probably due to the property of phosphorylated proteins to shift slightly to 
the acidic end, and the more a protein is phosphorylated, the more acidic is its pI. So 
while Sypro Ruby stain revealed the main isoform as a well focused spot (figure 5.13B), 
ProQ Diamond showed a trail of spots for highly phosphorylated proteins (figure 
5.13A). The overlay image (figure 5.13C) shows the phosphorylated proteins (in green) 
compared total proteins (in pink). Most of the spots revealed by Sypro Ruby represented 
non-phosphorylated isoforms of proteins as both stained pictures did not align well.  
Because there were so many phosphorylated proteins, they did not focus very well using 
pI 3-10 strips and differences between MPTP treatment and control were not obvious. 
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Figure 5.13: Detection of phosphorylated proteins in mitochondrial fractions using 2DE 
(pI 3-10) 
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM 
MPTP for 24 hours or not (controls). Subcellular fractionation was then carried out. 50 μg 
protein from mitochondrial fractions for each treatment were fractionated by 2DE (pI 3-10, 12 
% resolving gel) followed by staining with: A. ProQ Diamond for the detection of total 
phosphorylated proteins, and B. Sypro Ruby for the detection of total proteins. C. Both images 
were overlaid using the Samespots software. Pink: total proteins; Green: phosphorylated 
proteins. This representative gel shows a profile from a MPTP treated sample. 
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b) pI 5-8 
 
Following the sensitivity limitation of broad range pI 3-10 strips, the analysis of 
phosphorylated proteins was carried out using pI 5-8 strips for the first dimension of 
2DE. Figure 5.14 shows the effects of MPTP on the mitochondrial phosphoproteome as 
compared to the total proteome. Gels were analysed using the Samespots software and 
differences between the two treatments were observed. The major changes in 
phosphorylation levels are shown in figure 5.14C. Following MPTP treatment, spots α 
to γ showed and increase in phosphorylation levels while spots δ to ζ showed a decrease 
in phosphorylation levels. 
Interestingly spot α co-localised with a spot that was previously observed to be 
increasing following MPTP toxicity in the total proteome analysis using pI 5-8 (section 
5.2.1.2). The spot was annotated as spot N in figure 5.2 and hypothesised to be an 
isoform of heat shock cognate 71 kDa protein (spot 3 in figure 5.15 and 6.14B). A 
phosphorylated spot (spot β), in the proximity of Hsp 60 (spot 6) also showed an 
increase in phosphorylation following MPTP treatment. 
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C. Quantitative analysis of changes in phosphorylation 
 
Spot 
number 
+/- % change compared to 
controls 
α + 57 % * 
β + 17 % * 
γ + 59 % 
δ - 70 % 
ε - 20 % * 
ζ - 22 % * 
 
 
 
 
 
 
Figure 5.14: Detection of phosphorylated proteins in mitochondrial fractions using 2DE 
(pI 5-8 range strips) 
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM 
MPTP for 24 hours or not (controls). Subcellular fractionation was then carried out.  
50 μg protein from mitochondrial fractions for each treatment were fractionated by 2DE (pI 5-8, 
12 % resolving gel) followed by staining with: A. ProQ Diamond for the detection of 
phosphorylated proteins, a) with control sample and b) with MPTP treated sample, spots α to ζ 
showed variations in levels between treatments; B. Sypro Ruby for the detection of total 
proteins c) with control sample and d) with MPTP treated sample. Spot 3 identified by peptide 
mass fingerprinting as Hsc70; Spot 6 identified as Hsp60. (refer to figure 3.12 for spot 
identification map). 
C. Densitometry of spots circled was quantified using Samespots software. * p < 0.05 against 
control using a paired t-test with a two-tailed distribution (n =3).  
α and β are in the vicinity and thought to be post-translationally modified forms of spots 3 and 
6, respectively. 
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5.3 DISCUSSION 
 
5.3.1 Effects of MPTP on N2a neuroblastoma mitochondrial proteome 
 
Using a proteomic approach consisting of 2DE followed by image analysis and peptide 
mass fingerprinting, around 32 proteins from the mitochondrial proteome were observed 
to vary in levels following sub-cytotoxic treatment with MPTP. Out of these proteins, 
nine were identified and the identities of three more were hypothesised as they were in 
close proximity with identified proteins. The identities of these proteins are shown in 
table 5.3. They are related to different functions in the cell including chaperone and co-
chaperone family proteins, metabolic enzymes, enzymes linked to oxidative 
phosphorylation and an outer mitochondrial membrane channel. A potential role for 
these proteins in MPTP-induced toxicity will be discussed later (see section 5.3.3). 
Changes observed using both pI 3-10 and pI 5-8 strips were between 17 and 115 %. 
Although these changes occurred for each replicate between the two treatments (MPTP 
versus control), the use of a validation process was necessary to confirm these changes 
and the validation of the 8 non-validated identified proteins would be required to 
confirm their involvement in MPTP-induced toxicity.  
Fukada and colleagues (2004) used a similar approach to study the mitochondrial 
proteome using a cellular model of familial amyotrophic lateral sclerosis (ALS). They 
identified up to 45 proteins changing in expression levels using pI 3-10 broad range IPG 
strips (using triplicates). Similarly, Van Laar et al. (2008) identified 17 proteins varying 
in expression in the mitochondrial proteome of a rat model exposed to dopamine 
quinone (using 5-6 replicates). These two analyses demonstrated that 2D-PAGE using 
broad range pI 3-10 analysis was acceptable and efficient. In the former study, no 
validation of observed changes in expression was undertaken. In the latter analysis, 2 
out of the 17 proteins were validated using western blot analysis. Although several 
studies have been carried out using 2DE using narrower pI ranges (De Iuliis et al., 
2005), none were carried out using mitochondrial proteomes. 
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Spot 
symbol 
1 
pI 
spectrum 
analysis 
Protein identification 2 
+/- % change 
in 2DE 
analysis3 
+/- % 
change in 
western blot 
analysis4 
6 pI 5-8 60 kDa heat shock protein + 27 % † + 37 % * 
13 pI 3-10 Glutamate oxaloacetate transaminase 2 + 24 % 
* + 54 % * 
19 pI 3-10 Voltage-dependent-anion channel 1 + 30 % 
† + 201 % † 
5 pI 5-8 Stress-induced-phosphoprotein 1 + 34 % 
†  
9 pI 3-10 ATP synthase, F1 complex α-subunit isoform 1 - 17 % 
†  
10 pI 3-10 Fumarate hydratase + 28 % †  
15 pI 3-10 Malate dehydrogenase + 56 % *  
18 pI 3-10 Electron transfer flavoprotein subunit α + 49 % 
*  
21 pI 5-8 ATP synthase, F0 complex subunit d + 43 % 
*  
B pI 3-10 In the smear of Hsp60 - 40 % †  
E pI 3-10 In the smear of putative β-actin + 51 % 
*  
N pI 5-8 In the smear of Hsc70 + 68 % † 
+ 51 % * 
(total 
protein) 
Table 5.3: Identified proteins showing changes in levels following sub-cytotoxic 
MPTP treatment 
Normalised density obtained using Samespot software (Progenesis) .  
1 Spot symbols confer to figures 5.1 and 5.2 
2 Proteins identified by peptide mass fingerprinting. For accession numbers and more details on 
the Mascot databse results refer to table 3.8. 
3 Change fold as shown in tables 5.1 and 5.2 using 2DE analysis 
4 Change fold as shown in figures 5.4 to 5.7 using western blot analysis 
* Statistically significant increases p < 0.05 using a paired t-test 
† Statistically significant increases p < 0.1 using a paired t-test 
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5.3.2 Effects of MPTP toxicity on phosphorylating pathways 
 
The present study shows that mouse N2a neuroblastoma cells have a complex 
mitochondrial phosphoproteome. Based on 1D-western blots, a higher number of 
proteins were shown to be phosphorylated via threonine residues than via serine and 
tyrosine residues. In broad terms this mitochondrial proteome followed the total cell 
consensus where threonine phosphorylation ratio is 1000 to 100 serine phosphorylation 
to 1 tyrosine phosphorylation (Raggiaschi et al., 2006). Several mitochondrial proteins 
have been observed to vary in phosphorylation status following MPTP-induced toxicity, 
6 of which were shown to vary using the ProQ Diamond dye. Consistently, heat shock 
family proteins seemed to be targets of phosphorylation modulated by MPTP treatment. 
Increase in serine phosphorylation was observed for GRP75, and overall 
phosphorylation was increased in what was thought to be forms of Hsc70 and Hsp60. 
Nakamura et al., (2006) used 2-DE followed by ProQ Diamond staining to look at the 
effects of 6-OHDA, another toxin mimicking PD’s biochemical features, on the whole 
phosphoproteome of SH-SY5Y cells. Using pI 3-10 strips they observed changes in 
phosphorylation patterns of 4 different proteins. None of them were mitochondrial.  
All three most commonly phosphorylated residues (threonine, serine and tyrosine) were 
sensitive to MPTP-induced toxicity showing that several kinases must have been 
involved. Recently, many kinases and phosphatases have been found in the 
mitochondria. Some of them have been linked to PD. First of all PINK1 and LRRK2, 
both kinases, have been linked with genetic cases of the disease and have been found 
within or interacting with the mitochondria (Henchcliffe and Beal, 2008). Moreover, 
several signaling kinases are known to be modulated in PD and have been co-localised 
with the mitochondria. For example, activated ERK 1/2 was found to translocate to 
mitochondria following 6-OHDA treatment (Kulich et al., 2007), indicating that ERK 
1/2 specifically localised in the mitochondria could be a marker of mitochondrial 
dysfunction. Similarly, in mice GSK3-β was shown to be increased following MPTP 
toxicity in both mitochondria and cytosol (Petit-Paitel et al., 2009). Moreover, the 
mitochondrial form of GSK3-β was found to inhibit complex I when constitutively 
active in SH-SY5Y cells, leading to ATP depletion and ROS production (King et al., 
2008). These two kinases as well as other mitochondrial kinases could be causing the 
modulations in phosphorylation found in the mitochondrial phosphoproteome of mouse 
N2a cells following MPTP treatment. 
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5.3.3.1
Both quantitative and phosphorylation analyses of the mitochondrial proteome have 
been shown to be more sensitive with narrower pI ranges. Further work could be 
undertaken focusing in even narrower pI ranges to observe more subtle shifts of spots. 
Moreover, a further optimisation of basic narrow pI range analyses could be highly 
useful for both the total proteome and phosphoproteome as many changes were 
observed in the basic end of broad range pI analyses.  
 
5.3.3 Mitochondrial markers of MPTP-induced toxicity  
 
 Chaperone and co-chaperone proteins sensitive to MPTP-induced toxicity 
 
2DE analysis of the mitochondrial proteome of  N2a cells revealed an increase of 30 % 
in Hsp60 levels following MPTP treatment compared to controls. This increase was 
validated using western blot analysis showing an increase in levels of 37 % in the 
mitochondrial fraction. Increased levels in the other subcellular fractions and total 
extract were also observed although these were smaller and not statistically significant. 
 
Although identification has not been confirmed, another spot close to and on the basic 
side of Hsp60 also increased following MPTP treatment. This spot was shown to 
change using the broad range pI but was not repeated in the pI 5-8 analysis, where spots 
were better focused. Consequently, there were concerns that it was an artefact due to pot 
smearing. A 2D-western blot analysis of Hsp60 showed that there were spots on each 
side of the main Hsp60 spot, probably post-translationally modified forms. However, 
this analysis did not conclusively reveal whether these isoforms were changing in 
levels. Later analysis involving ProQ Diamond staining showed that the acidic form 
(spot β in figure 5.14) of the protein (spot 6 in figure 5.14) aligned with a 
phosphorylated spot that was slightly (17%) increased following MPTP treatment. Since 
Hsp60 (spot 6 in figure 5.14) has been observed to have ATPase activity (Weissman et 
al., 1995), it was not surprising to observe that it could be phosphorylated. It is also 
worth noting that Hsp60 expression has been linked to the activation of ERK1/2 (Zhang 
et al., 2004). 
Hsp60, also called chaperonin, is mostly found in mitochondria, although there has been 
evidence of Hsp60 in the cytoplasm in recent studies (Chandra et al., 2007). Hsp60 has 
mainly been found in the mitochondrial matrix where it plays an important role in the 
folding of mitochondrial proteins following their entry to the organelle. It also has a role 
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in preventing misfolding that can occur in stress conditions (reviewed in Deocaris et al., 
2006). Other extra-mitochondrial roles include intracellular trafficking of proteins, 
interaction with survival proteins such as p53 and survivin along with a pro-death role 
in its ability to activate caspase-3 when released from mitochondria in response to 
specific stimuli (Cappello et al., 2008).  
Dysregulation of Hsp60 has previously been observed in a variety of 
neurodegenerations. Indeed, it has been observed that a missense mutation could cause a 
brain hypomyelating leukodystrophy in certain individuals (Magen et al., 2008). The 
mutated form was observed to have lost its chaperone activity. Hsp60 expression was 
also observed to be decreased in models of Alzheimer disease (Tsuji et al., 2002). 
Interestingly, Hsp60 was upregulated in a rat model of schizophrenia (Paulson et al., 
2005). More particularly, using models mimicking PD, Jin and colleagues (2006) used a 
proteomic approach to measure protein expression levels in the substantia nigra of 
patients using post-mortem samples and, amongst many other proteins, found that 
Hsp60 protein levels were increased. Moreover, Barzilai and colleagues (2000) 
observed an upregulation in Hsp60 mRNA expression in response to dopamine toxicity 
in dopaminergic neurons as a model mimicking PD. Upregulation and downregulation 
of Hsp60 expression observed in different models of neurodegeneration demonstrates 
its antagonistic dual role in survival and death pathways. However, consistent with our 
findings, Hsp60 mRNA and protein levels have been observed to be upregulated using 
different PD-models (Jin et al., 2006; Barzilai et al., 2000).  
. 
Following MPTP treatment, the pI-5-8 2-DE analysis of mitochondrial fractions showed 
an increase in the level of a spot in the proximity of a spot identified as heat shock 
cognate 71 kDa protein (also called Hsc70, HspA8 and Hsc73). 1D-blot analysis 
confirmed a 50% increase in Hsc70 in  the mitochondrial fraction,  and no change in 
levels of the protein in other subcellular fractions. The 2D-blot analysis showed that 
there was an acidic isoform of the protein, highly increased in intensity following 
MPTP treatment. This increase, in the gel analysis, was quantified as 70 %, which was 
underestimated in the 1D-blot analysis because the total level of Hsc70 included two 
forms: the main spot and the acidic spot. This represented an acidic shift of the Hsc70 
protein probably due to post-translational modifications. Further analysis using ProQ 
Diamond staining showed that the acidic form of the protein aligned with a 
phosphorylated spot that increased in levels following MPTP treatment.  
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Hsc70 is a constitutively expressed protein of the Hsp70 family. It is found ubiquitously 
in the cell. Meimaridou and colleagues (2009) recently reviewed the different roles of 
Hsc70 and some of its modes of action. They related that one of its main roles as a 
chaperone was to bind nascent peptides and facilitate their folding as they exited the 
ribosomes. Hsc70 has been reported to have a role in endocytosis acting as an ATPase 
in the disassembly of clathrin vesicle during transport of membrane components, for 
example, and in exocytosis by interacting with a protein essential for exocytosis 
(Meimaridou et al., 2009). Hsc70 has also been attributed to have a role in protein 
degradation by targeting proteins (including membrane proteins) to the ubiquitin 
proteasome system (UPS) or the lysosomes, depending on the protein to be degraded 
(Meimaridou et al., 2009). While Hsp60 was observed to have a role both in pro- and 
anti-apoptotic pathways (Capello et al., 2008), Hsc70 has been observed to have anti-
apoptotic activity by inhibiting p53, inhibiting stress-activated kinases (such as JNK) 
and permeabilising lysosomal membranes (Guarrido et al., 2006). 
The role of both Hsc70 and Hsp60 in folding proteins in the cytoplasm or mitochondria, 
respectively, is ATP-dependent (Hartl and Hayer Hartl, 2009). The cycle by which 
Hsc70 is folding nascent pre-proteins is also dependent on other co-chaperones. 
Interestingly, one of these co-chaperones was observed to be stress-induced 
phosphoprotein 1 (STIP1), also called Hop (Meimaridou et al., 2009), which was 
increased by 34% following MPTP treatment in the present study. Although the 
increase in STIP1 was not validated, it could be linked to the increased levels of Hsc70. 
 
In disagreement with our findings, the proteomic analysis conducted by Jin and 
colleagues (2005) showed decreased levels of Hsc70 in the mitochondria of MPTP 
treated mice. Heat shock has long been observed to be protective of MPTP toxicity in a 
variety of models (Freyaldehoven and Ali, 1996; Quigney et al., 2003; Donaire et al., 
2005) by inducing the expression of a variety of heat shock proteins. Moreover, the 
substrate of dopamine, L-DOPA, used as a treatment of PD, was shown to increase 
Hsc70 expression (Calabrese et al., 2007). All these studies related the protective effects 
of Hsc70 in PD and in MPTP-induced toxicity. Thus in the present study, the 
upregulation of phosphorylated Hsc70 protein in the mitochondria following treatment 
with sub-cytotoxic concentrations of MPTP probably has a protective role. It would be 
interesting to check levels of Hsc70 following treatment with cytotoxic concentrations 
of MPTP.  
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5.3.3.2
Other previous studies using models mimicking PD have shown changes in expression 
of different members of the Hsp70 family (Freyaldenhoven and Ali, 1996; Fan et al., 
2006) and more precisely mitochondrially expressed members such as Heat shock-
related 70 kDa protein2 (Hsp72) and glucose-regulated protein 75 (Grp75) (Fan et al., 
2005; Van Laar et al., 2008). However, in the present study, no changes in the levels of 
Grp75 was detected (refer to figure 3.12 spot 4 for location of GRP75 on profile map).  
 
Overall, the upregulation of chaperones and co-chaperones following exposure of N2a 
cells to sub-cytotoxic concentrations of MPTP could be due to their pro-survival and 
anti-apoptotic roles. It could also be due to their ability to reshape misfolded proteins 
and participate in the degradation of misfolding and aggregating proteins due to 
oxidative stress observed in Parkinson’s disease (Jin et al., 2005).  
 
 Metabolic enzyme protein levels 
 
The levels of several metabolic enzymes increased following treatment with sub-
cytotoxic concentrations of MPTP. 
Glutamate oxaloacetate 2 transaminase (GOT2), also called mitochondrial aspartate 
amino transferase, increased by 24 % according to 2DE analysis and 54% according to 
1D-western blot analysis. Using western blot analysis, non-significant increased levels 
were also observed in nuclear and cytoplasmic fractions. 
GOT catalyses the transfer of amine groups between aspartate and glutamate following 
the reaction below.  
It is a reversible enzyme from the amino acid synthesis pathway, including the 
neurotransmitter glutamate and the urea cycle. Two isoforms have been found: GOT1 in 
the cytoplasm and GOT2 in the mitochondria. GOT2 is found in the matrix but can 
interact with the IMM close to complex I (McKenna et al., 2000). 
L-aspartate + α-ketoglutarate <=> oxaloacetate + L-glutamate 
 
Although their expression levels have not been validated, two other metabolic enzymes 
increased following MPTP-induced treatment. Indeed, malate dehydrogenase (MDH) 
protein levels increased by 56 % and fumarate hydratase (FMH) by 28 %. Both 
enzymes are subsequent enzymes of the Krebs cycle as shown in figure 5.15. 
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Figure 5.15: Biochemical reactions involved in the TCA cycle and the link with the first 
enzyme of amino acid synthesis, GOT2 
Blue print: metabolic enzymes involved in the TCA cycle that did not show significant changes 
or were not identified in mouse N2a neuroblastoma following 1 mM MPTP treatment for 24 
hours 
Red print: metabolic enzymes involved in the TCA cycle that showed significant upregulated 
protein levels in mouse N2a neuroblastoma following 1 mM MPTP treatment for 24 hours 
CS: citrate synthase; IDH: isocitrate dehydrogenase; α-KDGH: α-ketoglutarate; SDH: succinate 
dehydrogenase; FMH: fumarase; MDH: maldate dehydrogenase; GOT2: glutamate oxaloacetate 
transaminase 2. 
 
Increased protein levels are not always linked to increased enzyme activity. There are 
several hypotheses that can be drawn from an increased protein level. The three main 
causes could be an upregulation of protein levels independent of protein function due to 
upregulation of transcription factors, for example, or increased protein translation. 
Another cause could be a decreased proteolysis of the protein. The enzyme protein 
could also have an increased level for a role other than enzymatic activity. 
Interestingly, these three upregulated enzymes were consecutive enzymes sharing 
substrates and products (figure 5.15). Moreover, all three were reversible, which made 
difficult the interpretation as no substrate or product was analyzed and thus the direction 
the enzyme was driven is not known . Following inhibition of complex I by MPTP via 
MPP+ (Langston et al., 1983), the metabolites of the Krebs cycle (NADH+ FADH2) 
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cannot be re-oxidised via the ETC. A study of the effects of MPTP on monkeys showed 
that MDH and GOT2 activities were increased following the treatment in the 
cerebellum (Villa et al., 1994). In another study, the overall rate of the Krebs cycle was 
shown to decrease in MPTP treated monkeys (Kanamatsu et al., 2007). Consequently 
the Krebs cycle was expected to show dysregulation and other pathways capable of re-
oxidising co-factors are expected to be activated. For example, instead of using 
oxaloacetate to initiate the Krebs cycle and produce citrate via citrate synthase, MDH 
might be reversed and use oxaloacetate to form malate which can be shuttled out of the 
mitochondria and used as substrate for other metabolic processes (Mazzio and Soliman, 
2003). Mazzio and Soliman (2003) proposed this hypothesis, following their work using 
different carbohydrate and amino acid substrates to try and protect mouse N2a cells 
against MPP+ toxicity. They found that glucose, phosphoenolpyruvate, pyruvate, as well 
as malate all increased ATP production but not oxygen consumption showing that 
energy production was from a pathway other than the oxidative phosphorylation. They 
hypothesized that MPP+ led to the reversion of the Krebs cycle to produce 
phosphoenolpyruvate and  to the use of anaerobic pathways such as lactate production 
in mouse N2a neurons.  
Alternatively, malate can be metabolized to fumarate via fumarase and the product 
could be used to increase complex II activity by re-oxidising FADH2. However, this 
pathway would require intact ETC components, excluding complex I activity. 
Extracelllular glutamate levels have been previously described in PD (Lange et al., 
1997) and a role for glutamate excitotoxicity in cell death following MPTP-induced 
toxicity have also been observed more recently in a mouse model (Meredith et al., 
2009). Whether GOT2 upregulation would favour glutamate synthesis as well as 
oxaloacetate synthesis for it to be used to produce phosphoenolpyruvate as described 
previously or favours glutamate scavenging and amino acid synthesis, has not been 
resolved here.  
 
Although only GOT2 upregulation was validated, over-expression of MDH and FMH 
both made sense when compared to GOT2 over-expression in the context of using 
Krebs cycle products as substrates to produce energy via anaerobic means in the 
cytoplasm. Whether this would lead to glutamate excitotoxicity or would be a protective 
consequence still remains to be resolved. 
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5.3.3.3 Proteins linked to oxidative phosphorylation 
 
Three proteins related to the oxidative phosphorylation system were showing altered 
levels. Of the three, two of them were subunits of ATP synthase, also called complex V. 
Indeed, a spot identified as ATP synthase F1 complex α-subunit isoform 1 showed a 
significant decrease in level by 17 %. Interestingly, another spot identified as ATP 
synthase, F0 complex subunit δ showed an increase by 43 % in level following MPTP-
induced toxicity. ATP synthase F1 complex β-subunit was also identified but did not 
show any significant changes in levels following MPTP treatment. Whether the latter 
subunit was not affected by sub-cytotoxic MPTP treatment or the proteomic approach 
used in the study was not sensitive enough to observe a change has not been 
investigated. However, a western blot analysis using human post-mortem substantia 
nigra by Ferrer and colleagues (2007) showed a decreased level of ATP synthase β-
subunit while the levels were increased in frontal cortex of the same patients. Dys-
regulation of complex V following MPTP treatment could be a direct consequence of 
complex I inhibition as less electrons are transferred through the ETC and the proton-
motrice force would be weaker as a direct consequence. 
Inconsistency in the different subunits of mitochondrial ATP synthase has already been 
observed in the literature. In a proteomic study of post-mortem neurons of the substantia 
nigra, Basso and colleagues (2004) had already observed a significant increase in ATP 
synthase δ-subunit while a non-significant decrease in ATP synthase α-subunit was 
observed, consistent with the present findings. Due to the complexity of mitochondrial 
ATP synthase structure and the different roles of each subunit, inconsistency of the 
different subunits following MPTP-induced toxicity could be possible. Both α and β-
subunits were observed to bind nucleotides such as ADP while only the β-subunit had 
the catalytic activity of synthesising ATP (Grover et al., 2008). The decrease in α-
subunit might be linked to a decrease in nucleotide binding probably due to a drop in 
ADP substrate in mitochondria since it was previously hypothesised that ATP 
production might be increased in the cytoplasm via lactate formation. On the contrary, 
an increase in δ-subunit was observed. This subunit was observed to participate in 
holding both F1 and F0 subunits of complex V. Because the catalytic unit seemed to 
decrease in levels, there might have been a compensatory mechanism that increased 
structural subunit levels in order to try and maintain complex V integrity. 
Another oxidative phosphorylation-related protein showed a change in level following 
MPTP-induced toxicity. Electron transfer flavoprotein subunit α (ETF α) was up-
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5.3.3.4
regulated by 49 % compared to controls. ETF was observed to participate in the transfer 
of electrons from reduced acyl CoA via the acyl CoA dehydrogenase in the fatty acid β-
oxidation pathway to FADH2. Electron transfer flavoprotein (ETF) transfers  the 
electrons from FADH2 to electron transfer-:ubiquinone reductase on the ETC. This 
reaction occurred between complex II and complex III of the ETC (Schapira et al., 
2006). Although it has not been observed in previous studies, increased levels seemed 
coherent as a decrease in complex I activity could lead to an increase of complex II 
activity to try and increase ATP synthesis as a compensatory effect.  
 
Although such observations seemed to be in accordance with the literature, it would be 
important to validate these changes in expression using western blot analysis. This 
validation would be important for supporting the hypotheses stated but also to check the 
overall level of each subunit as only one spot was identified for each subunit not taking 
in account any post-translational modifications that could occur following MPTP 
treatment. 
 
 Voltage-dependent-anion channel 1 
 
The last spot identified to show changes in levels following MPTP treatment was 
VDAC1. Two-dimensional gel electrophoresis analysis showed an increase of 30 % 
compared to controls. One-dimensional western blot analysis showed an increase of 200 
%. This difference between the two methods might be due to an underestimation of the 
level of change in the proteomic approach due to variability issues. Moreover 2DE was 
measuring the level of one spot while the antibody based method was measuring the 
total VDAC1 level corresponding to 5 different spots as shown by 2D-blot analysis. 
This observation led to the thought that more than one VDAC1 spot might have 
increased levels following MPTP-induced toxicity. 
VDAC is an outer mitochondrial membrane gated channel (Lemasters and 
Holmuhamedov, 2006) with many important roles in the cell. It can channel small 
molecular weight molecules including cations, nucleotides, creatine and NADH 
(Lemasters and Holmuhamedov, 2006) and has been linked with apoptosis (Shoshan-
Barmatz et al., 2006; Tsujimodo and Shimizu, 2002) and energy storage (Vyssokikh 
and Brdiczka, 2003). 
MPTP-induced toxicity has not previously been linked to VDAC protein levels. 
Nevertheless, VDAC protein and mRNA levels were observed to be elevated following 
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rotenone-induced toxicity in Human SH-SY5Y neuronal cells. This upregulation could 
be inhibited by pre-treatment with an antioxidant (Xiong et al., 2009). Another group, 
Premkumar and Simankov (2002), linked VDAC level dysregulation with dopamine 
toxicity in neuronal cells. In their study, they discovered that VDAC isoforms 1, 2 and 3 
were down-regulated and that overexpression of VDAC was protective of the cells. 
Even though the results were not correlated, dopamine toxicity acted differently to 
rotenone and MPTP, both complex I inhibitors. The role of VDAC in complex I 
inhibition-induced toxicity is not yet fully resolved. 
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CHAPTER VI  MODIFIED EXPRESSION OF VDAC 
 
6.1 INTRODUCTION 
 
6.1.1 The voltage-dependent anion channel 
 
6.1.1.1 Structure and general functions 
 
The voltage-dependent-anion channel (VDAC), also called the mitochondrial porin, was 
first described by Schein and colleagues in 1976 (reviewed in Lawen et al., 2005). It is the 
most abundant protein of the OMM (Vyssokikh and Brdiczka, 2003) and composes a 
channel that is permeable to molecules up to 5 kDa depending on the gating voltage 
(Lemasters et al., 2006). Its structure, as deduced from biochemical and function studies, is 
composed of a transmembrane α-helix and 13 transmembrane β-strands enclosing an 
aqueous channel of 2.5 to 3 nm of internal diameter (Colombini et al., 2009) (Figure 6.1). 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: VDAC folding pattern in the OMM as deduced by functional studies 
Mitochondrial 
IMS 
OMM 
Cytoplasm 
Taken  from Colombini et al., 2009  
  
Three isoforms exist in humans and mice with between 67 % and 71 % homology in amino 
acid sequence (Lawen et al., 2005). VDAC1, the most abundant isoform, has no targeting 
segment in its amino acid sequence and has been found to a lesser extent in other cellular 
membranes, for example the plasma membrane (Lawen et al., 2005). Interestingly, two 
splice-variants of VDAC1 have been found. The VDAC1 isoform found in the plasma 
membrane has 13 more amino acids on the N-terminal end of the sequence than the variant 
found in the OMM (Buettner et al., 2000). 
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Knockdown and overexpression analyses have helped to understand the roles of each 
VDAC isoform. VDAC1 has been found to have a role in foetal survival, which was 
enhanced with VDAC3 expression knockdown (Anflous-Pharaya et al., 2007). Moreover, 
single knockdown of VDAC1 and double knockdowns of VDAC1 and 3 showed a decrease 
in glycolysis, due to an inhibition of hexokinase interaction to the mitochondria (Anflous-
Pharayas et al., 2007). VDAC2, the less prevalent isoform, has been associated with anti-
apoptotic activity (Shoshan-Barmatz et al., 2006). 
Interestingly, VDAC has been observed to be enriched in contact sites between 
mitochondria and between mitochondria and endoplasmic reticulum (ER), indicating a role 
for the channel in the interactions between mitochondria and ER, in addition to between 
mitochondria and the cytoplasm (Shoshan-Barmatz et al., 2006). The list of molecules 
which can pass through the channel includes creatine phosphate, adenine nucleotides (e.g. 
ATP and ADP), inorganic phosphates, succinate, citrate, glutamate, cations (e.g. Ca2+, Na+, 
K+,…) (Lemasters and Holmuhamedov, 2006) and superoxide anion (Han et al., 2003a). 
Permeabilisation of the OMM is thought to be mainly regulated by the permeabilisation of 
VDAC, depending on the voltage state of the channel and on the action of several 
modulators. The channel is known to have different states: the “open state” with high 
conductance, allowing the passage of a range of metabolites, preferentially anions; and the 
“closed state”, with low conductance and, despite the name, allowing cations, such as Ca2+, 
Na+ and K+ to travel through (Rostovtseva and Berzrukov, 2008). Many molecules have 
been observed to interact with VDAC including NADH (tends to a closed state and reduce 
ADP permeability), glutamate, cytoskeletal proteins (e.g. MAP2, actin, gelsolin, dynein 
light chain), GRP75 (decrease channel voltage), the superoxide anion (increases the 
permeability of the channel), ROS and RNS (Hajnoczsky et al., 2002; Lemasters et al., 
2006; Shoshan-Barmatz et al., 2006). Additionally, VDAC has been found to be a target for 
phosphorylation, more particularly for signaling kinases. Kinases able to modulate VDAC 
function include C-Raf, pKA, pKC, GSK-3β, p38 and tyrosine phosphorylating kinases; 
thought to have different effects on the protein state (Lemasters et al., 2006; Hajnoczsky et 
al., 2002, Das et al., 2008; Schwertz et al., 2007). 
Moreover, VDAC has been found to bind a number of proteins. For example, Bcl2-family 
proteins have been found to bind VDAC, resulting in modulation of apoptotic cell death 
(Hajnoczsky et al., 2002). Moreover, VDAC has been also linked to the mitochondrial 
transition pore by interacting with the adenine nucleotide translocator (ANT) and 
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benzodiazepine receptor, increasing the possible involvement of the protein in cell death 
(Tsujimoto and Shimizu, 2002). Other proteins binding and modulating VDAC in a 
metabolic context are hexokinase (HK, specific to VDAC1), creatine kinase (CK) and 
glycerol kinase (Shoshan-Barmatz et al., 2006; Vyssokikh and Brdiczka, 2003). In this 
context, VDAC is proposed to be a link between ATP levels and glycolysis rate, as a 
modulator between the mitochondrial and cytoplasmic metabolic pathways. 
 
6.1.1.2 The role of VDAC in cell death 
 
Whether or not VDAC plays a role in cell death has become a controversial topic. Many 
molecular events described in the last decade tend to show an interaction of VDAC 
isoforms with anti- and pro-apoptotic molecules, implying a role of VDAC in apoptotic cell 
death. Several proteins from the Bcl2 family have been co-immunoprecipitated with VDAC 
isoforms, such as Bax, Bak, Bcl2, Bcl-xL and Bim (Lawnen et al., 2003; Shoshan-Barmatz 
et al., 2006). More particularly, anti-apoptotic molecules have been linked to an “open 
state” (high conductance) of VDAC, while pro-apoptotic molecules have been linked to a 
“closed state” (low conductance). For example, the anti-apoptotic molecule Bcl-xL was 
shown to promote the VDAC “open state” configuration and prevent the low conductance 
configuration, allowing passage of metabolites between both the cytoplasm and the 
mitochondrial intermembrane space, as observed in the normal, healthy cellular state 
(Vander-Heinden et al., 2001). Pro-apoptotic molecules, such as Bax, Bak and truncated 
Bid (tBid) have been shown to interact with VDAC (reviewed in Shoshan-Barmatz et al., 
2006). For example, Bax is thought to oligomerise with tBid molecules to form a pore on 
the OMM, mediating cytochrome c release. The interaction between VDAC and Bax is 
thought to be a trigger for this pore formation, although whether VDAC is physically part 
of this pore still remains to be elucidated (Tsujimoto and Shimizu, 2002; Shoshan-Barmatz 
et al., 2006). Baines and colleagues (2007), using multiple VDAC knockdowns, have 
postulated that these channels were dispensable for apoptosis to happen. Indeed, using a 
double knockdown (VDAC1/3(-/-)) and VDAC2 siRNA (silenced gene), they showed that 
STS-induced apoptosis still occurred, denying the role of VDAC in the apoptotic process. 
Nevertheless, the VDAC1/3(-/-) knockdown, with or without VDAC2 siRNA, seemed to be 
more sensitive to STS-induced toxicity than controls; showing that VDAC isoforms may 
have more an anti-apoptotic role than a pro-apoptotic role in their model. More recently, 
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Tomasello et al. (2009) have concentrated on the VDAC1 isoform in a combination of 
knockdown and overexpression studies. Overexpression of VDAC1 led to mitochondrial 
potential collapse, which could be inhibited by specific inhibitors of (a) the potential 
transition pore (cyclosporine A), (b) ROS production (N-acetyl-cysteine, NAC) and (c) 
apoptosis (Bcl2); however, a broad caspase inhibitor had no effects. Down-regulation of 
VDAC1 slowed cell growth and decreased ATP production but it was evident that VDAC1 
was a dispensable element for cell survival. They also showed that both knock down and 
overexpression of VDAC1 had no effect on STS-induced toxicity. ROS-induced toxicity, 
using selenium as an inducer of oxidative stress, was increased by overexpression of 
VDAC1 but cell death was unaffected by knocking down VDAC. Although there are still 
discrepancies on the specific molecular events involving VDAC, and more particularly 
VDAC1, in apoptosis, it seems clear that the porin has a role in at least some models of 
induced apoptotic cell death.  
As noted by Tomasello et al. (2009), the mitochondrial transition pore has been linked to 
cell death-induced by VDAC overexpression. Indeed, whether or not VDAC is part of the 
transition pore has been debated over the past few years. One of the reasons VDAC was 
originally thought to be part of the transition pore was the characteristics they shared 
(reviewed in Shoshan-Barmatz et al., 2006). They were enriched at contact sites between 
the IMM and OMM; they immunoprecipitated with ANT and cyclophylin D (also thought 
to be part of the transition pore); their voltage dependence, conductance and pore size were 
similar; they both had a role in apoptosis, were inhibited by NADH and were dependent on 
calcium concentrations. Moreover, anti-human VDAC1 antibodies have been shown to 
block the mitochondrial potential collapse and pore opening (Shimizu et al., 2001). 
Nevertheless, Baines et al.’s work (2007) has opened new questions about the potential role 
of VDAC in the transition pore and, although VDAC is thought to have a role in some 
death models in pore forming, it might not form the pore itself (reviewed in Halestrap, 
2009). Interestingly, it has recently been shown that Bax interacts with not only VDAC but 
also with the translocase of the OMM (TOM complex) (Ott et al., 2009). This re-enforced 
the observation that VDAC knock down cells express higher levels of the TOM complex 
protein TOM40; suggesting that the TOM complex can have some roles that are similar to 
VDAC (Antos et al., 2001; Kmita et al., 2004). 
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6.1.1.3 The role of VDAC in glycolysis 
 
The mitochondrial porin has been shown to also have a role in cell survival via its role in 
glucose metabolism. Indeed, HK has been found to bind VDAC1 and this interaction is 
thought to occur to facilitate the access of the enzyme to ATP being produced via the ETC, 
and this would lead to increased glycolysis and oxidative phosphorylation (Golshani-
Hebroni and Bessman, 1997). Binding of HK to VDAC is inhibited by changing glutamate 
72 of the VDAC1 sequence to glutamine (Zaid et al., 2005). Phosphorylation of VDAC1 by 
GSK-3β potentiates cell death accompanied with mitochondrial swelling, cytochrome c 
release and mitochondrial permeability transition (Rostovtseva and Berzrukov, 2008) with 
evidence of pro-apoptotic molecules (e.g. Bax) binding to VDAC1 instead of HK, at the 
same binding site (Anflous-Pharayas et al., 2007). 
 
6.1.2 Electron transfer chain inhibitors 
 
As noted earlier (refer to section 1.1), complex I of the ETC was observed to be decreased 
in PD patients (Brazilai and Mehamed, 2003). Moreover, the ETC was also observed to be 
impaired in other neurodegenerative conditions; for example, impairment of complex II 
was observed in Huntington’s disease (HD) patients (Perez de la Cruz and Santamaria, 
2007) and impairment of complex IV was observed in some models of Alzheimer’s disease 
(AD) (Atamna and Frey, 2007). Whether impairment of the electron transfer chain 
complexes are causes or consequences of neurodegenerative diseases has not yet been 
resolved; however, they are common biochemical characteristics that might lead to other 
features which are common in neurodegenerative conditions. This could be related to the 
fact that all complex inhibition lead to ATP depletion and ROS production (Casarino and 
Bennett, 1999; Coles et al., 1979; Han et al., 2008a; Szabados et al., 2004). 
 
6.1.2.1 Rotenone: a complex I inhibitor 
 
Similarly to MPP+, rotenone has been widely used in research to study the molecular events 
in PD (Zhou et al., 2004). Rotenone is a well known selective inhibitor of complex I that 
was shown to induce progressive degeneration of nigrostriatal neurons and glial cells in rats 
(Bové et al., 2005). Different experimental models showed that it produced Lewy body-like 
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cytoplasmic inclusions in the remaining dopaminergic neurons and rotenone-induced 
toxicity led to aggregation of ubiquitin and α-synuclein in dopaminergic neuroblastoma 
cells (Zhou et al., 2004; Diaz-corrales et al., 2005).  
 
6.1.2.2 3-nitropropionic acid: a complex II inhibitor 
 
3-nitropropionic acid (3-NP) was originally found to cause degeneration of the putamen 
and caudate nucleus associated with severe neurological symptoms in humans. Moreover, 
3-NP has been widely used in the study of HD as its effects on animals showed similar 
biochemical and behavioural features to the disease (reviewed in Brouillet et al., 2005). 3-
NP toxicity was shown to occur via irreversible inhibition of SDH, also known as complex 
II (Coles et al., 1979), which causes the inhibition of the Krebs cycle in addition to 
inhibition of the electron transfer.  
 
6.1.2.3 Antimycin A: a complex III inhibitor 
 
Antimycin A is a complex III inhibitor, more specifically the electron transfer between 
cytochrome b and cytochrome c1 (Izzo et al., 1978). The direct consequences of antimycin 
A toxicity in cultured cells were the usual effects due to ETC inhibition (increase in ROS 
production and ATP depletion) accompanied with collapse of mitochondrial potential, 
leading to apoptotic cell death (Han et al., 2008a).  
 
6.1.2.4 Sodium azide: a complex IV inhibitor 
 
Sodium azide has been shown to cause degeneration of cortical and hypocampal areas in 
rats (Cada et al., 1995); moreover, Bennet et al. (1992) showed that it led to learning 
memory deficit in rats. Sodium azide is a widely used complex IV inhibitor for the study of 
AD (Szabados et al., 2004). The specific molecular events consequent to sodium azide 
treatment in animal models are chemical hypoxia (Reviewed in Szabados et al., 2004). 
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6.1.3 Aims of the chapter 
 
VDAC1 protein level was previously observed to increase by 3-fold following treatment 
with sub-cytotoxic concentrations of MPTP (1 mM for 24 hours, refer to section 5.2.1). 
VDAC1 has been found to have various roles in energy consumption, cell metabolism and 
cell survival (reviewed in Vyssokikh and Brdiczka, 2003), regulated mainly by 
phosphorylation (Hajnoczsky et al., 2002, Das et al., 2008; Schwertz et al., 2007); and a 
variation in protein levels may underline an important process involved in the molecular 
events preceding cell death observed in PD.  
The overall objective of this chapter was to further characterise VDAC1 upregulation 
occurring prior to cell death following inhibition of the ETC. 
The first aim was to check whether other sub-cytotoxic concentrations of MPTP led to 
changes in VDAC levels. Secondly, since MPTP causes inhibition of complex I, via its 
metabolite MPP+, the effects of another complex I inhibitor (rotenone) and inhibitors of 
other complexes (3-NP, antimycin A and sodium azide) on VDAC1 levels were also 
investigated. 
In an attempt to explain how VDAC1 protein levels were upregulated, and more 
particularly, whether it was due to increased gene expression, another aim was to measure 
levels of VDAC1 mRNA following a range of sub-cytotoxic treatments with various 
complex inhibitors. 
A final aim was to investigate the phosphorylation status of VDAC1 following treatment 
with 1 mM MPTP. This hopefully would give some insights into the signaling status of the 
cells and VDAC1 upregulation, whether in favour of cell death or cell survival.  
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6.2 RESULTS 
 
6.2.1 Effects of neurotoxins on VDAC expression 
 
6.2.1.1 Identification of VDAC1 from 2DE using MALDI-TOF mass spectrometry 
 
Figure 6.2 shows a typical 2DE profile and the location of two identified isoforms of 
VDAC (spots 16 and 19). Figure 6.3A shows a typical mass spectrum obtained using 
MALDI-TOF analysis of tryptic fragments of spot 19. The mass list from the spectrum was 
transferred to the Mascot database and a significant positive identification was obtained as 
VDAC1 (figure 6.3B). The peptides covered 81 % of the sequence matched (compared to 
VDAC1_MOUSE sequence from SwissProt database in http://www.uniprot.org), which is 
a large coverage and the score of 215 was highly significant (score > 54). Moreover, this 
spot was identified 12 times using peptide mass fingerprinting using different 2DE, 
confirming the identification. It is worth noting that the Mascot database sequence to which 
the peptide list was compared corresponded to the splice-variant containing 13 extra amino 
acids. The VDAC1 protein found in vivo in the OMM was found to lack these 13 amino 
acids as previously explained. 
 
6.2.1.2 Concentration and time-dependent MPTP effects on VDAC levels 
 
Figure 6.4 shows that VDAC1 levels, monitored using an anti-VDAC1-specific antibody, 
increased following 24 hours exposure to MPTP in a dose-dependent manner. Because only 
one replicate is shown here, no statistical analysis could be undertaken, but VDAC1 levels 
increased with the lowest MPTP concentration used (10 μM).  
Increases in VDAC1 levels were also time-dependent, with some increase evident 
following 8 hours exposure to 1 mM MPTP, becoming significant at 24 hours (figure 6.5). 
Overall, the increase in VDAC1 levels following 1 mM MPTP treatment, normalised for 
total protein loading, was around 3-fold (300 %), in agreement with data shown previously 
(section 5.2.1.4 figure 5.7; n=7). 
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Figure 6.2: 2D-gel electrophoretogram (pI 3-10) stained with SyproRuby showing spots 
identified as VDAC isoforms following peptide mass fingerprinting 
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium supplemented 
with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM MPTP or not (controls) 
for 24 hours. Subcellular fractionation was then carried out. 50 μg proteins from mitochondrial 
fraction for each treatment were fractionated by 2DE (pI 3-10 strips and 12 % resolving gel) and 
visualized using SyproRuby. Spots were picked, trypsinisied, followed by MALDI-TOF mass 
spectrometry and attemps made to identify spots using Mascot database 
(http://www.matrixscience.com). Circled spots were previously identified (refer to chapter III figure 
3.12 and table 3.2). 
Green circled spots: 16. Voltage-dependent-anion channel protein 2 (VDAC2); 32 kDa, pI 7.44 
   19. Voltage-dependent-anion channel 1 (VDAC1); 30 kDa, pI 8.62 
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A. Mass spectrum of VDAC1 obtained by MALDI-TOF analysis  
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B. Mascot database results for VDAC identification 
 
 
 
 
 
 
VDAC1_MOUSE Score: 215 Expect: 5.1e-18 
Voltage-dependent anion-selective channel protein 1 OS=Mus musculus 
Nominal mass (Mr): 32502; Calculated pI value: 8.55 
 
C. Sequence coverage of peptide mass list for VDAC1 identification 
 
Number of mass values matched: 19 
Sequence Coverage: 81% 
     1 MCSFFLVLLL WQNMAVPPTY ADLGKSARDV FTKGYGFGLI KLDLKTKSEN  
    51 GLEFTSSGSA NTETTKVNGS LETKYRWTEY GLTFTEKWNT DNTLGTEITV  
   101 EDQLARGLKL TFDSSFSPNT GKKNAKIKTG YKREHINLGC DVDFDIAGPS  
   151 IRGALVLGYE GWLAGYQMNF ETSKSRVTQS NFAVGYKTDE FQLHTNVNDG  
   201 TEFGGSIYQK VNKKLETAVN LAWTAGNSNT RFGIAAKYQV DPDACFSAKV  
   251 NNSSLIGLGY TQTLKPGIKL TLSALLDGKN VNAGGHKLGL GLEFQA 
Figure 6.3: MALDI-TOF analysis and protein identification of VDAC1 spot 
Spot 19 (figure 6.2) from a silver stained 2DE of mitochondrial samples was picked, trypsinised and 
processed via MALDI-TOF mass spectrometry. The peptide mass list obtained was transferred to 
the Mascot database and one spot was identified as VDAC1.  
A. Mass spectrum obtained by MALDI-TOF.  
B. Identity probability of VDAC1. C. VDAC1 sequence and coverage of peptides from the 
spectrum. Italic amino acid sequence: 13 amino acids thought to be absent in the mitochondrial 
VDAC1 found in vivo. 
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A. Concentration-dependent MPTP effects on VDAC1 levels detected on 1D blots 
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 B. Quantification of concentration-dependent MPTP effects on VDAC1 levels 
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Figure 6.4: VDAC1 protein expression following exposure to different MPTP concentrations 
for 24 hours 
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium supplemented 
with 0.3 mM dbcAMP. Following incubation, cells were treated with different concentrations (0 to 
1 mM) MPTP for 24 hours. Subcellular fractionation was then carried out.  
A. 20 μg protein from mitochondrial fractions for each treatment were fractionated by 1D-SDS-
PAGE (12 % resolving gel) and then transferred onto a nitrocellulose membrane. Blots were stained 
with copper (refer to section 2.2.6.1) to check for protein loading before probing with anti-VDAC 
antibody (1 in 1,000 dilution) followed by the ECL detection procedure (refer to section 2.2.6.2). 
B. Densitometry of each band was quantified using Aida software. Each band was compared to total 
protein. The histogram bars represents % VDAC / total protein ratio versus controls (n = 1). 
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 A. Time-dependent MPTP effects on VDAC levels detected on 1D blots 
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Figure 6.5: VDAC protein expression following exposure to 1 mM MPTP treatment over 24 
hour time-course 
Mouse N2a neuroblastoma cells were differentiated for 16 hours in serum free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM MPTP 
over a 24 hour time-course. Subcellular fractionation was then carried out.  
A. 20 μg protein from mitochondrial fractions for each treatment were fractionated by 1D-SDS-
PAGE (12 % resolving gel) and then transferred onto a nitrocellulose membrane. Blots were stained 
with copper (refer to section 2.2.6.1) to check for protein loading before probing with anti-VDAC1 
antibody (1 in 1,000 dilution) followed by the ECL detection procedure (refer to section 2.2.6.2). 
B. Densitometry of each band was quantified using Aida software. Each band was compared to total 
protein. The histogram bars represents % VDAC / total protein ratio versus controls ± SEM. All * 
values p<0.05 when compared to respective controls. (n = 3). 
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6.2.1.3 Effects of other complex inhibitors on VDAC protein levels 
 
In order to investigate whether or not the effect of MPTP on VDAC1 levels was specific to 
complex I inhibition, the effects of other complex inhibitors were analysed.  
Sub-cytotoxic concentrations of different complex inhibitors were first established by 
analysing cell viability using a range of inhibitor concentrations. Figure 6.6 shows the 
highest concentration tolerated without cell death (sub-cytotoxic) and the minimum 
concentration leading to cell death (cytotoxic). The sub-cytotoxic concentrations, following 
24 hour exposure, used for further analyses were 2.5 μM for rotenone, 1 mM for 3-NP, 20 
μM for antimycin A and 0.2 mM for sodium azide; inhibiting complexes I, II, III and IV of 
the electron transfer chain, respectively.  
Using these sub-cytotoxic concentrations, the effects of each complex inhibitor on VDAC1 
protein levels were investigated using a western blot approach (figure 6.7). All inhibitors 
resulted in a mean increase in VDAC1 protein levels, statistically significant with MPTP, in 
agreement with previous data, and with rotenone. 3-NP and sodium azide did not show 
significant effects on VDAC1 levels following MPTP treatment since only duplicates were 
analysed, although both replicates showed an increase. With antimycin A, one of the 
duplicates showed upregulation of VDAC1 protein levels, while the second showed no 
effect (figure 6.7B).  
 
6.2.1.4 VDAC1 mRNA expression 
 
As VDAC1 protein levels were shown to be increased, it was interesting to investigate 
whether this was due to increased transcription.  
First, semi-quantitative RT-PCR was carried out, using GAPDH as a housekeeping gene. 
Mouse VDAC1- and GAPDH-specific primers were used to amplify gene transcripts in 
control and MPTP treated mouse N2a neuroblastoma cells (Figure 6.8A). Quantification of 
PCR products using the AIDA software (figure 6.8B) revealed a 30 % increase in VDAC1 
mRNA levels following MPTP treatment; however this was not significant using a paired t-
test. Nevertheless, the probability was approaching significance (p = 0.06; n = 5). 
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Figure 6.6: Sub-cytotoxic and cytotoxic concentrations of various complex inhibitors 
measured by MTT reduction assay 
Mouse N2a neuroblastoma cells were differentiated for 16 hours in serum-free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with different 
concentrations (0 to 5 mM) of complex inhibitors for 24 hours. MTT reduction assay was then 
performed. Sub-cytotoxic and cytotoxic concentrations are shown. All * values p<0.05 when 
compared to respective controls using a paired t-test. (n = 7). 
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 A. Effects of complex inhibitors on VDAC1 protein levels 
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B. VDAC1 protein levels following treatments with complex inhibitors 
 
Inhibitors Sample 1 Sample 2 Sample 3 Average Range of variation
1 mM MPTP 245 159 154 186 * + 59; - 32 
2.5 μM rotenone 179 117 187 161 * + 26; - 44 
1 mM 3-NP 363 201  282 +/- 81 
20 μM antimycin A 216 100  158 +/- 58 
0.2 mM sodium azide 260 128  194 +/- 66 
 
Figure 6.7: Effects of subcytotoxic concentrations of complex inhibitors on VDAC1 protein 
levels using western blot analysis 
Mouse N2a neuroblastoma cells were differentiated for 16 hours in serum-free medium 
supplemented with 0.3 mM dbcAMP prior to treatment with sub-cytotoxic concentrations of 
various electron transfer inhibitors for 24 hours. Subcellular fractionation was then carried out to 
isolate mitochondria.  
A. 20 μg protein from mitochondrial fractions for each treatment were fractionated by 1D-SDS-
PAGE (12 % resolving gel) and then transferred onto a nitrocellulose membrane. Blots were stained 
with copper (refer to section 2.2.6.1) to check for protein loading before probing with anti-VDAC1 
antibody (1 in 1,000 dilution) followed by the ECL detection procedure (refer to section 2.2.6.2). 
B. Table representing densitometry data showing the % VDAC1 / total protein ratio compared to 
controls. All * values p≤0.05 when compared to respective controls using a paired t-test. (n = 3).  
3-NP: 3-nitropropionic acid. 
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A. Effects of MPTP on VDAC1 mRNA expression using semi-quantitative RT-PCR 
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Figure 6.8: Effects of 1 mM MPTP for 24 hours VDAC1 mRNA expression as measured by 
semi-quantitative RT-PCR 
Mouse N2a neuroblastoma cells were differentiated for 16 hours in serum-free medium 
supplemented with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM MPTP 
for 24 hours. mRNA was then extracted and reverse transcribed to cDNA. Using VDAC and 
GAPDH specific primers, cDNA amplicons were amplified. PCR products were electrophoresed 
onto an agarose gel and visualized with U.V. light. A. Pictures were taken and B. bands were 
quantified using the AIDA software. % VDAC / GAPDH intensities ratios were calculated, 
compared to controls. All * values p<0.05 when compared to respective controls. (n = 5).  
–ve: negative control (primer mix with no DNA in the PCR mixture). 
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Thus, real-time PCR was used to provide more accurate estimates of mRNA levels (see 
section 2.2.14 for detailed information). Standards for each gene were used in order to 
quantify the exact number of mRNA copies in each sample, normalised against numbers of 
GAPDH mRNA copies. VDAC1 and GAPDH cDNA inserts were prepared, cloned, 
amplified, purified and serial dilutions were prepared to give standards with known copy 
number. Figure 6.9 shows an example of the results for VDAC1 standards.  
From the real-time PCR profile (figure 6.9A), the cycle number for the threshold value (Ct) 
was provided and used to compile a standard calibration of Ct versus concentration (figure 
6.9B), used to then calculate copy numbers in unknown samples (figure 6.9C). VDAC1 
mRNA was expressed as ratio of molecules VDAC1 mRNA per 1,000 molecules GAPDH 
mRNA. Figure 6.10 shows the average ratios for each sample. No significant differences 
were observed following 1 mM MPTP treatment over a 24 hour time-course compared to 
respective controls (figure 6.10A). Similarly, no significant differences were observed in 
samples treated with sub-cytotoxic concentrations of the other complex inhibitors following 
24 hour treatments (rotenone, 3-NP, antimycin A and sodium azide) (figure 6.10B). 
 
6.2.2 VDAC post-translational modifications 
 
6.2.2.1 Multiple forms of VDAC1 identified on 2D-western blot analysis 
 
Using 2D-blot analysis, multiple forms were detected by the anti-VDAC1 antibody (refer to 
figure 5.7). Figure 6.11 shows different replicates of pairs of MPTP treated and respective 
control samples electrophoresed, transferred to membrane and immunoprobed in parallel. 
In the pI 3-10 analysis, detection of VDAC1 forms was variable between replicates (figure 
6.11A). Despite the variability, the overall intensity increased following 1 mM MPTP 
treatment for 24 hours. Moreover, two to three small spots seemed to appear with an acidic 
shift and the intensity of the trail on the basic side of the main spot also increased 
consistently following MPTP exposure. 
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A. Real-time PCR graph results for VDAC1 mRNA standard quantitation 
 
 
 
 
 
 
 
 
 
No. Type Ct Given Conc (copies/reaction)
Calc Conc 
(copies/reaction) % Var 
A1 Standard 12.13 10,000,000.00 9,429,756 5.70% 
A2 Standard 15.76 1,000,000.00 996,254 0.40% 
A3 Standard 19.43 100,000.00 102,470 2.50% 
A4 Standard 23.00 10,000.00 11,261 12.60%
A5 Standard 26.92 1,000.00 998 0.20% 
A6 Standard 31.76 100 92 7.60% 
S1 24h control 15.07  1,531,103  
S2 24h MPTP 14.79  1,818,193  
Figure 6.9: Example of quantitative analysis of VDAC1 mRNA expression using real-time 
PCR  
VDAC1 PCR products were cloned into the pCR2.1 vector followed by transformation into TOP10 
E.coli. Following amplification of the plasmid, the DNA fragment was extracted, purified and 
linearised. Different dilutions were prepared prior to analysis by real-time PCR (refer to sections 
2.2.14.2-4).  
A. real-time PCR results using the Rotor-gene 6000 series software. Red line: threshold 
automatically calculated by the software. The no. cycles of each standard at the threshold are called 
Ct values for each sample.  
B. Standard calibration for VDAC1 standards of Ct values against dilutions (copies / reaction).  
C. Table showing the raw data for each standard value and two examples of samples. 
Conc: concentration; Var: variation 
C. Raw data from the standard calibration for VDAC1 mRNA expression analysis 
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 A. Effects of 1 mM MPTP on VDAC1 mRNA expression using real-time PCR 
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 B. Effects of different complex inhibitors on VDAC1 mRNA expression 
using real-time PCR  
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Figure 6.10: Effects of electron transfer inhibitors on VDAC1 mRNA expression as measured 
by real-time PCR 
Mouse N2a neuroblastomas were differentiated for 16 hours in serum-free medium supplemented 
with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM MPTP for up to 24 
hours (A) or with other complex inhibitors for 24 hours (B). mRNA were then extracted and reverse 
transcribed to cDNA. Using VDAC1 and GAPDH specific primers, cDNA amplicons were 
amplified using real-time PCR. Relative amount of VDAC1 and GAPDH amplicons could be 
calculated by comparing to a standard calibration for each gene (figure 6.8). The data are expressed 
as molecules VDAC1 mRNA / 1,000 molecules GAPDH mRNA ratios ± SEM and each was 
compared to respective control. All * values p<0.05 when compared to respective controls. (n = 3 
each run twice independently). 3-NP: 3-nitroprpionic acid. 
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Figure 6.11: Detection of VDAC1 isoforms on 2D-blot analysis using pI 3-10 and pI 7-10 strips 
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium supplemented 
with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM MPTP for 24 hours. 
Subcellular fractionation was then carried out. 50 μg protein from mitochondrial fractions for each 
treatment were fractionated by 2DE (12 % resolving gel) with A. pI 3-10 IPG strips (n = 4) and B. 
pI 7-10 IPG strips (n = 3) and then transferred onto a nitrocellulose membrane. Blots were stained 
with copper (refer to section 2.2.6.1) to check for protein loading before probing with anti-VDAC 
antibody (1 in 1,000 dilution) followed by the ECL detection procedure (refer to section 2.2.6.2). 
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Further analysis of these different spots was attempted using a more focused pI range (pI 7-
10) for 2D blot analysis. Figure 6.11B shows that only 2 forms were observed compared to 
the multiple spots detected with the same antibody using pI 3-10 IPG strips. Total VDAC 
detection using pI 7-10 strips consistently increased following 1 mM MPTP treatment. 
 
6.2.2.2 Serine phosphorylation of VDAC1 increased following MPTP treatment 
 
Following the observation that several spots were detected by the anti-VDAC1 antibody 
using 2D-blot analysis, it was hypothesized that these forms might be, at least in part, due 
to post-translational modifications. Anti-phospho-specific antibodies were then used to 
observe whether phosphorylated forms would co-localise with spots detected with the anti-
VDAC1 antibody.  
Figure 6.12A shows an electrophoretogram of 1 mM MPTP treated cells and controls 
blotted onto a membrane and probed with an anti-phosphoserine antibody. As before 
(section 5.2.2.1), background staining was high in these blots. However, two faint spots 
were detected in the controls. More intense spots were detected following MPTP treatment 
with the apparition of one or two more spots with an acidic shift. The same membranes 
were stripped to remove the primary and secondary antibodies and re-probed for VDAC1 
detection. The control showed two highly stained spots co-localised with phosphoserine. 
The MPTP treated sample showed one big VDAC1 spot accompanied by 3 small spots with 
an acidic shift and a trail on the basic side. The AIDA software was used to quantify the 
signal intensity in the main spot using the anti-phosphoserine and anti-VDAC1 antibodies 
in treated and control samples. The main spot was used because it was easily detected. 
Phosphoserine / VDAC1 ratio was 3.8-fold increased following 1 mM MPTP treatment for 
24 hours (n = 2, 3.0 and 4.6-fold increase for each replicate). 
 
6.2.2.3 Threonine phosphorylation of VDAC1 decreased following MPTP treatment 
 
Similar analysis to phosphoserine investigation was attempted using an anti-
phosphothreonine antibody. The detection of phosphothreonine proved difficult to observe 
and background staining was high, as previously recorded (section 5.2.2.1).  
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Figure 6.12: Co-localisation of phosphorylated residues and VDAC1 using 2D-blot analysis 
Mouse N2a neuroblastomas were differentiated for 16 hours in serum free medium supplemented 
with 0.3 mM dbcAMP. Following incubation, cells were treated with 1 mM MPTP for 24 hours. 
Subcellular fractionation was then carried out. 50 μg protein from mitochondrial fractions for each 
treatment were fractionated by 2DE (12 % resolving gel) and then transferred onto a nitrocellulose 
membrane. Blots were stained with copper to check for protein loading before cutting the blot at the 
molecular level of VDAC1. Then the membrane was probed with either A. anti-phosphoserine or B. 
anti-phosphothreonine antibodies at 1 in 500 dilution followed by the ECL detection procedure. 
Antibodies were then stripped of the blot and membranes were re-probed with anti-VDAC antibody 
at 1 in 1,000 dilution (refer to section 2.2.11). 
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However, on few occasions, successful staining was achieved. For example, using pI 7-10 
IPG strips, one distinct spot was observed with phosphothreonine detection in both MPTP 
treated samples and controls (figure 6.12B). This spot had a reduced intensity following 
MPTP treatment; indeed, the phosphothreonine / VDAC1 ratio was 53 % (n = 1).  
 
Additionally, tyrosine phosphorylation analysis was attempted but was not successful. 
 
6.2.2.4 Potential phosphorylated peptides observed using peptide mass fingerprinting 
 
Parallel to western blot analysis, peptide mass fingerprinting was used to observe the 
presence of phosphorylated peptides in the trypsinised spot formely identified as VDAC1 
using 2DE (spot 19 in figure 6.1). Two phosphorylated peptides were observed containing 
threonine and serine phosphorylation sites (Figure 6.13). Both peptides were identified to 
possess sites predicted to be kinase targets. As described in figure 6.13B, peptide (a) 
contained 2 sites for pKC, and peptide mass fingerprinting analysis showed that only one of 
these sites was phosphorylated. Peptide (b) had 3 predicted sites, two for pKC and one for 
both p38 and creatine kinase I (CKI), and peptide mass fingerprinting analysis showed that 
two out of the three were phosphorylated in the spot analysed. These data are consistent 
with antibody-based analyses since they infer the possibility that both serine and threonine 
phosphorylations are present in the main spot identified as VDAC1. 
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 A. Identification of two phosphopeptides by MALDI-TOF analysis 
 
AVPPTYADLG KSARDVFTKG YGFGLIKLDL KTKSENGLEF TSSGSANTET TKVNGSLETK 
YRWTEYGLTF TEKWNTDNTL GTEITVEDQL ARGLKLTFDS SFSPNTGKKN AKIKTGYKRE 
HINLGCDVDF DIAGPSIRGA LVLGYEGWLA GYQMNFETSK SRVTQSNFAV GYKTDEFQLH 
TNVNDGTEFG GSIYQKVNKK LETAVNLAWT AGNSNTRFGI AAKYQVDPDA CFSAKVNNSS 
LIGLGYTQTL KPGIKLTLSA LLDGKNVNAG GHKLGLGLEF QA 
 
B. Potential kinase phosphorylation sites on both phosphopeptides 
 
 
 
 
 
 
 
VDAC1 
sequence site 
Peptide 
mass (Da) 
Missed trypsin 
cleavage Amino acid sequence 
Phosphorylation 
site no. 
26-33 1002.57 1 SARDVFTK 1 (S/T) 
110-123 1688.79 1 LTFDSSFSPNTGKK 2 (S/T) 
 
Figure 6.13: Mouse VDAC1 amino acid sequence showing 2 phosphopeptides identified by 
MALDI-TOF PMF with potential  kinase phosphorylation sites on each peptide 
Mitochondrial fraction was electrophoresed onto a 2-DE (pI 3-10) followed by silver staining. Spots 
were picked, trypsinised and processed via MALDI-TOF mass spectrometry. The peptide mass list 
obtained was transferred to the Mascot database. 
A. Two phosphopeptides of VDAC1 were identified by PMF. 
B. Predicted kinase phosphorylation sites as calculated by the NetPhosK algorithm in 
www.expasy.org/tools. 
a) Peptide found only in the MPTP treated samples with one site phosphorylated out of the 
two predicted sites. 
b) Peptide found in both control and MPTP treatment samples with two sites 
phosphorylated out of the three predicted sites.  
C. The table describes the characteristics of each phosphopeptide as identified by peptide mass 
fingerprinting. CKI: creatine kinase I; pKC: protein kinase C.  
 
SARDVFTK
pKC pKC
a) 
LTFDSSFSPNTGK
pKC pKC 
P38 or 
CKI 
b) 
C. Characteristics of phosphopeptides as identified by Mascot database 
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6.3 DISCUSSION 
 
6.3.1 Identification of VDAC1 isoforms in the mitochondrial proteome  
 
Following evidence that VDAC1 protein levels were increased following treatment with 
sub-cytotoxic concentrations of MPTP using a quantitative analysis of the mitochondrial 
proteome resolved by 2DE, further analysis was carried out on the VDAC protein, 
concentrating particularly on the VDAC1 isoform.  
The mitochondrial proteome resolved using 2DE using pI 3-10 IPG strips and total protein 
stains (silver stain and SyproRuby dye) revealed only two spots identified as VDAC. 
Indeed, one spot was identified as VDAC1 with a molecular weight around 30 kDa and pI 
8.6 and one spot was identified as VDAC2 with a molecular weight around 32 kDa and pI 
7.44 (figure 6.1 and 3.12). VDAC3 was not identified in the proteome profile; this could be 
because it was hidden by the VDAC1 spot (VDAC3 molecular weight 31 kDa and pI 9), 
not focused as its pI is very basic, or not successfully identified by peptide mass 
fingerprinting. The spot representing VDAC1 was intense, particularly compared to the 
VDAC2 spot, consistent with observations that VDAC1 is the most abundant isoform 
present on the OMM (Yamamoto et al., 2006).  
Because VDAC1 was the isoform showing an upregulation in protein levels (section 
5.2.1.1, figure 5.1 and table 5.1), this study concentrated on the VDAC1 isoform. Peptide 
mass fingerprinting analysis of the VDAC1 spot covered 81 % of the total sequence 
showing a high confidence of the identity of the spot. However, the sequence compared 
with by the Mascot database was a total of 296 amino acids. As explained earlier, two 
splice-variants exist, differing in 13 amino acids and the form found in the OMM lacks the 
first 13 amino acids of the N-terminus (283 amino acids) (Buettner et al., 2000). Consistent 
with this comment is the observation that, out of the 12 successful attempts to identify 
VDAC1 using MALDI-TOF and the Mascot database, none of the 13 first amino acids 
were present. 
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6.3.2 Changes in VDAC1 protein levels following MPTP treatment 
 
6.3.2.1 Links between increased VDAC1 levels and cell death markers 
 
Increases in VDAC1 protein levels were MPTP concentration- and time-dependent; 
although the increase was only significant with 1 mM MPTP treatment for 24 hours. 
Because transient caspase activity was observed at the 2 hour time-point with 1 mM MPTP 
and 10 μM for 24 hours (refer to section 4.2.2.5), it could be argued that VDAC1 levels 
should have been checked at the 2 hour time-point with 1 mM MPTP and earlier time-
points. However, changes in VDAC1 levels with 1 mM MPTP were not significant at 4 
hours and it is possible that caspase activation is not linked to VDAC1 levels since transient 
activity of caspase-3/7 was observed following 10 μM MPTP treatment for 24 hours while 
no changes in VDAC1 levels were observed. 
By 24 hours, 1 mM MPTP led to a non-significant reduction (20 %) of mitochondrial 
membrane potential, while a higher dose, 2 mM MPTP, led to a significant decrease (40 %) 
(refer to section 4.2.1.5), suggesting that the increase in VDAC1 protein levels preceded a 
reduction in mitochondrial membrane potential. This agrees with the hypothesis that 
VDAC may be playing a role in the depolarisation of mitochondria and in the formation of 
the transition pore (see introduction section 6.1.1.1). Since there was no evidence of 
apoptotic factors in the present model (following 1 mM MPTP for 24 hours), a potential 
role of VDAC in apoptotic cell following MPTP is not discussed here. 
 
6.3.2.2 Effects of other inhibitors of the electron transfer chain on VDAC1 levels 
 
The main effects of MPTP are known to occur via the inhibition of complex I, via its 
metabolite MPP+ (Langston et al., 1983; Ramsay et al., 1987). To check whether increased 
VDAC1 protein levels were linked to specific inhibition of complex I or general inhibition 
of the ETC, the effects of other complex inhibitors on VDAC1 levels were investigated. 
Treatment with sub-cytotoxic concentrations of another complex I inhibitor, rotenone, also 
increased VDAC1 levels by around 60 %. Such an increase was also observed in a 
preliminary study carried out by an undergraduate student in-house (data not published) 
using the same cell model and analysing mitochondrial extracts following treatment with 
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sub-cytotoxic concentrations of rotenone. Additionally, Xiong et al. (2008) showed similar 
increases in VDAC following rotenone treatment of human SH-SY5Y neuronal cells. 
3-NP and sodium azide, inhibiting complex II and IV, respectively, also resulted in 
increases in VDAC1 levels, based on duplicate samples, whilst antimycin A (complex III 
inhibitor) treatment increased VDAC1 levels in one of the two replicates. Since a study 
undertaken in-house by an undergraduate student using the same model also showed an 
increase in VDAC1 levels following treatment with antimycin A, it is likely that complex 
III inhibition leads to increased VDAC1 levels. Thus it can be concluded that general ETC 
inhibition leads to increases in VDAC1 protein levels in mouse N2a neuroblastoma cells.  
Using a similar proteomic approach with post-mortem brain regions of patients with Down 
syndrome and AD, Yoo and colleagues (2001) have also observed changes in VDAC 
isoforms. They found that VDAC1 levels were elevated and VDAC2 levels were 
unchanged in brain patients of Down syndrome compared to controls, similar to the results 
observed in the present study in the PD model. However, in brains of AD patients, they 
found that VDAC1 protein levels were decreased, while VDAC2 levels were increased in 
the frontal cortex and thalamus of patients. The combined results indicate dysregulated 
levels of VDAC isoforms in neurodegeneration. 
 
6.3.2.3 Significance of increased levels of VDAC1 
 
Increased levels of a protein can be due to a number of factors, including (a) upregulation 
of transcription and/or (b) increased translation and/or (c) decreased degradation of the 
protein. In the present study, VDAC1 mRNA levels, as shown by semi-quantitative RT-
PCR and quantitative real-time PCR, were not significantly increased following treatment 
with 1 mM MPTP over 24 hours or treatment with sub-cytotoxic concentrations of other 
complex inhibitors, showing that the increased protein levels were not regulated at the 
transcriptional level in the present model. This is not in agreement with the work carried 
out by Xiong et al., (2008), where rotenone treatment of human SH-SY5Y neuronal cells 
led to increased VDAC mRNA expression; however they did not define precisely which 
isoform was studied and they used cytotoxic concentrations of rotenone, which could 
explain the difference with the present study. 
Thus, in the present model, increased VDAC1 protein levels could be due to an increase in 
VDAC1 mRNA translation and/or in a decrease in VDAC1 degradation. Impairment in 
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proteolytic pathways is one of the hallmarks of PD and other neurodegenerative conditions 
such as AD and HD (Lee et al., 2004; McNaught et al., 2002; Van Tijn et al., 2007; Hunter 
et al., 2007). More particularly, MPP+ treated human SH-SY5Y cells showed a decreased 
activity of the 20S component of the ubiquitin-proteasome system (Caneda-Ferron et al., 
2008); moreover, proteins from the OMM have been found ubiquitinated and thought to be 
degraded by the proteasome (Neutzner et al., 2007). It is therefore possible that VDAC1 
protein levels increased as a result of decreased proteolysis of the protein, although 
increased translation of the protein could still be accompanying this phenomenon. 
 
Complex I inhibition, as well as inhibition of other complexes from the ETC, could result 
in two common events: decrease in ATP production by oxidative phosphorylation and 
increased ROS production (Wu et al., 1990; Chiueh et al., 1993; McGeer and McGeer, 
1998; Perez-de la Cruz and Santamaria, 2007). Upregulation of VDAC1 could be linked to 
these two events as it was observed by inhibiting the four complexes. The channel has been 
linked to ATP energy stores by its interaction with several molecules, of which the two 
most interesting for the present project are HK and CK. At normal physiological 
conditions, VDAC has a high conductance with preference for channelling anionic 
metabolites (e.g. ATP, ADP and AMP). Following ATP production via oxidative 
phosphorylation, ATP tends to exit mitochondria via VDAC and ADP enters the organelle 
to be used as substrate for renewal of ATP production. It is thought that HK and CK bind 
VDAC to have a direct access to their common substrate, ATP. VDAC-bound hexokinase 
drives the glycolysis rate, while VDAC-bound creatine kinase drives ATP storage, both 
kinases competing for the same binding site on VDAC channel as well as competing with 
pro-apoptotic molecules, preventing apoptosis (Anflous-Pharayas et al., 2007). 
Interestingly, Chalmers-Redman et al. (1999) have shown that supplementation of glucose 
reduced MPP+ toxicity in PC12 cells. Moreover, when glycolysis was blocked by glucose 
depletion, MPP+-induced toxicity was exacerbated (Basma et al., 1992). This protective 
effect of glycolysis could be illustrated by a corresponding binding of HK competing with 
pro-apoptotic molecules and preventing apoptosis. Similarly, another well known 
protective event that has not been completely explained yet was the protective effect of 
creatine in neurodegeneration and other diseases. For example, in ischemia, creatine was 
found to buffer depletion of ATP stores and to delay synaptic failure by preventing muscle 
and heart cell death (Matthews et al., 1999). Brewer and Wallimann (2000) found that 
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creatine was protective of glutamate- and β-amyloid-induced toxicity in rat hippocampal 
neurons, as a model of AD. Ferrante and colleagues (2000) found that creatine was 
neuroprotective in a mouse model of HD. Thus, creatine has been studied as a potential 
therapeutic molecule for neurodegenerative diseases in the last decade. It was originally 
thought to be due to its role in buffering ATP energy (Brewer and Wallimann, 2000) but an 
additional or combinational effect could be due to the binding of CK to VDAC, preventing 
pro-apoptotic molecules from interacting with the channel and mitochondrial pore opening. 
Another common effect of inhibition of the ETC is increased ROS production (Han et al., 
2003). Han and colleages (2003a) have shown that VDAC had a role in the diffusion of O2-• 
from the IMS to the cytoplasm. This diffusion can exacerbate the oxidative damage by 
extending the effects all over the cell. This could be a molecular event that might contribute 
to MPTP-induced toxicity.  
 
In general, VDAC1 overexpression has often been linked to cell death in a variety of 
organisms (Tomasello et al., 2009 as discussed in introduction; Xiong et al., 2008, as 
discussed previously; and reviewed in Shoshan-Barmatz et al., 2006). It is worth quoting 
that overexpression of VDAC has also been observed in cell survival conditions, in cancer 
cells but this could account as a consequence of upregulation of HK, leading to increased 
cell survival (Shinohara et al., 2000). Thus, in the present model, following electron 
transfer inhibition and, more particularly, MPTP-induced complex I inhibition, the 
upregulation of VDAC1 protein levels could be linked to pro-apoptotic events. As 
illustrated in figure 6.14, several molecular events can lead to the same consequence. This 
is a very important hypothesis as this upregulation of VDAC1 occurred prior to cell death 
and could be used as a marker of neurodegeneration. However, such a model still needs to 
be validated by investigating other molecular events such as HK and CK binding to 
VDAC1, expression and localisation of Bcl2 family molecules and cellular state following 
MPTP-induced toxicity (as opposed to sub-cytotoxicity).  
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Figure 6.14: Hypothetic molecular events of MPTP effects leading to cell death  
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Additionally, VDAC has been observed to be the target of many signaling kinases, 
regulating the binding of molecules to the channel (Das et al., 2008; Schwertz et al., 2007). 
Variations in kinase activities have been observed in MPTP-induced toxicity and in other 
models of PD (Salinas et al., 2001; De Girolamo et al., 2006; King et al., 2008). 
Investigating VDAC1 phosphorylation states and uncovering the kinases involved in this 
process following MPTP-induced toxicity could unravel more particular molecular events 
involved in MPTP-induced toxicity.  
 
6.3.3 Phosphorylation state of VDAC1 following MPTP treatment 
 
An attempt to analyse VDAC1 phosphorylation state was undertaken using 2D-blot 
analysis. Such analysis was difficult as the anti-phospho-amino acid antibodies were not 
specific to VDAC1, leading to a high background and necessity to co-localise the VDAC1 
spots with spots observed using anti-phosphoserine and anti-phosphothreonine antibodies. 
Nevertheless, preliminary data indicated an increase in serine phosphorylation and a 
decrease in threonine phosphorylation on the VDAC protein, but of course the precise 
phosphorylation sites could not be ascertained using these antibody reagents.  
In order to investigate VDAC1 phosphorylation sites, peptide mass fingerprinting was 
performed to search for phosphopeptides in the peptide mixture. Several phosphorylation 
sites were detected on two different phosphopeptides. However, no confirmation using 
post-source decay analysis was obtained so the presence of these peptides and exact site of 
phosphorylations were not validated. Moreover, the phosphorylated sites shown in these 
phosphopeptides are predicted sites by consensus sequences and only one of the sites was 
found in vivo in previous studies (the pKC serine phosphorylation site on peptide a; Jaburek 
et al., 2006).  
Nevertheless, these analyses showed that VDAC1 spots were phosphorylated on serine and 
threonine residues, particularly the main spot originally identified by peptide mass 
fingerprinting following 2DE. 
A few phosphorylation sites and targeting kinases of VDAC1 have been found in vivo, 
related in the literature. Indeed, pKC-ε was found to phosphorylate serine 12 on VDAC1; 
however, the consequences of this phosphorylation have yet to be resolved (Jaburek et al., 
2006). Another kinase shown to phosphorylate VDAC1 is GSK-3β. Two sites have been 
found to potentially be phosphorylated by this kinase on the VDAC1 sequence, threonine 
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51 (Pastorino et al., 2005) and serine 136 (Jaburek et al., 2006). Pastorino et al. (2005) 
showed that Akt inhibition led to GSK-3β activation leading to VDAC1 phosphorylation on 
threonine 51, decreasing the binding of HK to VDAC1. The inverse pathway was also 
happening, activation of Akt led to inhibition of GSK-3β leading to decreased 
phosphorylation of VDAC1, increasing the binding of HK to VDAC1. Other consequences 
of GSK-3β activation were blockade of the transition pore and decrease in ATP production 
(Das et al., 2008) probably due to a decrease in complex I activity (King et al., 2008). 
Interestingly, activation of GSK-3β also exacerbated the toxic effects of MPP+ toxicity in 
SH-SY5Y cells (King et al., 2008). The latter is consistent with observations in PC12 cells 
showing that phosphorylation (i.e. activation) of Akt was protective from MPP+ toxicity 
(Salinas et al., 2001), probably due to increased hexokinase binding to VDAC1 as shown in 
rat fibroblasts (Gottlob et al., 2001).  
Another signaling kinase, p38 MAPK, is involved in VDAC1 phosphorylation and possibly 
in PD molecular events. Indeed activation of p38 indirectly increases VDAC1 
phosphorylation (Schwertz et al., 2007), and a p38 consensus sequence is present on 
VDAC1 (figure 6.13Bb). Moreover, p38 inhibition was shown to be protective of the pro-
apoptotic events consequent to VDAC1 overexpression in Human Hela cells (Tomasello et 
al., 2009). The neurotoxin 6-OHDA, mimicking PD biochemical features, has been shown 
to cause transient p38 activation concomitant with Bax-dependent apoptosis (Gomez-
Lazaro et al., 2008), consistent with the previous observations that inhibition of p38 was 
protective.  
The mode of actions of GSK-3β and p38 in cellular models of PD are consistent with the 
consequences following VDAC1 phosphorylation via these two kinases, directly or 
indirectly. Nevertheless, additional research is needed to confirm a role for GSK-3β and/or 
p38-dependent VDAC1 phosphorylation in MPTP-induced cytotoxicity in mouse N2a 
neuroblastoma cells. In addition it should be noted that other signaling kinases have been 
linked to VDAC phosphorylation, such as C-Raf kinase (LeMellay et al., 2002) and cAMP-
dependent pKA (Bera et al., 1995), in particular, both known to be involved in the 
interaction of VDAC with Bcl2 family proteins. 
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7.1 STUDY OF THE MITOCHONDRIAL PROTEOME  
 
7.1.1 Mitochondrial enrichment and purity following subcellular fractionation 
 
Following subcellular fractionation of mouse N2a neuroblastoma cell extracts, 
mitochondrial fractions were observed to be enriched over 5-fold. These fractions were 
found to have negligible contamination by cytosol, nuclei andendoplasmic reticulum. 
Although some proteins from the ER were detected in the mitochondrial proteome on 2DE, 
these were mainly proteins known to interact with the mitochondrial membrane.  
Mitochondrial fractions were found to be slightly contaminated with lysosomes; however, 
compared to the mitochondrial enrichment and the low amount of material available from 
cultured cells, it was decided that this contamination was not an issue in the present study. 
2DE analysis also showed that proteins from all mitochondrial sub-localisations were 
present including from the OMM, for example VDAC isoforms, showing the integrity of 
the organelle. 
 
7.1.2 Mitochondrial proteome resolved on mini-2DE 
 
Mitochondrial fractions resolved on 2DE showed up to 400 spots (using mini-2D-gels and 
broad range pI 3-10). Although this number seemed low compared to 1,098 proteins found 
in a comprehensive study of the mouse mitochondrial proteome (Pagliarini et al., 2008), 
phosphorylated forms could be observed using ProQ Diamond that were not visualised 
using total protein stains indicating that more proteins were present in the gel. 
 
7.1.3 Limitations of 2DE protocol and further recommendations 
 
Although 2DE is a powerful tool able to resolve in theory up to 1,000 proteins on a gel 
electrophoresis, there are still several limitations that need to be addressed.  
Due to the large number of hydrophobic proteins found in mitochondria, mainly due to its 
double membrane composition, the choice of detergent during sample preparation was 
important. A comprehensive analysis of the effects of different detergents on the 
mitochondrial proteome showed that CHAPS was the detergent of choice, which was not 
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expected as other detergents have been shown to solubilise membranes more effectively 
(Luche et al., 2003). 
Another problem was the limited amount of mitochondrial material available from cell 
culture, which meant that only 3 replicates could be used for the analysis. Additionally, the 
number of replicates analysed in parallel was also a limiting factor. The number of 
replicates is an important factor to overcome the low reproducibility that has been observed 
using the 2DE approach. Several reviews about 2DE reproducibility and analysis planning 
have been written in an attempt to standardise the approach intra- and inter-laboratories 
(Moxon et al., 2009; Biron et al., 2006), although each group is still following its own 
analysis procedure. In the present study, triplicates were used for practicability purposes 
due to material limitations but it has been proposed that 5 replicates should be the 
prerequisite (Biron et al., 2006); however, mitochondrial proteome studies have been 
published using triplicates for each treatment (Fukada et al., 2004). A sensible 
recommendation for similar analysis would be to increase the number of replicates 
whenever possible. 
 
7.1.4 Study of the mitochondrial phosphoproteome: limitations and future 
recommendations 
 
In parallel to a quantitative analysis of the mitochondrial total proteins, a study of the 
phosphoproteome was attempted using two different detection approaches. Phospho-amino 
acid specific antibodies were useful for probing 1D and 2D western blots of mitochondrial 
proteins. Nevertheless, identification of proteins using the 1D approach was not undertaken 
due to the poor resolution. 2D western blot analysis allowed alignment with total protein 
stain in some cases. However, the sensitivity of the antibody was a limiting factor and the 
background was relatively high. 2D-blot analysis was only successful with one replicate of 
serine phosphorylation analysis. Therefore, more sensitive antibodies are needed before this 
approach can be used routinely. 
The second approach to study the phosphoproteome used the phosphoprotein specific 
fluorescent dye ProQ Diamond. The poor resolution of 1D gels and the complexity of the 
mitochondrial phosphoproteome made it difficult to detect changes between treatments. 
The 2D approach showed an even more complex profile with multi-phosphorylated forms 
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of the same protein, although resolution was improved. As for the antibody-based 
approach, the background of the 2DE profile was high.  
As the background was lower using pI 5-8, recommendations for the analysis of the 
mitochondrial phosphoproteome would be to use such IPG strips in further analyses and/or 
fractionate samples to enrich phosphoproteins prior to 2DE.  
Antibody-based microarrays, allowing the visualisation of the phosphorylation states of a 
range of molecules, are commercially available. More particularly, future work could, for 
example, include the use of one of these arrays to study the phosphorylation status of a 
range of proteins involved in apoptotic and signaling pathways. 
 
7.2 MPTP EFFECTS ON MOUSE N2a NEUROBLASTOMA 
 
7.2.1 Cellular effects 
 
Sub-cytotoxic effects of MPTP on differentiated N2a cells were studied using 1 mM MPTP 
for 24 hours because, at this concentration, the cells lacked axon-like processes, had a 
round cell body but were still intact and overall metabolic activity was unaffected (chapter 
IV). However, although no apparent cell death was observed, the cellular ATP levels were 
down to 50 % of control values mostly due to a decrease in ATP production via oxidative 
phosphorylation as a consequence of complex I inhibition. Although some mitochondria 
were swollen, the majority were still polarised as opposed to following a higher 
concentration of MPTP (2 mM MPTP for 24 hours) where mitochondria were significantly 
depolarised.  
There was no evidence of caspase-3/7 or caspase-2 activation following exposure to 1 mM 
MPTP but a transient caspase-3/7 activation was observed at lower concentrations. Overall, 
although no cell death was observed, metabolic activity and morphology of mitochondria 
seemed to be showing early signs of being affected by the chosen conditions of MPTP 
exposure, indicating that the mitochondrial proteome might consequently be altered. 
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7.2.2 MPTP effects on the mitochondrial proteome 
 
Initial studies using 2DE showed that sub-cytotoxic MPTP concentrations modulated the 
levels of at least 32 proteins. Interestingly, ten of those proteins identified are involved in 
key mitochondrial and cellular pathways including oxidative phosphorylation, metabolic 
pathways such as the Krebs cycle and amino acid synthesis (notably aspartate and 
glutamate transamination), protein folding and an OMM channel. 
The change in levels of four of these proteins, VDAC1, GOT2, Hsp60 and Hsc70 were 
validated by western blotting analysis but the potential involvement of the other proteins 
(MDH, SDH, ATP synthase subunits, ETF-α and STIP1) has also been discussed in section 
5.3.3. 
The main molecular events resulting from MPTP-induced toxicity observed in previous 
studies were ATP depletion (Singer et al., 1988), ROS production (Chiueh et al., 1993), 
glutamate excitotoxicity (Meredith et al., 2009) and disruption of calcium homeostasis 
(Chiueh et al., 1993) leading to cell death. Further work is needed to establish the links 
between complex I inhibition on the IMM to the above mentioned phenomena. 
Although ATP depletion could be explained by complex I inhibition and the decrease in 
proton motive force, in accordance with previous studies (for example Ferrer et al., 2007), 
the present study showed that ATP synthase subunit levels were also altered. This suggests 
that complex I inhibition may have led to molecular variations in complex V, further 
accentuating ATP depletion.  
One could expect that, since NADH can not be oxidised via complex I due to its inhibition, 
metabolic and ETC enzymes would have decreased in activity and levels. However, 
increased protein levels of ETFα, MDH and FMH suggested that Krebs cycle might be 
induced to increase ATP production via other means than NADH oxidation by complex I 
(discussed in section 5.3.3.2) although these processes, if occurring, were not able to 
completely prevent ATP depletion.  
The hypothesis of reversed Krebs cycle would be consistent with increased glutamate levels 
observed in MPTP-induced toxicity (Meredith et al., 2009; Lange et al., 1997). 
Another aspect of MPTP-induced toxicity in the mitochondrial proteome was the elevated 
levels of chaperones and co-chaperones (Hsc70, Hsp60 and STIP1) and alterations in their 
phosphorylation states. These changes (validated by western blot analysis in the case of 
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Hsp60 and Hsc 70) could have a protective role due to anti-apoptotic properties as well as a 
role in protein folding allowing proper function of proteins (section 5.3.3.1). 
These events are links between complex I inhibition by MPTP-induced toxicity and some 
of the hallmarks of the disease observed elsewhere in the cell such as glutamate 
excitotoxicity, ATP-dependent processes impairment, Ca2+-dependent processes activation, 
ROS-induced damages and proteolysis impairment. A potential link between mitochondrial 
events and cytoplasmic events has been described in the present study by the observation of 
changes in the levels and phosphorylation status of the OMM channel VDAC1, in MPTP-
induced toxicity. Indeed, VDAC1 has been observed to channel ATP, ROS, Ca2+, NADH 
and glutamate, all involved in MPTP toxicity (described in section 6.1; Lemasters et al., 
2006; Han et al., 2003a; and represented in figure 7.1).  
 
7.3 VDAC 
 
7.3.1 The role of VDAC in neurodegeneration 
 
VDAC1 protein levels were increased following sub-cytotoxic concentrations of several 
electron transfer chain inhibitors, whilst no mRNA changes were observed, suggesting a 
common effect of electron transfer inhibition on VDAC1 protein levels. Two molecular 
events are known to be common following inhibition of complexes, ATP depletion and 
ROS production, both types of molecules channelled through VDAC. From these results, it 
can be hypothesised that ATP depletion could increase VDAC protein levels, for example 
due to a need of increased exchange of ATP / ADP between the cytoplasm and the 
mitochondria; and / or ROS production via the electron transfer chain, particularly O2-● 
might lead to increased VDAC1 levels as the channel has a role in releasing ROS to the 
cytoplasm (Han et al., 2003). Interestingly, Xiong et al. (2008) showed that hydrogen 
peroxide could lead to increased levels of VDAC in human SH-SY5Y cells and this could 
be inhibited by an antioxidant (called Asiatic acid), further suggesting a role of ROS in 
VDAC levels regulation. Shimada et al. (2009) recently showed that the toxicity of 
paraquat, another complex I inhibitor, was potentiated by VDAC1 over-expression via 
increased levels of O2-● in Hela cells; both Paraquat-induced cytotoxicity and O2-●increased 
production were suppressed in VDAC1-knockdown cells.  
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VDAC1 phosphorylation levels were also modulated following MPTP treatment suggesting 
that VDAC1 might change its conformation, leading to different molecules binding the 
channel. 
The observation that VDAC1 level and phosphorylation state was changes following MPTP 
and other complex inhibitor-induced toxicity was an important novel insight into the 
molecular pathways involved in neurodegenerative diseases, particularly as a mediator 
molecule between mitochondria and the rest of the cell (figure 7.1). 
 
7.3.2 Future recommendations for VDAC studies 
 
Further investigations on the role of ROS in the regulation of VDAC1 levels, including the 
effects of antioxidants would be of great interest to further understand the role of VDAC in 
neurodegeneration and cell death. 
It would be useful to study the effects of electron transport inhibitors on global interactions 
of VDAC with other proteins using, for example, immunoprecipitation techniques. 
Interactions with the Bcl-2 family of proteins, HK and CK would be of particular interest, 
but new interactions could be revealed using this approach.  
Finally the phosphorylation state of VDAC seems to be an important feature of the channel 
and further investigation of the phosphorylation status of the channel and molecules 
binding the channel following treatment with complex inhibitors could help to improve our 
understanding of the molecular events involved in neurodegeneration. This could not only 
help to identify new biomarkers of effect but also aid the development of new therapeutic 
agents by targeting the different phosphorylation states of VDAC (in order to select a 
conformation of the channel that would prevent the cell death pathway in which VDAC is 
involved. 
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Figure 7.1: Schematic representation of MPTP effects on mitochondrial processes and 
cellular consequences  
Mitochondrial protein regulated by MPTP-induced toxicity. 
Potential consequences of mitochondrial markers previously observed also found as consequences 
of MPTP-induced toxicity in the literature. 
A detailed description can be found in the text. 
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7.4 CONCLUSION 
 
In conclusion, the present project used a range of cellular and molecular approaches to 
study the effects of sub-cytotoxic concentrations of MPTP on the mitochondrial proteome 
from cultured cells. Indeed the study of the mitochondrial fraction from mouse N2a cells 
using a proteomic approach allowed the observation of markers in MPTP-induced toxicity. 
• 32 mitochondrial proteins were potentially involved in MPTP-induced toxicity, 
of which 10 were identified by peptide mass fingerprinting, suggesting the 
involvement of chaperones, components of the Krebs cycle and amino acid 
synthesis pathway, electron transfer proteins and an OMM protein in MPTP-
induced toxicity (VDAC1). 
• Altered levels of Hsc70, Hsp60, GOT2 and VDAC1 were validated as potential 
markers of MPTP-induced toxicity. 
• Changes in the mitochondrial phosphoproteome were observed, particularly 
phosphorylation of chaperones, suggesting a role of altered protein kinase 
activity in mitochondrial dysfunction. 
• Further investigations of the effects of complex inhibitors on VDAC1 protein 
levels and phosphorylation states, suggested an important role of the channel as 
a modulator between the mitochondria and the rest of the cell. 
 
A continued understanding on the role of VDAC in neurodegeneration and other 
pathologies could make the channel a potential target of therapy. 
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